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Abstract 
Chronic lymphocytic leukaemia (CLL) is a common type of adult leukaemia that accounts for 
approximately 30% of all mature B-lymphocyte malignancies. An important contributor to 
CLL pathogenesis is B-cell receptor (BCR) signalling which promotes survival of the 
malignant clone. BCR engagement on CLL cells provides survival signals by activating the 
NFB pathway. Previous work to this thesis showed that CLL cells overexpress PKCII and 
c-Abl, kinases which have been implicated in mediating NFB pathway activation in normal 
B cells. In particular, PKC mediates activation of the CARMA1-Bcl10-MALT1 (CBM) 
complex leading to eventual activation of I-κB kinases (IKKs) in normal B cells responding 
to BCR engagement. Considering the importance of the BCR in providing pro-survival 
signals to CLL cells, the initial aim of this thesis was to characterise any potential role of 
PKCII and c-Abl in BCR-mediated activation of the NFB pathway. We addressed this 
question in Chapter 3 and showed that inhibition of PKC had no effect on BCR-induced 
activation of IKK, likely because Bcl10 is expressed at low levels in CLL cells. Investigation 
of the role of c-Abl using the inhibitor imatinib showed that the presence of this compound 
partially inhibited IKK phosphorylation in BCR-stimulated CLL cells, but the observed effect 
was variable between CLL patients, and this variability was unrelated to c-Abl expression. 
Imatinib can also inhibit Lck, a T cell-specific Src-family tyrosine kinase involved in antigen 
receptor signalling that is also expressed by CLL cells. A further aim of this thesis, answered 
in Chapter 4, is to define a possible role for Lck in BCR signalling in CLL cells. We showed 
that inhibition of this Src family kinase (SFK) with the specific inhibitor [4-amino-5-(4-
phenoxyphenyl)-7H-pyrrolo[3,2d] pyrimidin -7-yl-cyclopentane (Lck-i)], or reduction of its 
expression with siRNA blocked BCR-stimulated induction of CD79a, Syk, IKK, Akt and 
ERK phosphorylation in CLL cells. Furthermore, we demonstrated that CLL cells with high 
levels of Lck expression had higher levels of BCR-mediated IKK, Akt and ERK 
phosphorylation as well as cell survival than did CLL cells with low levels of Lck expression. 
These data demonstrated a major role for Lck in proximal and distal BCR signalling in CLL 
cells. Importantly, these data suggested that Lck expression levels may be linked to disease 
prognosis. In Chapter 5 we investigated this possibility and showed that high Lck expression 
was associated with good disease outcome. We hypothesized that this may be because of a 
dual role played by Lck in promoting and suppressing BCR-induced signalling. We provided 
data to support this hypothesis and showed that CLL cells bearing low levels of Lck 
expressed a significantly higher proportion of mannosylated BCR than did CLL cells bearing 
high levels of Lck, a finding which was consistent with the presence of in vivo constitutive 
BCR signals. Furthermore, we found that Lck mediated the phosphorylation of ITIMs within 
CD22 during BCR stimulation of CLL cells. Taken together, these data suggest that high 
levels of Lck expression within CLL cells may function to interact with phosphatases and set 
an activation threshold to limit in vivo BCR signalling. 
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Chapter 1: General introduction 
1.1. Overview 
This project is mainly concerned with investigation of the signalling pathway(s) that are 
triggered by B cell receptor (BCR) crosslinking in chronic lymphocytic leukaemia (CLL) 
cells. This is important because BCR engagement provides CLL cells with signals that are 
critical for the survival and proliferation of the malignant clone. The first chapter of this 
thesis gives a general introduction about the project. The second chapter details the materials 
and methods used in this thesis. In the third chapter, we concentrate on the pathway leading 
from the BCR to activation of nuclear factor κ B (NFB), because this pathway is an 
important mediator of pro-survival signals. The fourth chapter focuses on the role of Lck in 
mediating BCR signalling in CLL. In the fifth chapter we investigated the importance of Lck 
levels in determining disease prognosis and the role of this kinase in downregulating BCR 
signalling. This project may contribute to development of new therapeutic strategies for 
treating this, so far incurable, B cell malignancy. 
1.2. B-cell chronic lymphocytic leukaemia (CLL) 
CLL is a common type of adult leukaemia
1
, and accounts for approximately 30% of all 
mature B lymphocyte  malignancies (SEER-9, 2007)
2
. This disease is characterised by a 
clonal accumulation of CD5
+
, CD23
+
 mature malignant B lymphocytes in the peripheral 
blood, bone marrow and lymphoid tissues
1 3
. In some individuals, the tumour is confined to 
lymphoid tissue without the involvement of blood or bone marrow; these patients are known 
as having small lymphocytic lymphoma (SLL) 
1
 which is considered to be a different 
manifestation of CLL according to the 2001 World Health Organisation classification scheme 
2 
 
of haematopoietic malignancies
4
. However, although CLL is designated as a single entity, 
this disease is heterogeneous with respect to its biological, clinical and cytogenetic aspects
2
. 
1.3. B-cell development 
Haematopoiesis of all blood cell types takes place in the bone marrow where the 
haematopoietic stem cells (HSCs) are resident. There are two major cellular lineages of 
haematopoietic cells derived from HSC; the lymphoid lineage which is responsible for the 
development of T and B lymphocytes and natural killer cells, and the myeloid lineage which 
is responsible for the development of granulocytes, erythrocytes, megakaryocytes, and 
monocytes
5-6
. It is suggested that these lineages arise from a common lymphoid progenitor 
(CLP) or a common myeloid progenitor (CMP) during differentiation from CD34 positive 
multipotent progenitor (MPP) cells
5 7-8
. The model presented in Figure 1.1 is a simplistic 
representation of this differentiation pathway. Although recent work has suggested additional 
steps within the pathway of MPP differentiation to CLP cells
5 9-10
, for the purposes of this 
thesis it is not important to discuss these steps.   
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Figure 1.1: The classical model of haematopoiesis (CMP vs. CLP). LT-HSC: long term 
haematopoietic stem cell, ST-HSC: short term haematopoietic stem cell, MPP: multipotent 
progenitors, CLP: common lymphoid progenitor, CMP: common myeloid progenitor 
(adapted from Lai et al.
5
) . 
 
 
CLP commitment and differentiation to B lineage cells requires the expression of the 
transcription factors E2A, EBF, and Pax5
11
. Importantly, these transcription factors stimulate 
the genes responsible for expression and rearrangement of the BCR. In particular, the genes 
controlling antigen receptor rearrangement (the RAG/TdT genes) promote diversity in the 
BCR through a process involving recombination of the variable (V), diversity (D), and 
joining (J) gene segments of the heavy chain locus, and the V and J segments of the light 
chain loci  and 12-13. This results in the generation of pre-B lymphocytes with clonally 
4 
 
diverse surface immunoglobulin receptors that recognise specific antigenic epitopes. What 
follows is a process of clonal selection where B cells that strongly react with self-antigen are 
deleted, and B cells that weakly react with self-antigen are silenced through a process of 
anergy. This prevents further development of self-reactive B lymphocytes
14
. These stages of 
development are shown in figure 1.2
15
. The product of the bone marrow stage in B cell 
differentiation is the production of a naive B-cell that has undergone V(D)J recombination. 
Each of these cells expresses mature BCR which is distinct from all others at three levels: the 
choice of V, D, and J segments, the combination of rearranged heavy and light chains, and 
junctional insertions and deletions which occur during rearrangement
16
. 
In the next stage, naïve mature B cells with functional immunoglobulin (Ig) migrate to the 
secondary lymphoid tissues such as the lymph nodes, where antigen-dependent 
diversification occurs. This results in B lymphocytes capable of producing antibodies with 
higher affinity for specific antigens. This affinity maturation takes place in the germinal 
centres of the lymph nodes and is believed to involve two processes: 1) Somatic hypermutatin 
(SHM) which introduces point mutations into the complementarity-determining regions 
(CDR)) of the Ig genes. Activation-induced cytidine deaminase (AID) is thought to initiate 
this process
16
. 2) Clonal selection involves antigen presentation by follicular dendritic cells 
(FDCs) to the B cells in the germinal centres. B cells that bind antigen with low affinity will 
be deleted by apoptosis. While those which bind and subsequently present antigen fragments 
on their surface receive positive selection signals from CD4+ T helper cells and undergo 
terminal differentiation to either long lived plasma cells or memory cells
17-19
. 
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Figure 1.2: summary of B cell development stages in the bone marrow and the 
peripheral lymphoid tissues (adapted from Cambier et al
15
) 
 
In mice, B1 cells differ from B2 cells in their anatomic localisation, phenotype, ability to 
produce natural antibodies and self-renewing ability
20
. This subset of B cells is classified into 
the CD5
+
 B1a and the CD5
- 
B1b cells, both of which live in the peritoneum
21
. There is a lot 
of controversy about the origin of these cells and whether they evolve from the same or 
different progenitors as B2 cells
22
. The function of B1a cells is secretion of natural antibodies 
which is a source of innate immunity against bacterial infections, whereas B1b cells represent 
a source of long term adaptive immunity by producing antibodies against polysaccharides in 
response to infections
23
. However, little is known about this distinct subset of B cells in 
humans
22
. 
Marginal zone (MZ) B cells is another distinct subset of B cells with specific functions. 
These cells reside in the marginal zone of the spleen and have features of naive and memory 
B cells. These cells are thought to account for immunity against encapsulated bacteria in the 
blood in human and rodents. Human MZ B cells differ from their murine counterparts in their 
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ability to recirculate and reside in anatomical sites that are in addition to the spleen. However, 
the spleen is important for MZ B cells in both mice and humans
24
. 
1.4. CLL ontogeny 
The cause of CLL has not been identified, and although it is known that CLL cells develop 
from a mature B cell population, the exact stage of differentiation where the neoplasm forms 
has not been determined. It is suggested that CLL cells can originate from marginal zone 
(MZ) B cells
25-26
, a notion that is supported by 3 facts: (1) After antigen ligation, MZ B cells 
display an activated surface phenotype
27-29
. (2) MZ B cells also express BCR with mutated 
and unmutated IgHV genes
30-31
. (3)  MZ B cells respond to T- cell dependent and 
independent antigens
27
. 
Human CD5 positive B1 cells are also suggested to be the normal counterpart of CLL; this is 
because CLL cells and B1 cells share similar phenotypes (e.g. both are CD20
+ 
CD27
+ 
CD43
+ 
CD70
-
). Furthermore, most normal B1 cells are CD5
+
 as are malignant CLL cells
32-34
. In 
addition, both B1 and CLL cells express ZAP70
33 35
. In mice during B cell differentiation in 
the bone marrow, B1 cells originate from the population of pre-B cells that are undergoing 
positive selection by low affinity interaction with self-antigens at low concentration. 
Although this may not necessarily represent human physiology, it is nevertheless interesting 
that when B1 cells are absent due to genetic manipulation of the mouse (e.g. through targeted 
disruption of particular genes, in this case prckb)
36
, CLL development does not occur in 
mouse models of this disease
37
. Further evidence supporting a B1 cell origin of CLL comes 
from structural studies of the BCR. The antigen binding spectrum of B1 and CLL cells is 
similar with respect to showing reactivity to autoantigens
25 38
. More recently, a study 
comparing the transcriptomes of CLL cells and normal B cell subsets from human blood and 
spleen has suggested that CLL cells can derive from a human counterpart of B1 cells, and 
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that germinal centre differentiation may also be involved in order to account for the 
appearance of somatic hypermutation of IgHV genes
39
. This latter aspect is important 
because more than 50% of CLL patients 
32 34
 bear somatic hypermutation within the IgHV 
genes of the malignant clone, and this is not a feature of B1 cells
22
.  
A hallmark of CLL is the accumulation of mature malignant B lymphocytes in circulation 
that have escaped apoptosis and are arrested in the G0/G1 phase of the cell cycle
1 40
. CLL 
cells overexpress the anti-apoptotic protein BCL-2, and expression of pro-apoptotic proteins 
within these cells is very low
40-42
. This imbalance in favour of anti- over pro-apoptotic 
proteins was thought to lead to an accumulation of malignant cells due to resistance to 
apoptosis
43
. This view was disputed in a study by Messmer et al
44
 who showed using 
deuterium labelling to identify newly divided CLL cells that this disease was more dynamic 
than previously thought, with birth rates ranging from 0.1% to greater than 1.0% of the total 
clone per day. These authors also suggested that patients in whom the malignant cells 
proliferated at rates greater than 0.35% of the total clone per day were more likely to have 
progressive disease. Nevertheless, subsequent studies have shown that CLL cells proliferate 
at lower levels than do normal B cells in healthy individuals, but that their survival in the 
circulation is considerably longer
45
. 
A potential precursor state of CLL has been characterised. Using flow cytometry, researchers 
studying otherwise healthy individuals have reported the presence of B-cell clones which 
have a similar immunophenotype to that of CLL cells
46-48
. These seemingly healthy 
individuals have either normal or slightly increased lymphocyte counts, but because the 
presence of these “pre-CLL” B-cell clones occurs more frequently in people of advanced 
age
49
 and in first degree relatives of CLL patients
48
, it is thought that this condition may 
precede the development of CLL
2 19
. This potential disorder has been designated monoclonal 
B-cell lymphocytosis (MBL). A link between MBL and CLL is supported by studies showing 
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that MBL B cell clones have genetic abnormalities that are typical for CLL cells
19 50-51
. 
However, it should be noted here that only a small proportion of patients with MBL cases 
will develop into CLL
19 52
. 
The pathogenetic mechanisms involved in the evolution of CLL include microenvironmental 
stimuli consisting of T cell interactions, stromal cell-derived soluble factors and antigenic 
drive
53
. Internal genetic events also contribute to the pathogenesis of CLL; in particular, 
cytogenetic abnormalities are very common in the malignant cells of CLL patients. The most 
frequent of these aberrations are deletions on 13q-, 11q-, 6q-, 17p-, and trisomy of 
chromosome 12
40 54
. More recently, oncogenic mutations in NOTCH1, XPO1, MYD88, 
SF3B and KLHL6 have also been identified
55
. It is likely that a combination of all these 
factors contribute to the evolution of the malignant clone in CLL, particularly with respect to 
the generation of drug resistant clones as has been suggested in two recent studies
56-57
. 
Microenvironmental stimulation such as antigen receptor engagement is likely to be the glue 
binding these elements together because it provides key survival signals for each step in the 
clonal evolution of CLL cells. 
1.5. Epidemiology of CLL  
According to the Surveillance, Epidemiology, and End Results programme (SEER), the US 
incidence rate (IR) of CLL is 4.2 per 100 000 per year, with a higher incidence rate among 
males compared to females (the male: female IR ratio is 1.93)
58
. In the United Kingdom, data 
from Leukaemia and Lymphoma Research (LLR) has indicated a higher incidence rate of 
CLL in the population with an incidence of 6.15 per 100 000 per year
1
. This disease mainly 
affects older individuals, and the median age at diagnosis of CLL is 70 years for males and 74 
years for females. This disease is incurable, and the median age for death from CLL is 76 and 
81 years for males and females, respectively 
1
. CLL is also a race-related disease; it is 
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reported that its incidence rate is slightly higher among White Americans than African 
Americans (3.9 vs 2.8 per 100 000 per year), and this is five times greater than that in 
American people of Chinese, Japanese, and Filipino origin
1
. A family history of leukaemia or 
lymphoma is one of the strongest risk factors for development of CLL
2 19
. The overall risk of 
developing CLL is reported to be three times higher in first-degree relatives of patients with 
CLL compared to the general population
1 59-60
.  
1.6. Clinical overview 
1.6.1. Clinical features 
Signs and symptoms of CLL develop slowly and it is difficult to identify the onset of the 
disease. Therefore, it is common for CLL to be discovered coincidentally during routine 
blood tests
61
. The most common clinical features of this disease include lymphocytosis, 
lymphadenopathy and hepato-splenomegaly. Anaemia and thrombocytopenia are also 
common in CLL patients in the early stages of the disease
61-62
. Night sweats, fever, and 
weight loss may also develop as the disease progresses into a more aggressive tumour
40 61
. 
Viral and bacterial infections are the major causes of death in patients with CLL, caused by 
immune suppression leading to hypogammaglobulinemia
61 63
. Autoimmune syndromes such 
as autoimmune haemolytic anaemia are also frequent in CLL
40 61-62
. 
1.6.2. Diagnosis 
Diagnosis of CLL is defined by peripheral blood lymphocytosis of at least 5×10
9
 cells/L. 
These cells have a distinctive immunophenotype; high expression levels of CD5 and CD23, 
and weak levels of surface immunoglobulin, CD19 and CD20. The antigens FMC7, CD22, 
CD79b, and CD10 are expressed at very low levels or not at all on CLL cells
19 61-62 64
. 
Furthermore, because of the non-cycling state of these cells, cyclin D1 expression is absent. 
Morphologically, CLL cells are small and appear relatively mature with hypercondensed 
10 
 
nuclear chromatin. Smudge cells are also common in CLL
61
.  Figure 1.3 shows the 
differential diagnosis of CD19+ lymphocytosis depending on the immunophenotype. 
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Figure 1.3: Differential diagnosis of CD19
+
 lymphocytosis. This figure represents a 
clinical pathway for the diagnosis of mature B cell malignancy based on the 
immunophenotype of circulating cells (adapted from Dighiero et al 
1
). 
 
 
1.6.3. Clinical staging  
CLL is heterogeneous with respect to progression and clinical course. This problem has been 
addressed in many ways, but initially it was solved by introducing clinical staging systems; 
one in Europe proposed by Binet et al
65
, and one in North America proposed by Rai et al
66
. 
These staging systems are based on clinical observations and blood tests
61-62 66-68
, and include 
observations on lymphocytosis, lymph and spleen adenopathy and bone marrow suppression. 
Table 1.1 shows the Rai and Binet systems along with the clinical features and median 
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survival by stage. These systems are especially used to define whether and when to start 
treatment
59
. Although these staging systems are able to predict disease outcome, this applies 
mainly to late-stage and not to early-stage CLL because of an inability of these systems to 
identify the factors which contribute to indolent or progressive disease
1 61
. 
 
Table 1.1: Rai and Binet staging systems
67
 
Stage Risk group Criteria Median survival 
(months) 
Rai stage    
0 Low Lymphocytosis >150 
I Intermediate Lymphocytosis+ 
lymphadenopathy 
101 
II 
 
Intermediate 
 
Lymphocytosis+ 
splenomegaly or 
hepatomegaly 
71 
 
III High Lymphocytosis+ anaemia 19 
IV High 
 
 
Lymphocytosis+ 
thrombocytopenia 
19 
 
 
Binet stage    
A Low <3 nodal sites involved Not reached 
B Intermediate ≥3 nodal sites involved 84 
C High Anaemia and/or 
thrombocytopenia 
24 
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1.6.4. Treatment 
As discussed above, Rai/Binet staging is used as a guide to determine whether and when to 
start treatment. According to the NCI-WG guidelines, asymptomatic patients at Binet stage A 
and Rai stage 0 (low risk) can be managed by a wait-and-watch approach, whereas patients at 
Binet stage B and Rai stage I and II (intermediate risk) should be treated once they exhibit 
progressive or symptomatic disease. However, it is recommended that early treatment should 
be considered for patients at Binet stage C and Rai stage III and IV (high risk)
59 64 69-70
. 
For many years, first line treatment had consisted of alkylating agents such as chlorambucil 
or cyclophosphamide, either as a monotherapy or in conjunction with corticosteroids such as 
prednisone. However these therapies typically give a response rate of less than 10% and the 
effect they have on overall survival is questionable
71
. 
In the last two decades, complete remission rates and overall survival rates have improved 
drastically with the advent of purine analogues and monoclonal antibody therapies which are 
often used in combination with cyclophosphamide. This regimen is known as FCR 
(fludarabine, cyclophosphamide, rituximab) and is the most effective current combination 
according to phase II clinical data
72-73
. The CLL8 trial also supports these findings, with 
results showing a significantly higher progression free survival time when compared to 
fludarabine-cyclophosphamide (FC) therapy
74
. The increased efficacy of the FCR regimen 
appears to be the result of synergy between rituximab and fludarabine
75
. 
Unfortunately due to the aggressive nature of FCR, many elderly patients are often unable to 
tolerate it. In this instance chlorambucil still has a role to play, and indeed according to 
results from the CLL5 study
76
 fludarabine monotherapy does not appear to have any 
significant benefit to chlorambucil in this demographic. 
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Several studies have observed CLL cells in vitro rapidly undergo spontaneous apoptosis
77-78
 
and these same cells may be rescued with stromal cell contact or addition of soluble factors, 
such as thioredoxin which are present in the tumour microenvironment
79-80
. Taken together, 
this evidence suggests that resistance to apoptosis is not an intrinsic characteristic of CLL 
cells and that signals from the microenvironment play a significant role in their survival. 
Given the advances in understanding the importance of BCR signalling in CLL survival in 
the recent years, targeting these signalling pathways has lately been introduced as a 
therapeutic procedure. Several kinases, including spleen tyrosine kinase (Syk), Lyn, Bruton’s 
tyrosine kinase (Btk) and phosphatidylinositol 3-kinase (PI3K), have been targeted by small 
molecular inhibitors. CAL-101, a PI3Kδ specific inhibitor, has proven to be safe and use of 
this drug leads to reduced lymphadenopathy in relapsed CLL patients. Another way of 
targeting BCR signals is inhibiting the B cell specific kinase Btk using PCI-32765 (ibrutinib). 
This drug showed encouraging clinical effectiveness in CLL patients. These two orally 
available BCR signalling antagonists are still under ongoing studies
81-83
. 
Another drug that showed encouraging results in the treatment of high risk CLL patients is 
lenalidomide, an immunomodulatory agent with anti-angiogenic properties
84
. Lenalidomide 
monotherapy resulted in an overall response rate that varied between 32% and 54% in 
different clinical trials
85-87
. However, the combination of lenalidomide and rituximab resulted 
in a better response rate without a higher risk of toxicity
88
. 
Haematopoietic stem cell transplantation (HSCT) has been proposed as a possible curative 
therapy in selected young patients; however, to date this therapeutic approach has not met 
with a high degree of success as cure appears to be possible in one third to two thirds of 
patients undergoing this procedure for poor-prognosis CLL
40 59 89
.  
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1.6.5. Prognostic factors 
Due to failure of CLL staging systems to indicate CLL patients with higher risk of 
progression in early stages of the disease, several biological markers have been identified that 
can be used to predict CLL disease outcome. These markers were based on examination of 
peripheral blood or bone marrow, such as an identification of high rate of prolymphocytes, 
atypical morphology of CLL cells, or diffuse infiltration of bone marrow. These aspects are 
associated with poor disease outcome
66 68 90-91
. Furthermore, two papers were published in 
1999 which described somatic mutation of the variable region of immunoglobulin heavy 
chain (IgHV) genes within CLL cells and its relation to disease prognosis
32 34
. Thus, patients 
where the level of mutation of these genes in the malignant cells is less than 2% (bearing 
germline or unmutated IgHV genes) have a significantly shorter overall survival 
(approximately 8 years) than those where the level of mutation exceeds 2% (bearing mutated 
IgHV genes) (approximately 25 years). This discovery is possibly the most reliable general 
indicator of disease prognosis in CLL. Newer factors have also been identified and include 
lymphocyte doubling time (LDT), CD38 and zeta-associated protein-70 (ZAP70) expression, 
serum levels of β2-microglobulin, thymidine kinase (TK) and soluble CD23 (sCD23), P53 
expression and the presence of certain chromosomal abnormalities
19 59 61 90
. 
The expression levels of ZAP70 remain constant over the course of the disease. 20% is the 
proposed cutoff value to classify patients as ZAP70 positive or ZAP70 negative, as measured 
by flow cytometry. However, standardization of ZAP70 measurement is still a challenge. 
Furthermore, ZAP70 expression was shown to be associated with unmutated IgHV status and 
poor disease outcome. Expression levels of CD38 also correlate with CLL disease outcome. 
The proposed threshold to classify patients is 30% CD38
+ 
CLL cells. Thus,   patients  with 
higher than 30% CD38
+
 CLL cells (CD38
+
) are reported to have significantly poorer 
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prognosis regarding PFS and OS. CD38 expression on CLL cells has been shown to correlate 
with the absence of IgHV mutations
64 90-93
. 
Chromosomal aberrations in CLL patients have crucial prognostic importance. In this respect, 
13q deletion, found in up to 50% of CLL cases, is associated with good disease outcome. 
While 17p deletion, 11q deletion, trisomy 12, are associated with rapid disease progression, 
short survival, and resistance to treatment
54 64 90
. 
 Table 1.2 summarizes the impact of each of these factors in the prognosis of CLL. 
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Table 1.2: Prognosis factors in CLL. Clinical risk is divided into two categories, low and 
high. Low risk is associated with the potential of the disease to remain indolent while high 
risk is associated with the potential of the disease to progress. This table is taken from 
Herishanu et al 
62
. 
Prognostic factor clinical risk 
 
 
Low High 
Patient gender Female Male 
Clinical stage 
 
Binet A 
Rai 0, I 
Binet B or C 
Rai II, III, IV 
Pattern of bone marrow 
biopsy infiltration 
Non-diffuse Diffuse 
Lymphocyte 
morphology 
 
Typical Atypical 
Lymphocyte doubling 
time 
>12 month 
 
<12 month 
CD38 expression <20-30% >20-30% 
Genetic abnormalities None Del 11q23 
 Del 13q Loss/mutation of  P53 
Serum thymidine kinase 
levels 
Low High 
IgHV mutational status Mutated Unmutated 
ZAP70 expression Low High 
Beta-2-microglobulin Low High 
Soluble CD23 Low High 
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1.7. Importance of the B-cell receptor (BCR) in CLL pathogenesis 
The relationship between IgHV mutation and disease prognosis raised questions about the 
role of the BCR in CLL pathogenesis. Studies of the genetic structure of BCR showed that 
CLL cells have a preferred repertoire of IgHV gene usage that is remarkably similar between 
patients. This observation has led to the generation of the hypothesis that antigen receptor 
engagement is responsible for expansion of the malignant clone
25
. In particular, studies have 
shown that the BCR from CLL cells bearing mutated IgHV genes have restricted antigen 
specificity compared to that from CLL cells bearing unmutated IgHV genes. Thus, if two 
CLL cell clones are similar with respect to IgHV gene usage, the clone which bears 
unmutated genes will be polyreactive whereas the clone bearing mutated genes will be more 
monoreactive
94
.  
This notion of polyreactive versus monoreactive BCR was then investigated in relation to 
BCR signalling in CLL cells. Thus, studies investigating this phenomenon have suggested 
that the ability to signal is related to disease pathogenesis. UM-CLL cells respond to BCR 
engagement whereas M-CLL cells do not, and it is thought that cell anergy is responsible for 
this inability of M-CLL cells to respond
95-96
. However, comparisons of gene expression 
between UM- and M-CLL cells identified ZAP70 as a feature of UM-CLL cells
97
. Analysis 
of the function of ZAP70 in CLL cells revealed that ectopic expression of this protein in M-
CLL cells restores BCR signalling without the need for kinase function of ZAP70
98
. This 
implies that ZAP70 enhances BCR signalling using a mechanism different to its established 
role in T cell receptor signalling. Further evidence linking BCR signalling to CLL 
pathogenesis comes from studies showing that signal strength is also related to disease 
prognosis
99-100
. Finally, the importance of BCR signals in promoting growth and survival of 
the malignant clone of CLL is further highlighted by the clinical activity of agents such as 
Btk, Syk, and PI3K inhibitors in CLL treatment
81 83 101-104
.  
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Evidence that BCR is engaged on CLL cells whilst in vivo is suggested in studies showing 
increased expression of BCR target genes and low expression of surface IgM in freshly 
isolated CLL cells
80 105-106
. Moreover, a recent study by Krysov et al
107
 has measured 
glycosylation of the BCR on CLL cells and shown it to bear signs of activation particularly in 
patients with UM-CLL. Cell surface IgM in normal B cells bears mature complex glycans. 
Persistent antigen stimulation of these cells converts them to expressing the immature 
mannosylated form with smaller molecular weight
107
. CLL cells exhibit higher levels of 
immature heavy chain of sIgM compared to normal B cells
108-109
 with variable levels of this 
immature mannosylated form among the cases
107
, particularly with respect to UM-CLL cases. 
When these cases are cultured in vitro, the glycosylation reverts to the expression of the 
mature glycan forms
107
. This supports the notion that CLL cells undergo continuous BCR 
ligation in vivo. This notion is further supported by one study showing that the BCR on CLL 
cells is capable of antigen-independent cell autonomous signalling
110
. This study has 
suggested that such autonomous signalling could be a driver of disease pathogenesis in CLL 
and links together the above observations of BCR target gene expression and changes in 
glycosylation. This study may also mean that mechanisms exist in CLL cells that act to 
downregulate these autonomous signals, and this may be the difference between M-CLL and 
UM-CLL cells.  
1.7.1. Structure of the BCR 
BCR is a multimeric complex composed of a surface immunoglobulin homodimer molecule 
and a non-covalently associated heterodimer consisting of Igα (CD79a) and Igβ (CD79b)1 95 
111
.  This general structure of the BCR is illustrated in Figure 1.4. CD79a and b contain the 
immunoreceptor tyrosine activation motifs (ITAMs) within their cytoplasmic domains, and it 
is here where signalling is initiated once the BCR is engaged
112
. CD19 also co-associates 
with the BCR, functioning as a signal enhancer by acting as a scaffold for further signalling 
19 
 
proteins
113
. CD22 can also co-associate with the BCR where it acts to downregulate 
signalling by recruiting SH2-containing tyrosine phosphatase-1 (SHP-1) to its 
immunoreceptor tyrosine inhibition motif (ITIMs)
114-115
.  
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Figure 1.4: Structure of the BCR 
 
1.7.2. BCR signalling in normal B cells 
In normal B cells, BCR crosslinking by its cognate antigen induces tyrosine phosphorylation 
of ITAMs within Igα and Igβ by the Src family tyrosine kinase Lyn116 and by Syk117. The 
phosphorylated ITAMs are then able to recruit and activate several signalling elements 
including Syk, Btk, Lyn, the Rac guanine exchange factor Vav proteins, Grb2 and B-cell 
linker (BLNK). Syk is activated by a multistep phosphorylation process by Src family kinases 
and autophosphorylation. After recruitment of Syk and Lyn to the phosphorylated ITAMs, 
BLNK then binds to the non-ITAM part of CD79a through its Src homology domain
118-119
and 
becomes phosphorylated by Syk. Phosphorylated BLNK then acts as a scaffold and recruits 
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phospholipase C γ2 (PLCγ2) and Btk120-121. Once recruited from the cytosol to the plasma 
membrane by the adaptor protein BLNK, and then dually phosphorylated by Btk and Syk, 
activated PLCγ2 cleaves plasma membrane lipid phosphatidylinositol 4,5-bisphosphate 
(PIP2) into inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 induces the 
release of intracellular calcium Ca
2+
, and together with DAG, leads to the activation of 
classical protein kinase C (PKC) isoforms within the cell
115
.  
BCR stimulation also results in the activation of PI3K. This is thought to be regulated by 
Lyn-mediated phosphorylation of CD19, which attracts the binding of the p85 regulatory 
subunit of PI3K via SH2 domain interaction and leads to activation of the p110 catalytic 
subunit. Activated PI3K in turn phosphorylates PIP2 generating phosphatidylinositol-3,4,5- 
trisphosphate ( PIP3) which then recruits pleckstrin homology (PH) domain-containing 
effectors such as Vav, Btk, 3-phosphoinositide dependent protein kinase-1 (PDK1) and Akt 
to the cell membrane where they become activated
95 111 115 122-124
. Once activated, Akt 
promotes cell survival in a myriad of ways including phosphorylating Bad to negate its pro-
apoptotic effects at the mitochondrial membrane, phosphorylating TSC2 leading to the 
activation of mTOR and stimulation of cell metabolism, and phosphorylating GSK3 which 
inhibits the activity of this kinase and promotes nuclear accumulation of several transcription 
factors, including NFAT
125
. 
Btk belongs to the Tec protein tyrosine kinase family, and mediates B-cell development, 
survival and function through its role in BCR signalling
126
. It has been reported that 
mutations in the gene encoding Bruton's tyrosine kinase (Btk) cause the human disease X-
linked agammaglobulinemia (XLA)
127-128
. In B cells BCR cross-linking activates Btk through 
membrane recruitment, association with BLNK and phosphorylation at Tyr551in the kinase 
domain by Lyn and Syk. Active Btk then autophosphorylates on Tyr223 in the SH3 
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domain
129-130
, and goes on to phosphorylate and activate PLC2. In addition to its role in 
PLC2 activation, Btk is also reported to play roles in PI3K/Akt as well as NFκB pathway 
activation
131
 
102
.  
Activation of the ERK pathway by the BCR is initiated by convergence of active tyrosine 
kinase and PLC2 pathways. Thus, Son of sevenless (SOS) is recruited and activated by Grb2 
binding to ITAM motifs within CD79, and DAG generated by active PLC2 results in the 
activation of the Ras guanine exchange factor (RasGEF) RasGRP1. The GTP-Ras generated 
by RasGRP1 acts on SOS to amplify GTP-Ras formation by this RasGEF. GTP-Ras then 
leads to the membrane recruitment and activation of BRaf and c-Raf1, leading to downstream 
activation of MEK and finally ERK
132
. 
Activation of PKCs, and, in particular, PKCβ is important for stimulating signalling to the c-
Jun N-terminal kinase (JNK) and NFB pathways in cells responding to BCR crosslinking. 
Active PKC phosphorylates the scaffold molecule CARMA-1which in turn recruits two 
adaptor proteins Bcl-10 and MALT-1 to lipid rafts. These three proteins (i.e. CARMA-1, Bcl-
10 and MALT-1) form a signalosome called the CBM complex which facilitates the 
recruitment and activation of Transforming growth factor (TGFβ) Activated Kinase 1 
(TAK1) by facilitating K63 ubiquitination of IB kinase  (IKK). This also acts to assemble 
the catalytic kinase subunits, IκB kinase  (IKKα or IKK1) and IKKβ (IKK2), which are 
essential for further downstream signalling in the NFB pathway133-135. TAK1is thought to 
play a role in this process by phosphorylating IKK within this complex. Once activated, the 
IKK complex phosphorylates IB and this leads to the release of RelA (p65) to translocate 
to the cell nucleus
134
. Active TAK1 can stimulate the JNK pathway by phosphorylating 
MKK4 and 7 to eventually activate JNK itself.  
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Activation of PI3K and generation of PIP3 also has the effect of recruiting the RacGEF Vav 
to the cell membrane. Formation of GTP-Rac1 then leads to important cytoskeletal changes 
in cells responding to BCR stimulation, and also to the activation of the p38 MAPK 
pathway
136
. 
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Figure 1.5: BCR signalling in normal B cells. This diagram is representative of the 
signalling pathways that become activated in B cells responding to BCR crosslinking 
(adapted from Dal Porto et al
115
) . 
 
1.7.3. The Nuclear factor κ B (NFB) pathway 
Nuclear factor κ B (NFB) is a family of transcription factors consisting of five proteins that 
can form homo- or heterodimers. These proteins are termed RelA (p65), RelB, c-Rel, p50 
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(NFB1) and p52 (NFB2). NFB factors play an essential role in B cell development, 
proliferation, immune responses, and survival. NFB exists in the cytoplasm of resting cells 
as an inactive form associated with inhibitory proteins. These inhibitory proteins, which 
include IκBα, IκBβ and IκBγ, mask the nuclear localisation sequence (NLS) of NFB factors 
such as RelA and sequester it in the cytoplasm. NFB1 and NFB2 exist as, respectively, 
p105 and p100 precursors in the cell cytoplasm, and must first be proteolytically cleaved 
before p50 and p52 can translocate to the nucleus
102 103
.  
The process that catalyses NFB translocation to the nucleus can occur through either a 
classical (canonical) or an alternative (non-canonical) pathway. Both of these pathways 
depend on the complex of I-B kinases ,  and  known as the IKK complex (Figure 1.6). 
The canonical pathway is triggered by ligation of receptors such as the antigen receptor on B 
and T cells, Toll-like receptors (TLRs) and the Tumour necrosis factor  (TNF) receptor. 
These stimuli catalyse, through various processes, K63 ubiquitination of IKK leading to 
activation of TAK1 which then phosphorylates and activates IKK. Phosphorylation of IB 
by IKK triggers K48 ubiquitination of IB and subsequent proteosomal degradation. This 
releases RelA to translocate into the nucleus and engage its enhancer elements to activate the 
expression of target genes. Alternatively, non-canonical pathway activation is stimulated by 
receptors such as CD40, BAFF receptor and LTβR. Stimulation through these receptors 
activates NFB-inducing kinase (NIK), which phosphorylates and activates IKKα, which, in 
turn, phosphorylates p100 to induce its proteosomal processing and release p52/RelB dimers. 
These p52/RelB dimers then translocate to the nucleus where they regulate distinct 
transcriptional responses, particularly with respect to B cells. This pathway is independent of 
IKKγ137-139. 
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Figure 1.6: NFκB pathway. The canonical vs. the alternative pathway of NFκB activation 
(Adapted from Jost et al
137
).  
1.7.4. BCR signalling in CLL cells 
It is well known that crosslinking of the BCR on CLL cells leads to heterogeneous responses, 
particularly with respect to the proximal events of antigen receptor signalling
95
. In CLL cells 
bearing unmutated IgHV genes BCR crosslinking generally induces a response. However, in 
some cases of CLL where the malignant cells bear mutated IgHV genes, the response to BCR 
crosslinking is more muted
140
. One possible reason for this heterogeneity is that higher levels 
of surface Ig are often found on the malignant cells from UM-CLL cases compared to those 
from M-CLL cases
106 141
. The inability of BCR to signal in M-CLL cells has also been 
attributed to these being in an anergic state and unable to fully respond to such 
crosslinking
142
. Such anergy may be because the BCR on M-CLL cells fails to translocate 
into membrane lipid raft structures following crosslinking whereas this does occur on UM-
CLL cells
96
. Heterogeneous ZAP70 expression could also explain this difference in ability to 
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signal. ZAP70 expression is significantly higher in the malignant cells from UM- compared 
to M-CLL cases, and has been proposed as a pseudomarker of IgHV mutation
97 143-144
. 
ZAP70 plays an essential role in antigen receptor signalling on T cells
145-146
, and in CLL cells 
the expression of this protein also facilitates antigen receptor signalling by acting as an 
adaptor molecule rather than a kinase
147
 
111 141
. This notion is supported by studies showing 
that ectopic expression of ZAP70 as a kinase-dead mutant restores BCR signalling in M-CLL 
cells 
98
.  
Despite the ability of BCR engagement to provide signals in UM-CLL cells, the 
immunogenic response in these cells is incomplete and does not induce proliferation
95
. BCR 
crosslinking on UM-CLL cells with soluble anti-IgM has been shown to stimulate the Akt, 
NFB and ERK pathways in the majority of cases. However, in these same cases JNK is 
almost never activated
148-150
. Thus, CLL cells respond to antigen receptor stimulation 
differently than do normal B cells. 
Heterogeneity in CLL cell response to BCR crosslinking could also be an adaptation to 
antigen independent cell autonomous signals that are generated by the BCR. A recent study 
has shown that BCR on CLL cells contains structural elements that are conducive to antigen 
independent cell autonomous signalling, and has suggested that such signalling drives CLL 
cell pathogenesis
110
. In this context, certain signalling pathways will be constitutively active 
and CLL cell response to BCR crosslinking may be a function of regulatory elements that 
limit the generation of intracellular signals. In support of this, a characteristic of CLL cells is 
the constitutive activation of certain kinases such as Lyn and Syk. It has been shown that both 
of these kinases are overexpressed in CLL compared to normal B cells, and that their activity 
is also upregulated in unstimulated cells
151
. Inhibition of Syk either with fostamatinib or by 
siRNA knockdown shows that this kinase plays an important pro-survival role in both 
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unstimulated
152
 CLL cells as well as in BCR stimulated
153
 cells where it controls influx of 
Ca
2+
 and the phosphorylation of Akt and ERK
153
. However, the role of Lyn in these processes 
is less clear because inhibitor studies have not been able to target this kinase specifically, and 
it is resistant to siRNA-mediated knockdown due to association with HSP90
154
. The 
PI3K/Akt pathway is also reported constitutively active, and inhibition of this pathway using 
PI3K inhibitors such as CAL-101 or LY294002 reduces CLL cell survival by downregulating 
the expression of anti-apoptotic proteins such as Mcl-1, XIAP, and the induction of Bcl2 
family member Bax
155-156
. Finally, constitutive activation of NFB and ERK in CLL cells is 
demonstrated in a subset of patients, and is associated with low responsiveness to BCR 
ligation 
142 157-158
.  
 
1.7.4.1. The role of SFKs in CLL 
The differences between CLL cell and normal B cell response to BCR crosslinking may be 
due to differences in expression of the Src family tyrosine kinases (SFKs) responsible for 
proximal signalling. SFKs are a family of non-receptor protein tyrosine kinases that are 
involved in, depending on the cell lineage and particular SFK, regulating cellular processes 
including proliferation, survival, metabolism, differentiation, and migration. This family of 
proteins consists of 8 members: Lyn, Lck, Src, Fyn, Fgr, Hck, Blk, and Yes
159-160
.  
The general structure of an SFK is shown in Figure 1.7. It is composed of 8 functional 
domains, the order of which starting from the N terminus is: a domain containing a 
myristoylation site that targets SFKs to membrane structures, a Src homology domain 4 
(SH4) domain, a unique region that is specific for each Src family member, an SH3 domain, 
an SH2 domain, a linker domain, a kinase (SH1) domain and a regulatory domain
161
. There 
are two important tyrosine phosphorylation sites within SFKs, one within the kinase domain 
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and a second in the regulatory domain
162-164
. Phosphorylation of the tyrosine residue located 
in the regulatory domain of an SFK allows this domain to interact with its SH2 domain and 
hold the enzyme in an inactive state. Phosphorylation at this residue is catalysed by kinases 
such as Csk (carboxy-terminal Src kinase). Enzyme activation is achieved when phosphatases 
such as SHP-1, SHP-2 and PTP1 dephosphorylate the SFK within the regulatory domain 
allowing unfolding of the protein and autophosphorylation of the tyrosine residue within the 
catalytic domain. Such autophosphorylation stabilizes the protein structure and allows the 
SFK to phosphorylate its target substrates. 
 
R -COOHNH2- Catalytic domainLSH2SH3USH4M
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Tyr416 Tyr527Unique
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Figure 1.7: Structure of SFKs. This figure represents the general structure of SFKs (adapted 
from Hu et al
161
). 
 
An important SFK in B lymphocytes is Lyn. This kinase can act as a positive and negative 
regulator of BCR signalling
165-166
 through its ability to phosphorylate both ITAMs and 
ITIMs
167-168
. This kinase has two isoforms resulting from alternative splicing that differ from 
each other by 20 amino-acids within the SH4 domain
169-171
. Inactive Lyn is phosphorylated 
on Y
508
 within its regulatory domain by Csk. Activation of Lyn is dependent on CD45 
mediated dephosphorylation of this tyrosine residue triggering its autophosphorylation at the 
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activating tyrosine Y
397
 within the catalytic domain
170 172
. The tyrosine phosphatases SHP-1 
and SHP-2 are involved in Lyn inactivation by mediating dephosphorylation of Y
397
. This 
occurs upon recruitment of these phosphatases to ITIM motifs within substrate proteins of 
Lyn, and is important for downregulating Lyn kinase activity
173
. 
As indicated above, Lyn is overexpressed by CLL cells, is constitutively active and cannot be 
further activated by BCR crosslinking. This constitutive activity of Lyn results in high basal 
levels of tyrosine phosphorylated proteins in CLL cells. The importance of constitutively 
active Lyn to CLL cell pathophysiology is demonstrated in experiments using the SFK 
inhibitors PP2 and SU6656; treatment of CLL cells with either of these compounds induces 
apoptosis
174
. However, these experiments do not reveal a true role for Lyn because PP2 and 
SU6656 are not just specific for Lyn and inhibit other SFKs when used at the concentrations 
reported in this study
174-175
. Attempts to address the potential role of Lyn in CLL cells have 
used geldanamycin to disrupt Lyn association with HSP90
154
. Such treatment results in 
downregulation of Lyn expression and induction of CLL cell apoptosis. However, because 
HSP90 regulates stability of other proteins that may be important to the survival of CLL cells, 
further insight into the role of Lyn is not achieved.  
CLL cells also express Fyn, Fgr, Blk and Lck SFKs. The function of these SFKs in CLL cells 
has not been well studied, but Lck is of particular interest because it, like ZAP70, is normally 
highly expressed only in T cells. Similar to Lyn and other SFKs; Lck phosphorylation has a 
major role in regulating its activity. Activation of this kinase requires dephosphorylation of 
Y
505
 in the regulatory domain, a process that is mediated by CD45 and results in unfolding of 
this protein to trigger autophosphorylation of Y
394
 in the kinase domain
176
.  Like Lyn, 
dephosphorylation of Y
394
 in Lck and phosphorylation of Y
505
 by Csk result in the 
deactivation of Lck
176-178
. Dephosphorylation of Y
394
 in Lck can be mediated by CD45
179-181
, 
SHP-1
182
 and other protein tyrosine phosphatases.  
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Unlike Lyn, Lck can be additionally phosphorylated on serine residues within the unique 
region of the N-terminus. Such additional phosphorylation has been documented in studies 
reporting a shift in the apparent molecular weight of Lck protein in Western blots
183-185
. This 
shift in the molecular weight is attributed to phosphorylation of Lck on serine residues 42 and 
59, and is mediated by PKC and by Erk, respectively
186-187
. Serine phosphorylation of Lck is 
thought to regulate its interaction with tyrosine phosphatases such as SHP-1 and prevent its 
inactivation by this phosphatase
188-189
. Another function of serine phosphorylation of Lck is 
to label this protein for ubiquitination and subsequent proteosomal degradation
190
. 
Although Lck is expressed mainly in T cells, it has been shown that this kinase is also 
expressed in normal B1 cells, as well as in CLL cells
191
.  In T cells, Lck plays an important 
role in proximal antigen receptor signalling. However, in B1 cells the role of Lck is 
controversial; one study has shown that Lck expression is responsible for peritoneal B1 cell 
hyporesponsiveness to BCR stimulation
192
, while another study has suggested that Lck 
facilitates BCR signals in these cells
193
. However, a third study has indicated that Lck does 
not play any role in BCR signalling in B1 cells
194
. In CLL cells Lck may contribute to 
glucocorticoid resistance as has been suggested in one study
195
. This contribution may be 
independent of BCR signalling because Lck expression levels in CLL cells do not correlate 
with ZAP70 levels, the principle substrate of Lck in T cells
196
. Lck in CLL cells may be 
important for downregulating BCR signals because this kinase can phosphorylate ITIMs 
within CD5 in T cells to result in downregulation of T cell receptor signalling. However, a 
role for Lck has not been defined with respect to BCR signalling or otherwise in CLL cells or 
in B1 cells.  
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1.7.4.2. The role of PKCβ in CLL 
The differences between CLL cell and normal B cell response to BCR crosslinking could also 
be explained by differences in the level of expression of protein kinase C (PKC). This 
protein functions to regulate the activation of IKK and deactivation of Btk during BCR 
stimulation. Previous work in this Department has shown that PKCβII is overexpressed in 
CLL cells compared to normal peripheral B cells. Furthermore, this study also showed that 
PKC activity correlates inversely with the ability of CLL cells to respond to BCR 
crosslinking, most likely through its ability to phosphorylate and deactivate Btk
197
. Another B 
cell malignancy where the malignant cells overexpress PKCβII is the subset of diffuse large 
B-cell lymphoma (DLBCL) that have an activated B-cell like phenotype. In these cells 
overexpressed active PKC functions to activate the NFB pathway to provide pro-survival 
signals and impart an aggressive clinical course of this disease
198-199
. However, whether 
PKCII functions in a similar capacity in CLL cells has not been addressed.  
1.7.4.3. The role of c-Abl in CLL 
The non-receptor tyrosine kinase c-Abl may also be important for BCR signalling in CLL 
cells. This kinase is heterogeneously expressed in CLL cells, and it has been reported that the 
levels of c-Abl protein expression are higher in CLL B lymphocytes than in normal 
peripheral blood B lymphocytes. Moreover, there is a positive correlation between the 
expression level of c-Abl and tumour burden, and a negative correlation between c-Abl and 
IgHV mutation
200
. This kinase has a variety of functions within the cell, including cell 
adhesion, regulation of cytoskeletal reorganisation, survival, response to DNA damage, 
oxidative stress, and growth factor stimulation. c-Abl is thought to play an important role in 
normal B cell development
200-205
, where it acts to phosphorylate CD19, a BCR co-receptor,  
under conditions of antigen receptor stimulation. This notion is supported by experiments 
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showing that BCR engagement in c-Abl deficient B-cells leads to defective activation of 
these cells
200 204 206
, and by observations that c-Abl protein levels and activity are elevated 
following BCR crosslinking in some B cell lines
206
. The role c-Abl plays in this context may 
be in relation to activation of the NFB pathway. Work in this Department has demonstrated 
a connection between c-Abl and activation of NFB200, and has further demonstrated that this 
contributes to CLL cell survival by modulating Mcl-1 expression through a mechanism 
involving the release of IL6 and stimulation of STAT3
207
. Whether c-Abl functions in CLL 
cells in relation to BCR engagement has not been investigated.  
 
1.7.5. Negative regulation of BCR signalling 
BCR signalling is modulated by inhibitory co-receptors including CD22, FcγRIIB and CD72, 
and in the B1 subset also CD5. These cell surface molecules play a key role in determining 
the intensity and duration of BCR signals. The cytoplasmic tails of these cell surface antigens 
contain ITIMs, which are targets of Lyn following BCR stimulation
208-211
. Phosphorylated 
ITIMs, in turn, recruit inhibitory phosphatases such as SH2 domain containing tyrosine 
phosphatase-1(SHP-1), SH2 domain-containing phosphatidyl 5-phosphatase-1 and -2 (SHIP-
1 and -2), and protein tyrosine phosphatase nonreceptor type 22 (PTPN22) to the BCR 
complex. This leads to downregulation of BCR signals through their ability to deactivate Lyn 
and PI3K signalling
168 212
. Absence of these regulatory mechanisms results in uncontrolled 
activation of the BCR and can lead to the development of autoimmune diseases and B cell 
malignancies
102
. Figure 1.8 shows an illustration of the BCR and these cell surface proteins. 
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Figure 1.8: B-cell receptor signalling in CLL. negative and positive co-receptors (adapted 
from Stevenson et al
212
). 
 
1.7.5.1. CD5 
CD5 is a 67-kDa type I trans-membrane glycoprotein with three scavenger receptor cysteine-
rich (SRCR) domains within its extracellular region
213-214
.  The cytoplasmic tail of CD5 
contains ITAM- like and ITIM-like sequences
215-216
. This protein is mapped to position 
11q12.2 in the human genome
217
. Normally this protein is expressed on T cells and on the 
B1a subset of B lymphocytes 
20
. 
B1a cells differ from B2 lymphocytes in their response to BCR crosslinking. Whereas B2 
cells proliferate in response to BCR crosslinking, stimulation of the BCR on B1 cells results 
in induction of apoptosis. The role of CD5 in regulating BCR signalling in B1 cells was 
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demonstrated using B1 cells from CD5 deficient mice; BCR crosslinking on these cells 
provided resistance to apoptosis and induced entry into the cell cycle. Thus, the role of CD5 
on B1 cells is as a negative regulator of BCR signalling
218
. That it is a target of Lyn was 
shown in a different study that demonstrated that BCR ligation on B1a cells from Lyn
-/-
 mice 
induced cell proliferation
219
. The role of CD5 in downregulating antigen receptor signalling 
on B1 cells is consistent with its function on T cells where it acts as a negative regulator of 
TCR signalling
220
. Experiments using CD5 knockout mice demonstrated that T cells from 
these mice display increased proliferation, release of intracellular Ca
2+
 stores and in tyrosine 
phosphorylation of PLCγ-1 and the adaptor molecule Linker Activator for T-Cells (LAT) in 
response to antigen receptor stimulation
220
. In T cells CD5 is a substrate of Lck
221
.  
The inhibitory role of CD5 in antigen receptor signalling in B and T cells is dependent on the 
recruitment of SHP1 to the antigen receptor complex
211
. Upon binding the phospho-tyrosine 
residue within the ITIM of CD5 via its SH2 domain, SHP1 undergoes conformational change 
to activate its phosphatase activity. Activated SHP1 then dephosphorylates the ITAM 
elements within the antigen receptor complex as well as the SFKs involved in their 
phosphorylation. This leads to termination of antigen receptor signalling
211 222
. 
The role of CD5 in regulating BCR signalling in CLL cells is not fully understood. A study 
by Perez-Chacon et al
223
 has shown that apoptotic or viability signalling in BCR stimulated 
CLL cells was similar between control cells and cells where CD5 was dissociated from the 
BCR complex by antibody-mediated crosslinking. This study also reported that CD5 has no 
effect on the phosphor-tyrosine pattern in response to BCR ligation in these cells. This study 
concluded that the enhanced survival of CLL cells could be due to impairment of the 
inhibitory role CD5 might normally play in normal B and T cells
223
. However, this 
conclusion has been challenged by a subsequent study showing that phosphorylation of ITIM 
sequences within CD5 on CLL cells is mediated by constitutively active Lyn, and that this 
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results in the recruitment of SHP-1 to downregulate BCR signalling in these cells
224
. 
Furthermore, a study by Gary-Gouy et al
225
 demonstrated that CD5 is constitutively tyrosine-
phosphorylated in CLL cells. This study also showed that CD5 phosphorylation on B cells 
led to upregulation of many apoptosis inhibitors such as Bcl2, NFκB and TLR-9, a feature of 
CLL cells. This supported a role for CD5 activation in CLL cell survival. 
 
1.7.5.2. CD22 
CD22 is a B-cell specific transmembrane sialoglycoprotein that belongs to the sialic acid-
binding immunoglobulin-like lectin (Siglec) family of adhesion molecules
226
, with a 
molecular weight of 140 kDa. High expression of this protein is observed on all subsets of 
mature B cells, with the exception of plasma cells where CD22 levels are downregulated
168 
227-228
. Figure 1.9 shows the basic structure of this protein; the extracellular domain consists 
of seven Ig-like domains, while the cytoplasmic tail contains six tyrosine residues with three 
(Y
762
, Y
822
, and Y
842
) considered to be within ITIM motifs. The cytoplasmic tail of CD22 also 
contains two ITAM motifs, and it has been suggested that CD22 can also provide positive 
signals promoting B-cell survival
229-230
. 
 
Cytoplasmic domainExtracellular domain
Y752 Y762 Y796 Y807 Y822 Y842
 
Figure 1.9: Structure of CD22. Illustration of the structure of CD22 showing the 
extracellular and cytoplasmic domains (adapted from Fujimoto et al 
231
). 
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BCR ligation by cognate antigen results in CD22 association with the BCR complex where it 
becomes phosphorylated
232
. Tyrosine phosphorylation of CD22 requires activity of the 
tyrosine kinase Lyn; this was demonstrated by reduced CD22 phosphorylation in Lyn-
deficient mice
208 233-234
. Tyrosine phosphorylated CD22 recruits SH2-domain containing 
proteins, such as SHP-1 which dephosphorylates BCR signalling components leading to BCR 
signal termination
235
. The inter-relationship between CD22, Lyn and SHP-1 is supported by 
an in vivo study whereby sustained Lyn activation in mouse B cells was achieved using a 
targeted gain-of-function mutation (Lyn 
(up/up) 
mice)
165
. Within this model CD22 and SHP-1 
were constitutively phosphorylated, and the B cells from these mice had features reminiscent 
of B cells rendered tolerant by constitutive BCR signalling. Other studies using targeted 
disruption of CD22 expression have shown that B cells derived from these mice are 
hyperresponsive to BCR engagement
236-238
.  Phosphorylated CD22 can also recruit SHIP-1 by 
forming a quaternary complex with the adaptor proteins Grb2 and Shc, and this also results in 
reduction of BCR-induced signalling
239
. 
That CD22 could be involved in positive regulation of BCR signalling is consistent with a 
study showing that CD22 coligation with the BCR downregulates activation of the MAPK 
pathway, but separate CD22 crosslinking on its own results in upregulation of this signalling 
pathway
240
. Moreover, crosslinking of CD22 initiates a signalling cascade that leads to JNK 
activation and proliferation of tonsillar B cells
229 241
. However, the inhibitory role of CD22 
seems to be the predominant function of this protein because of the enhanced BCR signalling 
that is observed in CD22-deficient mice
227 236-238
.  
CD22 is variably expressed on the malignant cells of different B cell leukaemias and 
lymphomas. Compared to normal B cells, low expression of CD22 was detected in acute 
lymphocytic leukaemia (ALL), CLL, follicular lymphoma (FCL), and mantle cell lymphoma 
(MCL). On the other hand levels of expression were moderate in marginal zone B-cell 
36 
 
lymphoma (MZL) and high in hairy cell leukaemia (HCL)
210 242-244
. However, different 
technical variables affect measurement of CD22 expression by quantitative flow cytometry, 
and delayed processing time, shipment time of the samples and the number of cells analysed 
can all contribute to altered readings of expression
242
. The level of CD22 expression varies 
among CLL cases with lower levels of expression observed on the malignant cells from 
patients with Binet Stage C disease compared to those with stage A and B
245
. The importance 
of CD22 expression in CLL cell pathophysiology is suggested by a recent study showing that 
the interrelationship between CD22, Lyn and SHIP is overcome by overexpressed PTPN22, 
and this leads to selective upregulation of the Akt pathway and downregulation of most other 
BCR signalling pathways
246
. This is important because Akt provides prosurvival signals to 
BCR stimulated CLL cells
246-248
. 
 
1.7.5.3. FcγRIIB (CD32) 
FcγRIIB is a 40 kDa transmembrane inhibitory regulator of BCR signalling containing an 
ITIM within its cytoplasmic domain
102
. Co-crosslinking of this low affinity receptor of IgG 
with the antigen receptor on B cells occurs as a result of BCR interaction with IgG-containing 
immune complexes. This leads to dampening of BCR signalling which, in turn, results in 
reduction of cell proliferation and antibody production
249-252
. The inhibitory function of 
FcγRIIB is due to its ability to recruit SHIP to the plasma membrane when it is coligated with 
the BCR
253
. Active SHIP hydrolyses PIP3 and consequently reduces the membrane binding 
of PLCγ2, Akt, and Btk254-256. Coligation of the BCR with FcγRIIB also leads to recruitment 
of SHP1 and downregulation of BCR signals
257-259
. However, it has been reported that 
recruitment of SHP1 is not essential for FcγRIIB-mediated inhibition of BCR signalling260, 
this effect is predominantly mediated by SHIP
261
. 
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In B cells, tyrosine phosphorylation of FcγRIIB is thought to be mediated by Lyn because 
this protein is not phosphorylated in B cells from Lyn knockout mice undergoing BCR 
engagement
166-168 208
. Lyn is also required within the BCR-FcRIIB complex for the 
phosphorylation of SHIP
165
. 
FcγRIIB is variably expressed in different types of B cell lymphomas with strong expression 
levels on MCL cells, splenic marginal zone lymphomas, mucosa-associated lymphoid tissue 
(MALT) lymphomas and B-CLL/SLL. A proportion of DLBCL (20%) also express this 
coreceptor on their cell membrane, with higher levels in transformed activated B-cell like 
DLBCL than in GC-like DLBCL. The higher levels of expression were linked with poor 
prognosis in this B cell malignancy
262
. 
Levels of FcγRIIB expression have been shown to be similar or even higher in CLL 
compared to normal B cells. Unlike normal B cells, a subset of CLL was shown to express 
the activating isoforms FcγRIIA which is usually expressed on myeloid cells262-264. However, 
functional studies have indicated that only FcγRIIB is biologically functional in CLL cells264.  
 
1.7.5.4. CD72 (Lyb-2) 
CD72 is a 45kDa transmembrane protein mainly expressed on B cells. The extracellular part 
of this protein contains a C-type lectin-like domain. On its cytoplasmic tail, CD72 carries an 
ITIM and an ITIM-like domain. This co-receptor is involved in modulating BCR signals
265-
267
, and engagement of the BCR results in phosphorylation of the ITIM and ITIM-like 
sequences of CD72. In vitro studies showed that this phosphorylation is mediated by Lyn
265
. 
Phosphorylation of CD72 results in the recruitment of SHP1 and consequent attenuation of 
BCR signalling
265-268
. Hyper-responsiveness and increased intracellular Ca
2+
 is observed in 
BCR-ligated B cells from CD72 knockout mice
269
, supporting the negative role of this 
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receptor in BCR-signalling. However, crosslinking of CD72 with antibody provides pro-
survival signals and promotes proliferation of BCR-stimulated B cells
270-271
, but this effect is 
thought to be due to sequestration of CD72 from the BCR signalosome so that SHP1 is no 
longer recruited
272
. CD72 has been reported to be expressed in different B cell malignancies 
including CLL
273
. However, its role in regulating BCR signalling in CLL cells is not fully 
characterised. One study reported that CD38-mediated signals upregulate expression of 
CD100 in a subset of CLL cells resulting in simultaneous down-modulation of CD72 
eventually leading to increased survival and proliferation of these cells
274
. 
1.8. Aims of the thesis 
Previous work to this thesis showed that CLL cells overexpress PKCII197 and c-Abl200. Both 
of these kinases have roles in activating the NFB pathway, an important pathway providing 
pro-survival signalling to CLL cells. In particular, PKCII has a role in mediating NFB 
pathway activation in response to BCR engagement in normal B cells. Considering the 
importance of the BCR in providing pro-survival signals to CLL cells, the initial aim of this 
thesis was to characterise any potential role of PKCII and c-Abl in BCR-mediated activation 
of the NFB pathway. We found that neither of these protein kinases was responsible for 
BCR-induced NFB pathway activation. However, our results suggested the involvement of 
another SFK, Lck. Thus, the remaining aims of this thesis were to fully characterise the role 
of Lck in BCR-mediated signalling in CLL cells, and determine its pathophysiological 
importance. 
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Chapter 2: Materials and methods 
2.1. Materials 
2.1.1. Reagents, kits and cell lines 
Nuclear extract kit and TransAM
TM
 NFB P65 activation assay (ELISA) were purchased 
from Active Motif (Rixensart, Belgium). ECL Advance Western blotting kits were from GE 
Healthcare Lifesciences (Buckinghamshire, UK). Protein G sepharose was from GE 
Healthcare (Buchinghamshire, UK). The CLL cell line MEC1 was from Leibniz Institute 
DSMZ-German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). 
The mouse B cell lymphoma line A20 was from American Type Culture Collection (LGC 
Standards, Middlesex, UK), N-Ethylmaleimide (NEM) was from Sigma-Aldrich (Gillingham, 
UK).  
2.1.2. Antibodies 
Mouse anti-pAkt (phospho-serine 473) (cat.# 4051) , rabbit anti-Akt (cat.#9272), rabbit anti-
pCD79a (tyrosine 182) (cat.#5173), rabbit anti-CD79a (cat.#3351),  mouse anti-pIκBα (serine 
32/36), rabbit anti-pSrc(tyrosine 416) (cat#2101), rabbit anti-Src (cat.#2123), rabbit anti-
pGSK3α/β (serine 21/9) (cat.#9331), rabbit anti-pCrKL (tyrosine 207) (cat.#3181), rabbit 
anti-Lck (cat.#2787), mouse anti-ubiquitin (P4D1) and rabbit anti-pIKK (serine 180)/ 
pIKK(serine181) (cat#2681) antibodies were purchased from Cell Signaling Technology 
(New England Biolabs, Hertfordshire, UK). Mouse anti-IKK (B-8), mouse anti-
IKK, mouse anti-Bcl-10 (331.3), mouse anti-MALT-1 (B-12), rabbit anti-CrKL, 
mouse anti-Lck (3A5), mouse anti-Lyn (H-6), mouse anti-Fyn (FYN3), mouse anti-Fgr (B-8), 
mouse anti-Yes (C-10), mouse anti-Hck (G-4), mouse anti-Src (H-12), mouse anti-pERK (E-
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4), rabbit anti-ERK (K-23), rabbit anti-IBα, mouse anti-CD5 (UCH-T2),  rabbit anti-
CD5(H-300), goat anti-CD5 (C-18), rabbit anti-CD22 (H-221), mouse anti-CD22 (MYG13), 
mouse anti-IKKγ (46B844), mouse anti-IKKγ(B-3), and horseradish peroxidase-conjugated 
goat anti-mouse and goat anti-rabbit antibodies were from Santa Cruz Biotechnology (Insight 
Biotechnology, Wembley, UK). Rabbit polyclonal anti-CARMA-1(AL220) antibodies were 
from Alexis Biochemicals (Exeter, UK). Mouse monoclonal anti- Actin antibody was from 
Sigma-Aldrich (Dorset, UK). Mouse anti-GSK3β was from BD Bioscience (Oxford, UK). 
Anti-phosphotyrosine (4G10) HRP conjugate, and anti-pCD22 (tyrosine 822) (cat. #04-458) 
was from Millipore (Dundee, UK). Anti-phosphotyrosine antibody (PY20) purchased from 
ICN Biomedicals (Ohio, U.S.A). 
2.1.3. Stimuli and inhibitors 
 F(ab’)2 fragments of goat anti-human IgM antibodies were purchased from Jackson Immuno-
Research Laboratories (Stratech Scientific Limited, Newmarket, UK). The specific 
PKCinhibitor LY379196 was kindly provided by Eli Lilly research laboratories 
(Indianapolis IN, USA). The c-Abl inhibitor Imatinib was purchased from LC Laboratories 
(Woburn, USA). The TAK1 inhibitor (9-Epimer-11, 12-dihydro-(5Z)-7-Oxozeaenol, known 
as antibiotic L-783,277) was purchased from AnalytiCon (Potsdam, Germany), and 
Bisdindolylmaleimide I, LFM-A13, mpV(pic) and the Lck inhibitor (4-amino-5-(4-
phenoxyphenyl)-7H-pyrrolo[3,2-d]pyrimidin-7-yl-cyclopentane (Lck-i))were from 
Calbiochem (Nottingham, UK). All inhibitors were dissolved in DMSO, aliquoted and stored 
at -20°C. 
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2.2. Methods 
2.2.1. Cell isolation and culture 
Peripheral blood samples were obtained from patients previously diagnosed with CLL after 
giving informed consent and with the approval of the Liverpool Research Ethics committee 
(LREC). Heparinised peripheral blood was overlayed carefully on to 15 ml of Lymphoprep
TM
 
(Alis-Shield PoC AS, Oslo, Norway) and then centrifuged at 800xg for 30 min at room 
temperature. The mononuclear cells were then carefully aspirated from the interface layer and 
washed in PBS and slowly resuspended in a 4ºC solution of RPMI 1640 (Sigma-Aldrich, 
Gillingham, UK) /10% foetal calf serum (FCS; Biosera, Ringmer, UK) /10% DMSO (Sigma-
Aldrich). Aliquots of 1ml were then transferred to cryotubes (Nuncbrand, Fisher Scientific, 
Loughborough, UK) and frozen at -80ºC for one week and then finally cryopreserved in 
liquid nitrogen. Normal cells were obtained from buffy coat preparations (British Blood 
Transfusion Service, Liverpool, UK) and prepared as above. 
2.2.2. Thawing of cryopreserved cells 
Cryopreserved CLL and buffy coat samples were taken from the University of Liverpool 
Leukaemia Bank. Cell suspensions were thawed in a 37ºC water bath, and then transferred 
into pre-chilled 25ml universals. Ice cold RPMI 1640 (supplemented with 2mM L-
Glutamine, 100 units/ml penicillin/streptomycin and 0.5%BSA) was added to the cell 
suspensions dropwise until a final volume of 10ml was reached. The suspensions were 
centrifuged at 500xg for 5 minutes at 4ºC, the supernatant was discarded and the cells were 
washed with 10 ml fresh media, and finally resuspended in the culture media. The 
viable/dead cells were counted using trypan blue solution and a Nexcelom Bioscience 
cellometer Auto T4 (Peqlab Ltd, Hampshire, UK). In general, CLL cases with viable cells 
exceeding 75% of the total cell count were used in further experiments. 
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2.2.3. Purification of normal B cells 
Using the B Cell Isolation kit II (MACS, Miltenyi Biotec, Surry, UK) human B cells were 
isolated by depletion of non- B cells (negative selection). The normal cells (obtained in 2.2.2) 
were washed with ice cold purification buffer (PBS with 0.1% BSA and 2mM EDTA), and at 
the final step the cell pellet was resuspended in 40µl purification buffer per 10
7
 cells. An 
antibody cocktail consisting of biotin conjugated monoclonal antibodies against CD2, CD14, 
CD16, CD36, CD43, and CD235a was added to the suspension using 10 µl antibody solution 
per 10
7
cells. This mixture was incubated for 10 min at 4ºC with agitation from time to time. 
This was followed by the addition of purification buffer to a final volume of 5 ml. The 
suspension was centrifuged at 500xg for 5 min at 4ºC, and the cell pellet was washed again 
with 5 ml purification buffer. Next, the cell pellet was resuspended in 30µl/10
7
 cells of the 
purification buffer, and Anti-Biotin MicroBeads were added at a concentration of 20µl bead 
suspension/10
7
 cells. This mixture was incubated for 15 min at 4ºC, and the cells were then 
washed twice with 5ml of the purification buffer. The final cell pellet was resuspended in 
400µl purification buffer /10
7 
cells and then passed through an appropriately sized MACS 
separation column that had been prewashed with purification buffer and located in a magnetic 
field. The column was washed three times with purification buffer. Purified B cells were 
collected in the eluant, while non-B cells remained bound to the column of Anti-Biotin 
MicroBeads. The purity of the purified B cells was checked using flow cytometry and CD19 
staining. In general, B cells treated in this way attained a purity that was greater than 90%. 
2.2.4. Purification of CLL cells 
CLL cells were also negatively purified. After thawing and counting CLL cells as described 
in 2.2.2, the cell pellet was resuspended in 400µl of the purification buffer and transferred 
into a microcentrifuge tube and centrifuged again. The cells were then resuspended in 40 µl 
of purification buffer per 10
7
 cells. 20µl per 10
7
 cells each of FITC-conjugated anti-CD3 , -
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CD14, and -CD16 antibodies (which bind to T cells, NK cells, monocytes and macrophages) 
(BD Biosciences, Oxford, UK) were added to the suspensions and incubated for 20 min at 
4ºC with mixing every 5 minutes. The suspensions were then centrifuged and washed in 
200µl of purification buffer. The pellet was then resuspended in 80 µl of purification buffer 
per 10
7
 cells. 20µl per 10
7
cells of Anti-FITC MicroBeads (MACS, Miltenyi Biotec, Surry, 
UK) was added to the suspensions and the mixture was incubated for 20 min at 4ºC with 
agitation every 5 min. After that the suspension was centrifuged and the pellet was washed in 
200µl of purification buffer. The cell pellet was resuspended in 40µl of the purification buffer 
and the suspension was then passed through a prepared MACS separation column prewashed 
with the purification buffer and located in a magnetic field. After leaving the cells in the 
column for 30 sec, the column was washed three times with the purification buffer. Purified 
CLL cells were collected in the eluant and contaminating cells remained with the column. 
CLL cell purity was checked using flow cytometry and CD5 / CD19 staining (as detailed 
below). In general, CLL cells treated in this way attained a purity that was greater than 90%. 
2.2.5. Flow cytometry 
Flow cytometry was used to determine the purity of the normal B and CLL cells from the 
above procedure (section 2.2.4). This was done using a Becton Dickinson FACSCalibur 
machine and FITC-labelled anti- CD19 for normal B cells, or anti-CD5/CD19 antibodies for 
CLL cells. A FITC-labelled non-specific IgG was used as a control. All the antibodies used in 
this section came from BD Biosciences (BD, Oxford, UK). The staining procedure involved 
incubation of 1x10
6
 cells with 10µg/ml final concentration of antibody for 30 minutes on ice, 
in the dark. The cells were then centrifuged at 500xg for 5 minutes at 4 ºC and washed twice 
using 500µl modified PBS (supplemented with 1%BSA and 0.1% sodium azide, pH7.2). 
Cells were finally resuspended in 100µl PBS to which 100µl FACS flow (BD biosciences) 
was added. This sample was then analysed by flow cytometric analysis. 
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For CD22 expression measurement, the cells were stained with FITC-conjugated anti-CD5, 
APC-conjugated anti-CD20 and PE-conjugated anti-CD22 (BD, Oxford, UK) prior to flow 
cytometric analysis. 
For quantification of Lck and ZAP70 expression: 5x10
6 
CLL cells were first incubated with 
FITC-conjugated anti-CD5 and APC-conjugated anti-CD20 mAbs. The cells were then 
washed times with 300µl modified PBS, fixed with the addition of 100µl 4% 
paraformaldehyde for 15min in the dark. These cells were washed 3 times with 300µl 
modified PBS, and they were then permeabilised with 1 ml of ethanol that had been cooled to 
-20C. This suspension was further incubated at -20C for 30 mins, and the cells were then 
washed 3 times with 300µl modified PBS. The final cell pellet was resuspended in 200µl 
modified PBS and incubated with a 1/20 dilution of either PE-conjugated anti-Lck (Santa 
Cruz, clone SPM413) or PE-conjugated anti-ZAP70 (Invitrogen, clone 1E7.2) for 30 mins at 
4ºC, in the dark. The stained cells were then washed with modified PBS and analysed by flow 
cytometry. CLL cells were gated as CD5
+
/CD20
+
 cells. 
2.2.6. Culturing CLL cells 
When required, suspensions of 1×10
7 
cells per ml were cultured under 5%CO2 at 37ºC for the 
required period of time. The culture medium used was RPMI 1640 supplemented with L-
glutamine (2mM), 100 units/ml penicillin/streptomycin, and BSA (0.5%). Cell suspensions 
were cultured in 24-well tissue culture plates that had been coated with polyHEMA to avoid 
cell adhesion. 
2.2.7. Preparation of cell lysates 
Cryopreserved CLL cells were thawed and 1×10
7 
cells were washed in PBS. The cell pellet 
following the final wash was lysed with 200l of lysis buffer (125mM Tris pH6.8, 5mM 
EDTA, 1% SDS). The lysates were sonicated to disrupt released DNA, incubated at 95ºC for 
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5-10 minutes and then centrifuged at 12,000xg for 5 minutes. The supernatant was transferred 
into a clean microtube and protein concentration was determined as outlined below in section 
2.2.8. The lysates were stored at -20ºC until needed for further use. 
2.2.8. Protein determination 
The protein concentration in lysates (as prepared in 2.2.7) was determined using a Bio-Rad 
DC protein assay kit (Hertfordshire, UK). The procedure followed was according to the 
instructions provided by the manufacturer. 
2.2.9. SDS-PAGE and Western blotting 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis was used to separate proteins in 
cell lysates. In general, 10µg of total protein was loaded per lane of gel. The separated 
proteins were then electroblotted to Immobilon
TM
 Transfer Membranes (Millipore, Fisher 
Scientific UK Ltd, Loughborough, UK). Membranes were blocked with blocking buffer 
(2.5% ECL advance blocking reagent in TBS-T (150mM NaCl, 25 mM Tris pH 7.5, 0.1% 
Tween 20)) for an hour to avoid non-specific binding between the membranes and antibodies. 
The membranes were then probed with the primary antibodies diluted with blocking buffer 
overnight at 4 ºC with gentle agitation. After that the membranes were washed with TBS-T 4 
times, and then incubated with horseradish peroxidase (HRP)-conjugated secondary 
antibodies (1/5000) in blocking buffer for 1 hour at room temperature. Following a final wash 
cycle of TBS-T x 4 the membranes were developed with ECL-advance Western Blotting 
Detection reagents. Chemiluminescence was read using a Fujifilm LAS-1000. 
Equal protein loading was validated by probing the blots with anti β-Actin antibodies used at 
a 1/10000 dilution. In the cases where protein phosphorylation was measured, protein loading 
was assessed using antibodies against the total protein. 
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2.2.10. Nuclear NFB quantification 
2.2.10.1 .Thawing and culturing the cells 
Cryopreserved CLL samples were thawed and cultured as in 2.2.2 and 2.2.6. 
2.2.10.2. Preparation of nuclear extracts 
Each sample (1×10
7
cells) was washed twice with 1 ml of ice cold PBS/Phosphatase inhibitors 
provided in the nuclear extract kit (Active Motif, Rixensart, Belgium). The pellets were then 
resuspended gently in 500 µl of 1× hypotonic buffer and incubated on ice for 15 minutes. 25 
µl of the detergent solution was added to the suspension and the mixture was vortexed for 10 
seconds at the highest setting. The cell suspensions were centrifuged for 30 sec at 14,000xg at 
4ºC in a pre-cooled microcentrifuge. Supernatant (cytoplasmic fraction) was transferred into 
a fresh microcentrifuge tube and stored at -80 ºC until required for further use. The pellets 
(containing the cell nucleus) were washed with PBS containing phosphatase inhibitors, and 
resuspended in 50 µl complete lysis buffer. This mixture was then vortexed for 10 sec at the 
highest setting, incubated for 30 min at 4 ºC on a rocking platform and subjected to a second 
vortexing step (30 sec at highest setting). To obtain nuclear extract the suspension was 
centrifuged at 14,000xg for 10 min at 4 ºC, and the supernatant taken and stored at -80ºC 
before it was used in the next step. 
2.2.10.3. Protein determination 
A BioRad RC DC protein assay kit was used for protein quantification.  
2.2.10.4. Quantification of NFB in the nuclear extract by ELISA 
NFB activation in CLL cell nuclear extracts was measured using a TransAM NFB ELISA 
kit (Active Motif, Rixensart, Belgium). The procedure followed was according to the 
manufacturer’s instructions. 
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2.2.11. SFK Immunoprecipitation 
CLL cell lysates were prepared by incubating 1x10
7
 CLL cells with 300μL modified 
radioimmunoprecipitation assay (RIPA) buffer (50mM Tris, pH 7.4, 1% Triton X-100, 10% 
glycerol, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 150mM NaCl, 50mM 
sodium fluoride, 25mM sodium pyrophosphate, 50mM sodium glycerophosphate, 2mM 
EDTA, and 2mM EGTA). After sonication for 10 seconds, cell lysates were centrifuged at 
14000xg for 20 minutes. Then 250μL of the supernatant was incubated overnight at 4°C with 
2 μg of anti-SFK antibody (either Lyn, Lck, Fyn, or Fgr). The immunocomplexes were 
precipitated onto 25μL Protein G Sepharose (GE Healthcare, Buchinghamshire, UK) for 1h, 
and these complexes were washed 3 times with RIPA buffer. To release the protein of interest 
from its immunocomplex. Laemelli buffer (2x) was added to the immunocomplexes, and then 
heated them for 10 minutes at 95°C. Protein and protein G sepharose were then separated by 
centrifugation at 14000xg for 1 minute. The supernatant was applied to a SDS-PAGE gel, and 
following transfer of the separated proteins to immobilon, Western blotted using an 
appropriate antibody.  
2.2.12. CD5 immunoprecipitation 
For CD5 general tyrosine phosphorylation, CD5 was immunoprecipitated from lysates of 
3x10
7
 CLL cells. Lysis was achieved using RIPA buffer (as detailed in methods section 
2.2.11) and CD5 immunoprecipitated using 10μL of the CD5 antibody (clone UCH-T2). 
Tyrosine phosphorylation of CD5 was determined by probing Western blots of 
immunoprecipitated CD5 with either anti-phosphotyrosine 4G10 or PY20 antibodies. 
2.2.13. CD22 immunoprecipitation 
For CD22 immunoprecipitation CLL cases that we determined to have high expression of this 
protein were used. Immunoprecipitation was done as described above in sections 2.2.11 and 
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2.2.12. However, for this experiment 1x10
7
 CLL cells were used, and CD22 
immunoprecipitated from RIPA-lysed cells with 10μL rabbit polyclonal anti-CD22. General 
tyrosine phosphorylation of CD22 was measured by probing the Western blots with anti-
phosphotyrosine 4G10 HRP conjugated antibody. 
2.2.14. Studies of IKKγ Ubiquitination 
For measurement of IKKγ ubiquitination, 2x107 CLL cells (or 5x106 A20 cells) were lysed in 
300μL modified RIPA buffer supplemented with 10mM N-Ethylmaleimide and briefly 
sonicated for 10 seconds. Following centrifugation at 14000xg and 4°C for 20 minutes, 
250μL of the supernatant was incubated overnight at 4°C with 25μL of agarose conjugated 
anti- IKKγ (FL-419). The immunocomplexes were then washed three times. The protein was 
released from the immunocomplexes, separated by SDS-PAGE and ubiquitination was 
detected by Western blotting using the anti-ubiquitin antibody (P4D1).  
2.2.15. Cell surface protein isolation and analysis of sIgM 
Cell surface proteins were isolated using Pierce Cell Surface Protein Isolation Kit (Pierce, 
Loughborough, UK). 5x10
7
 CLL cells were incubated in 0.5mg/mL Sulfo-NHS-SS-Biotin 
solution in PBS at 4 C in a T25 cm2 flask on a rocking platform. After 30 minutes the 
reaction was ended by adding 500µL Quenching solution (from the kit) to each flask. The 
suspension was then transferred into 50mL conical tubes, and centrifuged at 500xg for 3 
minutes. The cells were additionally washed once with TBS. The cells were then lysed by 
sonication in Lysis Buffer with protease inhibitors (from the kit). The cell lysates were 
incubated on ice for 30 minutes, vortexed for 5 seconds every 5 minutes, then centrifuged at 
12000xg for 2 minutes. Separation columns were prepared by adding 500µL NeutrAvidin™ 
Agarose into the column and washing it twice with 500µL of Wash Buffer. Clarified cell 
lysate was then added to the gel and incubated at room temperature for 60 minutes with end-
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over-end mixing using a rotator. The NeutrAvidin™ gel was then washed 4 times in Wash 
Buffer. Biotinylated proteins were eluted by boiling in 200µL SDS-PAGE Sample buffer 
supplemented with dithiothreitol (DTT) for 5 minutes at 95C. A trace of bromophenol blue 
was added to the eluate and proteins were resolved by SDS-PAGE.  Surface IgM was 
detected by Western blotting using goat anti-human IgM. 
2.2.16. Transfection of CD5 into the MEC1 cell line 
Full length CD5 and a truncated version of CD5 that lacked the cytoplasmic tail were 
subcloned into pEGFP-N1 (Clonetech, Saint-Germain-en-Laye, France) (Figure 2.2) to create 
CD5-EGFP and truncated CD5-EGFP. These constructs were kindly provided by Dr. Mark 
Glenn of this Department. To transfect the plasmids into MEC1 cells, after washing 2X with 
PBS 2x10
6
 cells were resuspended in 100µl nucleofector solution V (Amaxa® Cell Line 
Nucleofector® Kit V, Lonza Biologics plc, Tewkesbury UK). 2 µg of pCD5-EGFP or 
ptruncatedCD5-EGFP was added to the cell suspension. The mixture was then transferred 
into the chamber and programme X001 was used to initiate transfection (transfection by 
electroporation). 500µl DMEM was then added to the mixture and this was transferred into 
1.5 ml prewarmed complete DMEM (37C). The average post-transfection viability was 
80%. The cell suspension was then incubated overnight at 37 C using standard culture 
conditions. Analysis of GFP and CD5 expression was performed by flow cytometry. GFP 
expression was detected using the detector for FITC on the flow cytometer, whereas surface 
expression of CD5 was detected using a PE-conjugated CD5 antibody. 
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Figure 2.1: General structure of plasmid pEGFP-N1 
 
CD5 full length CD5 truncated
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A B
 
Figure 2.2: Expression of GFP and CD5 in transfected MEC1 cells.  MEC1 cells were 
transiently transfected using A) CD5-EGFP and B) truncated CD5-EGFP. After overnight 
incubation at 37ºC GFP expression was detected using the detector for FITC on the flow 
cytometer and surface expression of CD5 was detected using a PE-conjugated CD5 antibody. 
Transfection efficiency is 82% and 83%, respectively. 
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2.2.17. Nucleofection 
 Nucleofection of CLL cells was carried out according to established protocol
207
. Briefly, 
1x10
7
 CLL cells were transfected using the Amaxa solution V transfection kit according to 
the manufacturer’s instructions (Lonza Biologics plc, Tewkesbury UK). CLL cell 
suspensions were briefly incubated with no siRNA, or with 2µM of either non-specific 
control siRNA or siRNA targeting Lck prior to using and program U13 to initiate 
transfection. Following transfection CLL cells were cultured in polyHEMA-coated plates for 
48h prior to use. Transfected CLL cells were then harvested and divided into unstimulated 
and BCR stimulated cells. BCR stimulation was achieved by incubating CLL cells with 
20µg/ml F(ab’)2 anti-IgM for 15min. 
2.2.18. CLL cell viability assay 
5 x10
6
 CLL cells/ml were cultured for 3 days with RPMI 1640 supplemented with 0.5% 
BSA, L-glutamine and streptomycin in polyHEMA-coated plates. Cell viability was assessed 
by flow cytometry using DiOC6 to measure mitochondrial integrity and propidium iodide 
(PI) incorporation (as a measure of dead cells) according to established protocol
197
. Cell 
viability was determined by taking an aliquot of cell suspension and measuring the number of 
DiOC6bright/PIdim events (live cells) counted during a fixed time setting of 30 seconds 
where the flow cytometer (FACSCalibur™) was set to medium flow. 
2.2.19. Statistical analysis 
Data were analysed for statistical significance using Student’s t-test or Mann-Whitney U-test 
as indicated in Figure legends. The analysis was performed by computer using either 
Microsoft Excel™ or SPSS™ 17.0 software, respectively.
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Chapter 3: BCR- induced NFκB activation in CLL cells 
3.1. Introduction 
NFB transcription factors play an important role in B cell development, proliferation, 
immune responses, and survival
275-276
. BCR stimulation triggers NFκB activation through the 
canonical pathway
137 275
. In this pathway BCR crosslinking leads to phosphorylation and 
activation of the IKK complex. TAK1is thought to play a role in this pathway by 
phosphorylating IKK. Once activated, the IKK complex phosphorylates IB leading to its 
ubiquitination and subsequent proteosomal degradation. This releases NFB and allows it to 
translocate into the cell nucleus
134
. Figure (3.1) summarises this signalling pathway in normal 
B cells. 
The critical role of the NF-κB pathway in CLL pathogenesis has been confirmed by 
transgenic mouse models
277-278. NFκB seems to be aberrantly activated in CLL cells 
compared to normal B cells
158
. However, the mechanism of activation in CLL is still unclear. 
Targeting BCR-induced activation of NFκB pathway could be a potential strategy for CLL 
treatment. Thus, the aim of this chapter is to investigate the mechanism of BCR-induced 
NFκB signalling in CLL cells and characterise the elements involved in this pathway 
upstream of NFκB 
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Figure 3.1: BCR-induced NFκB pathway in normal B cells. Illustration of the canonical 
pathway of NFκB activation triggered by stimulation of BCR. 
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3.2. Results 
3.2.1. The role of Protein kinase C beta (PKCβ) in BCR-induced IKK 
phosphorylation in CLL cells 
PKCβ is a key mediator of BCR signalling to the NFB pathway where it plays an important 
role in stimulating IKK activation
36 279-281
. This is underscored by observations of constitutive 
NFκB activation in some B cell malignancies such as diffuse large B cell lymphoma 
(DLBCL) and mantle cell lymphoma (MCL). Here, overexpressed PKC in the malignant 
cells mediates tonic BCR signals that contribute to their survival and proliferation
282-284
. 
Thus, apoptosis can be induced in DLBCL and MCL cells by inhibition of IKK activation 
using PKCβ-specific inhibitors such as LY379196, LY333531 (ruboxistaurin) and LY317615 
(enzastaurin)
281 285
.  
Work in this Department has shown that CLL cells overexpress PKCII197, and we reasoned 
that this overexpression could facilitate NFB pathway activation in these cells, particularly 
when they experience BCR engagement. Figure 3.2 A shows that IKK can be activated when 
CLL cells are incubated with F(ab')2 fragments of anti-IgM antibody (to crosslink the BCR). 
To investigate the role of PKC within this process, CLL cells were pre-treated with either a 
PKC-specific inhibitor (LY379196), or a more general PKC inhibitor (Bisindolylmaleimide 
I). However, neither of these compounds affected BCR-induced IKK activation in the CLL 
cells tested. This is despite the fact that these compounds were used at concentrations 
exceeding the amounts needed for their PKC specific effects, and is exemplified by the 
ability of these compounds to inhibit BCR-induced phosphorylation of GSK3 and  (Figure 
3.2B). These results suggest that PKC is not involved in IKK activation resulting from BCR 
crosslinking on CLL cells. 
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Figure 3.2: Effect of PKCβ inhibitors on (A) IKK phosphorylation and (B) GSK3 
phosphorylation in CLL cells. CLL cells were treated with 2M LY379196 or with 5M 
Bisindolylmaleimide for 2 hours at 37ºC, and then BCR was stimulated with 20g/mL 
F(ab’)2 goat anti-human IgM for 15 minutes. The cellular lysates were analyzed by Western 
blot analysis for pIKKα/β (ser 180/181) or pGSKα/β (serine 21/9) antibody, and then for total 
IKKα/β or GSKβ in parts A and B, respectively MW: molecular weight ladder. 
MW 
MW 
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3.2.2. Expression of the CBM (CARMA-1, MALT-1 and Bcl-10) complex in 
CLL cells 
To further characterize BCR-induced IKK activation in CLL cells, we investigated the 
proteins forming the signalosome that transmits the signal from PKCβ to IKK. In B cells, 
antigen receptor stimulation of the NFκB pathway is achieved when PKC phosphorylates 
CARMA-1 of the CARMA-1 – Bcl-10 – MALT-1 (CBM) complex. When CARMA-1 is 
phosphorylated by PKC, it is then able to recruit MALT-1 and Bcl-10 which ubiquitinate 
IKK and recruit TAK1 resulting in phosphorylation and activation of IKKI 
analyzed the expression levels of the CBM complex in CLL cells and compared these levels 
with those in peripheral B cells.  We found that MALT-1 levels are approximately equal 
between CLL and normal B cells (Figure 3.3B). However, CARMA-1 is expressed in 2-fold 
excess in CLL over normal B cells (Figure 3.3A). Importantly, Bcl-10 is expressed in CLL 
cells at an eighth of the level it is expressed in normal B cells (Figure 3.3C). It has been 
reported that CARMA-1, MALT-1 and Bcl-10 must exist in a 1:1:1 stoichiometry in order for 
efficient antigen receptor signalling to the NFB pathway to take place288-290. The results of 
the present section indicate that this is not the case in CLL cells and suggest that this pathway 
is likely independent of the CBM complex.  
57 
 
C
A
R
M
A
1
 /
 
-a
c
ti
n
R
a
ti
o
(a
rb
it
ra
ry
 u
n
it
s
)
n=5 n=3
CARMA 1
 Actin
CLL
MALT 1
 Actin
CLL
Bcl-10
 Actin
n=5 n=3
B
c
l1
0
 /
 
-a
c
ti
n
R
a
ti
o
(a
rb
it
ra
ry
 u
n
it
s
)
CLL
M
A
L
T
-1
 / 

-a
c
ti
n
R
a
ti
o
(a
rb
it
ra
ry
 u
n
it
s
)
n=5 n=3
A
B
C
37kD
37kD
50kD
100kD
150kD
37kD
50kD
37kD
50kD
75kD
100kD
 
Figure 3.3: Analysis of CBM complex components in CLL compared to normal B cells. 
Western blot analysis of CLL cell lysates for (A) CARMA-1, (B) MALT-1 and (C) Bcl-10 
expression in CLL compared to normal B cells. Equal protein amounts were loaded (10μg) in 
each lane and -actin expression was used as a loading control. Tests for statistical 
significance were performed using a Mann-Whitney U-test using the indicated numbers of 
cases. 
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3.2.3. CD40 ligation on CLL cells induces Bcl-10 expression 
CD40 ligation on CLL cells changes gene expression
291-292
. We wished to determine whether 
the profile of upregulated proteins in CD40-stimulated CLL cells included Bcl-10. Thus, we 
cultured CLL cells on CD40 ligand-expressing (CD40L-L) and control fibroblasts (NT-L), 
and analysed the levels of Bcl-10 expression. Figure 3.4 shows that culture of CLL cells on 
NT-L cells did not largely affect the level of Bcl-10 compared to non-cultured CLL cells. 
However, CD40 ligation on CLL cells, achieved by culture on the CD40L-L cells, induced 
expression of significantly (p=0.037, n=3) higher levels of Bcl-10 than were observed in CLL 
cells cultured on the NT-L cells. These results indicate that CD40 stimulation of CLL cells 
stimulates Bcl-10 expression, and suggests that NFκB pathway signalling in response to BCR 
crosslinking may be restored. This notion is supported by experiments measuring Bcl-10 
levels in BCR-stimulated and unstimulated CLL cells. Bcl-10 levels in the former were 
slightly reduced compared to the latter (Figure 3.4). This is expected because Bcl-10 becomes 
phosphorylated and is degraded in BCR-stimulated B cells
293
. 
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Figure 3.4: CD40 ligation on CLL cells stimulates Bcl-10 expression. CLL cells were 
cultured on non-transfected fibroblasts (NT-L) or CD40-expressing fibroblasts (CD40L-L) 
for 48 hours at 37 C, the cells were then harvested, washed and recovered overnight prior 
stimulation of BCR using 20g/mL F(ab’)2 goat anti-human IgM for 15 minutes. The 
cellular lysates were analysed for the levels of Bcl-10 expression. β-Actin was used as a 
loading control. Statistical analysis was performed using a Student t-test for paired data on 
n=3 samples. 
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3.2.4. CD40 ligation on CLL cells downregulates BCR-induced IKK 
activation 
We next tested the effect of CD40 ligation on CLL cell response to BCR stimulation. Figure 
3.5 shows that CLL cells cultured on NT-L cells had a slightly enhanced response with 
respect to IKK phosphorylation induced by BCR engagement when compared to non-
cultured cells. However, BCR-induced activation of IKK was significantly (p=0.05, n=3) 
impaired in CLL cells cultured on CD40L-L cells. Taken together with the data presented in 
Figure 3.4, these results indicate that the upregulation of Bcl-10 in CD40-stimulated CLL 
cells does not lead to enhanced BCR signalling to the NFκB pathway.  
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Figure 3.5: CD40 ligation on CLL cells leads to reduced ability to activate IKK by BCR 
stimulation. CLL cells were cultured on non-transfected fibroblasts (NT-L) or CD40-
expressing fibroblasts (CD40L-L) for 48 hours at 37 C, the cells were then harvested and 
recovered overnight prior stimulation of BCR using 20g/mL F(ab’)2 goat anti-human IgM 
for 15 minutes. The cellular lysates were analysed for the levels of for pIKKα/β (ser 180/181) 
antibody, and then for total IKKβ. Statistical analysis was performed using a Mann-Whitney 
U-test on n=3 samples. 
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3.2.5. BCR- induced NFB activation and translocation into the nucleus of 
CLL cells 
The role of the CBM complex in antigen receptor-induced activation of the NFB pathway is 
to coordinate activation of IKK with its downstream elements. Thus, antigen receptor 
stimulation of T and primary splenic B cells induces phosphorylation of IKK and , but 
downstream phosphorylation of IB and resultant activation of NFB does not occur in the 
absence of either Bcl-10 or CARMA-1
133-134 287 294
. The role of these latter two proteins, in 
combination with MALT-1, is to facilitate the polyubiquitination of IKK which allows for 
the efficient transmission of antigen receptor signals to NFB294.  
The observation that CLL cells express low levels of Bcl-10 suggests that BCR-induced 
phosphorylation of IKK may not result in efficient activation of the NFB pathway. To test 
this possibility we performed an ELISA which measures the activated form of NFB (RelA) 
in nuclear extracts of CLL cells. Figure 3.6 shows that BCR crosslinking on CLL cells 
induces a marked increase in IKK phosphorylation that corresponds with increased levels of 
active NFB and IB phosphorylation and its subsequent degradation. We found that the 
levels of IKK / IB phosphorylation within the lysates of stimulated CLL cells appeared to 
correlate with the amount of active NFB within the nuclear extracts. This suggests that there 
is efficient transmission of BCR signals from IKK to NFB in CLL cells despite the low 
levels of Bcl-10 expression. 
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Figure 3.6: BCR-stimulated IKK and IκBα phosphorylation and activation of NFκB in 
CLL cells after 24h culture. CLL cells were cultured in polyHEMA plates for 24 hours at 
37 C, and then stimulated by BCR crosslinking with 20g/ml F(ab’)2 goat anti-human IgM 
for 15 minutes. The cellular lysates were analysed for the levels of (A) pIKKα/β (ser 
180/181) and (C) pB(serine 32/36). In part (B) the nuclear proteins were extracted and an 
ELISA assay was performed to measure the levels of active NFB (RelA) in the nucleus. 
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The experiment illustrated in Figure 3.6 required that the cells were incubated for a period of 
24h. This was required because the levels of active NFB in nuclear extracts from freshly-
thawed CLL cells were constitutively high. We found that BCR stimulation of freshly-thawed 
CLL cells did not cause any observable increase in the levels of active NFB despite the 
induction of IKK phosphorylation (Figure 3.7A). Moreover, IB phosphorylation levels 
were also high in freshly thawed CLL cells, and there was no observable increase in these 
levels upon BCR crosslinking (Figure 3.7B). To reduce the levels of background 
activation/phosphorylation of NFB/IB the CLL cells required 24h incubation under 
quiescent conditions. Therefore, it is possible that the levels of Bcl-10 expression could have 
changed during this time. To answer this question, we compared the levels of Bcl-10 in 
freshly-thawed CLL cells with those in cultured cells, and observed that there was no 
appreciable difference between the two (Figure 3.7C). Collectively, these data indicate that 
BCR crosslinking on CLL cells induces efficient signalling from the receptor to NFB 
despite low levels of Bcl-10. This suggests that this signalling pathway is independent of 
PKC and the CBM complex. 
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Figure 3.7: BCR-stimulated IKK and IκBα phosphorylation and activation of NFκB in 
freshly thawed CLL cells. CLL cells were recovered for 2 hours at 37 C, and then BCR 
was stimulated with 20g/ml F(ab’)2 goat anti-human IgM for 15 minutes. (A) The nuclear 
proteins were extracted and an ELISA assay was performed to measure the levels active 
NFB in the nucleus. (B) Whole cell lysates of freshly-thawed unstimulated and BCR-
stimulated CLL cells were analysed by Western blot for pIKK/IKK, pBα and IκBα. (C) 
Bcl-10 in whole cell lysates analysed by Western blot of freshly-thawed (time 0) and 24h-
incubated CLL cells (time 24). 
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3.2.6. The role of the transforming growth factor β (TGFβ)-activated 
kinase 1 (TAK1) in BCR-induced NFκB activation in CLL cells 
TAK1 is an important mediator of BCR-induced activation of NFκB, and is also essential for 
function and maturation of B cells. TAK1-deficiency in B cells results in an increase of BCR-
induced apoptosis and impairment of proliferation following BCR crosslinking
135
. After 
activation by ubiquitination, the TAK1/TAB2 (or TAB3) complex activates IKK by 
phosphorylating IKKβ at serine (Ser)-177 and Ser-181 in the activation loop295. To examine 
the role of TAK1 during NFκB activation in BCR-stimulated CLL cells we used the 
compound 9-Epimer-11, 12-dihydro-(5Z)-7-Oxozeaenol (Oxozeaenol). This compound was 
developed as a TAK1 inhibitor, and shows little inhibitory activity towards other MAP3Ks
296-
297
. We constructed a concentration-response curve of this compound versus levels of 
phosphorylated IKK following BCR ligation. Figures 3.8 and 3.9 show that the presence of 
500nM Oxozeaenol completely blocks BCR-induced phosphorylation of IKK in CLL cells, 
suggesting that TAK1 is involved in this process. Taken together with previous results from 
this chapter, this experiment suggests that TAK1 may be involved in BCR signalling to 
NFκB, but through a different mechanism of activation that does not involve PKCβ or the 
CBM complex. 
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Figure 3.8: Concentration-response curve investigating the effect of the TAK1 inhibitor 
on BCR-induced IKK phosphorylation in CLL cells. CLL cells were incubated with the 
indicated concentration of TAK1 inhibitor for 2h prior to BCR crosslinking with 20μg/ml 
F(ab')2 goat anti-human IgM. (left hand panel) Western blot analysis of CLL cell lysates for 
pIKK and total IKK. (right hand panel) Graphical representation of n=3 experiments using 
different CLL cases. 
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Figure 3.9: Effect of TAK1 inhibitor on IKK phosphorylation in CLL cells. CLL cells 
were treated with 0.5 M TAK1 inhibitor for 2 hours at 37ºC, and then BCR was stimulated 
with 20g/ml F(ab’)2 goat anti-human IgM for 15 minutes. The cellular lysates were 
analyzed by Western blot analysis for pIKKα/β (ser 180/181) antibody, and then for total 
IKKα/β. 
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3.2.7. IKK is constitutively ubiquitinated in CLL cells 
The above result suggested an involvement of TAK1 in the phosphorylation of IKK in CLL 
cells responding to BCR crosslinking.TAK1-mediated phosphorylation of IKK occurs when 
IKK (NEMO) becomes ubiquitinated, thereby allowing association of TAK1 with the IKK 
complex
298-299
. We next investigated the induction of IKK ubiquitination in CLL cells in 
order to determine whether BCR crosslinking induced this process. We performed this 
experiment by first immunoprecipitating IKK and then examining the ubiquitination of this 
protein by Western blot analysis. Figure 3.10A shows that IKK appeared to be constitutively 
ubiquitinated in CLL cells, and that BCR crosslinking did not seem to induce further 
ubiquitination. Analysis of IB showed that this protein was constitutively phosphorylated, 
and that this did not change in response to BCR engagement. As a control, we did the same 
experiment in A20 cells, a mouse B cell line that has been used to model various elements of 
the signalling pathway induced by BCR crosslinking
300-302
. Here, BCR crosslinking induced 
an increase in the level of IKK ubiquitination, and this was followed by phosphorylation of 
IB and downregulation of its expression (Figure 3.10B). In this latter experiment we used 
an antibody which immunoprecipitated mouse and human IKK, but the antibody used for 
identification of this protein within the immunoprecipitated material did not recognise mouse 
IKK. Western blot analysis of whole cell lysates with an antibody reactive against mouse 
IKK showed equal levels of expression for all the conditions used. Taken together, these 
data suggest that the mechanism involved in IKK activation in CLL cells responding to 
BCR crosslinking is different from that involved in A20 cells.  
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Figure 3.10: Measurement of IKKγ ubiquitination in CLL and A20 cells. (A) 2x107 CLL 
cells were incubated for the indicated time points with 20µg/mL F(ab')2 goat anti-human 
IgM. CLL cell lysates were immunoprecipitated with anti-IKK antibody and then probed 
with anti-ubiquitin antibody. (B) 3x10
6
 A20 cells that had been serum starved overnight were 
incubated for the indicated time points with 20µg/mL F(ab')2 goat anti-mouse IgG. The cell 
lysates were immunoprecipitated with anti-IKKγ antibody and then probed in Western blots 
with the indicated antibodies. 
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3.2.8. The role of Bruton’s tyrosine kinase (Btk) in BCR-induced NFB 
activation 
Looking upstream of PKCβ, we examined the role of the protein tyrosine kinase Btk in BCR 
signalling to NFκB in CLL cells. Btk is required for PLCγ2 tyrosine phosphorylation and 
activation
303-305
. Because PLC2 activation is required upstream of the CBM complex during 
BCR signalling, Btk is therefore upstream of NFB pathway activation. This was 
demonstrated in experiments where deletion of this tyrosine kinase in DT40 cells abrogated 
BCR-stimulated PLCγ2 activation123 306. 
In order to examine the role of Btk in the BCR-induced NFB pathway in CLL cells, we used 
the specific Btk inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-
dibromophenyl)propenamide (also known as LFM-A13)
307
. This compound has previously 
been used to show that Btk mediates cyclin D2 expression in a study of BCR signalling
308
. 
Figure 3.11 shows that pre-treatment of CLL cells with 100 µM LFM-A13 had no effect on 
BCR-stimulated IKK phosphorylation. In contrast, the presence of this compound completely 
inhibited the induction of IKK phosphorylation in A20 cells. This indicates that Btk does not 
seem to play a role in BCR-induced NFB activation in CLL cells. 
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Figure 3.11: Effect of Btk inhibition on BCR-induced IKK phosphorylation. Cells were 
treated with 100M LFM-A13 for 2 hours at 37ºC and then BCR was stimulated with 
20g/mL F(ab’)2 goat anti-human IgM (for CLL cells) or with 20g/mL F(ab’)2 goat anti-
mouse IgG (for A20 cell line) for 15 minutes. The cellular lysates were analyzed by Western 
blotting and probed with pIKKα/β (ser 180/181) antibody and then for total IKK. A20 cells 
were serum starved overnight prior to treatment. 
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3.2.9. The role of c-Abl in BCR induced NFκB activation in CLL cells 
The observation that efficient BCR-induced NFB signalling occurs despite low levels of 
Bcl-10, and in the presence of inhibitors blocking Btk and PKC activity suggests the 
existence of an alternative pathway. Previous work from this Department has shown that c-
Abl expression is higher in CLL cells than in normal peripheral blood B cells. Furthermore, 
this work also showed that treatment of CLL cells with the Abl-specific inhibitor imatinib 
results in the induction of apoptosis through a mechanism involving inhibition of the NFκB 
pathway
200
. This work is significant to the present study because c-Abl has been shown to 
contribute to BCR signalling
206
, and because in other cell types c-Abl can activate IKK 
through a pathway involving PKC and PKD309-311. 
To test whether c-Abl inhibition affected BCR-induced IKK phosphorylation we constructed 
a concentration-response curve to determine the minimal effective concentration of imatinib. 
Figure 3.12 shows that maximum inhibition of BCR-induced IKK phosphorylation was 
achieved using 20M imatinib.  In these experiments there remained a residual level of BCR-
induced IKK activation even when higher concentrations (30M) of imatinib were used 
(Figure 3.12). 
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Figure 3.12: Imatinib inhibits BCR-induced IKK phosphorylation in a concentration-
dependent way. CLL cells were incubated at 37C with the indicated concentrations of 
imatinib for 2h prior to BCR crosslinking for 15min with 20μg/ml F(ab')2 goat anti-human 
IgM. Whole CLL cell lysates were analysed by Western blot for pIKK and IKK (left hand 
panel). This experiment is representative of n=3 using different cases of CLL and is 
graphically represented in the right hand panel. 
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To further characterise the effects of imatinib, we screened 14 CLL cases for BCR-activated 
IKK phosphorylation. Figures 3.13A and B show that BCR crosslinking induces an 
approximate nine fold increase in IKK phosphorylation in CLL cells with variable responses 
among the screened cases. Pre-treatment of these cells with 20M imatinib inhibits BCR-
induced IKK phosphorylation by approximately 50 % (p=0.006). However, the ability of 
imatinib to inhibit this CLL cell response to BCR crosslinking was variable between different 
CLL cases; in some cases imatinib was able to inhibit BCR-induced IKK phosphorylation by 
more than 50%, and in other cases considerably less (Figure 3.13C).  
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Figure 3.13: BCR-induced IKK activation is variably affected by imatinib treatment in 
different CLL cases. CLL cells were incubated at 37C with 20μM imatinib for 2h prior to 
BCR crosslinking for 15min with 20μg/mL F(ab')2 goat anti-human IgM. (A) CLL cell 
lysates were analysed by Western blot for pIKK induction using pIKK (ser 180/181) and IKK 
antibodies (left hand panel). The right hand panel is a graphical representation of the left 
hand panel for n=14 CLL cases. (B) Graphical representation of the individual experiments. 
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In order to determine whether c-Abl level accounts for the ability of CLL to signal through 
the BCR, we compared the ability of CLL to induce IKK phosphorylation in response to BCR 
stimulation in high versus low c-Abl-expressing CLL cases. Figure 3.14 shows that the levels 
of IKK phosphorylation in BCR-stimulated CLL cells expressing high levels of c-Abl was 
not significantly different from those in stimulated cells expressing low levels of c-Abl. This 
indicates that the level of c-Abl in CLL cells does not seem to contribute to the intensity of 
BCR signalling with respect to NFB pathway activation. 
To further investigate the role of c-Abl we examined whether c-Abl levels account for 
imatinib sensitivity. This was done by comparing the percent inhibition of BCR-induced IKK 
phosphorylation by imatinib between high and low c-Abl cases. Figure 3.14 shows no 
significant difference in imatinib sensitivity between the two CLL groups. Imatinib treatment 
of CLL cells inhibited BCR-induced IKK phosphorylation by approximately 50% in c-Abl 
high- and c-Abl low-expressing cells. Thus, although imatinib inhibits BCR-induced NFB 
pathway activation, expression levels of its primary target, c-Abl, does not seem to affect the 
intensity of the BCR-induced signals or imatinib sensitivity in CLL cells. This suggested that 
the effect of imatinib in CLL could be due to its off target effect on other kinases in these 
cells. 
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Figure 3.14: BCR response intensity and imatinib sensitivity in CLL cases with high c-
Abl levels compared to cases with low c-Abl levels. (A) Graphical representation 
comparing fold induction of IKK phosphorylation following BCR-crosslinking of CLL cells 
with high and low c-Abl levels. (B) Graphical representation comparing per cent inhibition of 
BCR-induced IKK phosphorylation caused by imatinib in CLL cells with high and low c-Abl 
levels. Tests for statistical significance were performed using a Mann-Whitney U-test. 
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3.3. Discussion 
This chapter is mainly concerned with gaining insight into the signalling pathway that is 
initiated by the engagement of the BCR with its cognate antigen in CLL cells. In particular, 
we concentrate on the pathway leading to activation of NFκB and follow its translocation into 
the nucleus. Here we have shown that PKCβ does not play a role in BCR-induced NFκB 
activation in CLL cells suggesting an alternative mechanism for activation of this pathway. 
I initially investigated the role of PKCβ in BCR-induced NFκB activation in CLL cells. This 
serine/threonine kinase is a key mediator of NFκB activation in normal B cells following 
BCR stimulation
36 279-281
. The mechanism is as shown in figure 3.1, and involves 
phosphorylation of the CBM complex which leads to ubiquitination of IKK and activation of 
IKK by TAK1, and eventually the translocation of NFκB into the cell nucleus133. Our data 
show that inhibition of PKCβ using a specific PKCβ inhibitor LY379196, or a general 
inhibitor of PKCs Bisindolylmaleimide I, does not affect BCR-induced phosphorylation of 
IKK, even when used at very high concentrations to ensure complete inhibition of this kinase. 
This could have been important because CLL cells overexpress PKCII197 282, and/or may not 
be able to take up sufficient drug to inhibit this kinase. To confirm that the concentration we 
used in these experiments was sufficient to inhibit PKCβ we showed an obvious blockage of 
BCR-induced phosphorylation of GSK3α/β, a known downstream target of PKCβ312-313 as 
well as of the Akt pathway
125
. When used at the concentrations employed in the present 
study, compounds like LY379196 and ruboxistaurin also inhibit PDK1, the kinase 
responsible for T
308
 phosphorylation and eventual activation of Akt
314-315
 . Although we did 
not examine BCR-induced Akt activation in these experiments, our results showing that 
BCR-induced GSK3 phosphorylation is inhibited nevertheless indicate the compounds are 
acting as expected. Such detection of drug activity is proposed in a study that suggests 
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GSK3β phosphorylation may serve as a reliable pharmacodynamic marker for enzastaurin 
activity
316
, another inhibitor of PKC. Therefore, our experiments indicate that BCR- 
stimulated activation of the NFκB pathway in CLL cells is not transmitted via overexpressed 
PKCβII.  
Our findings do not rule out a role of the PKCβII-NFκB signalling pathway in the 
pathophysiology of CLL. Thus, a recent paper has reported that CLL cell contact with 
stromal cells induces expression of PKCII. This, in turn, provides pro-survival signals to 
CLL cells through a mechanism involving activation of the NFB pathway that is 
independent of Bcl-10
317
. This observation may explain why a CLL-like disease does not 
develop when the Tcl1-transgenic mouse is crossed with a mouse where the gene for PKC is 
deleted
37
.  
Our results indicate that the pathophysiology of CLL cells differs from other B cell 
malignancies with respect to activation of the NFB pathway by the antigen receptor. PKCβ 
is also overexpressed in the malignant cells of diffuse large B cell lymphoma (DLBCL) and 
mantle cell lymphoma (MCL)
282-283
. The NFκB pathway in these malignancies is 
constitutively active, and PKCβ mediates the tonic BCR signalling that contributes to cell 
survival and proliferation through a mechanism involving activation of IKK
281 284
. Inhibition 
of PKC using specific inhibitors such as LY379196, LY333531 (ruboxistaurin) and 
LY317615 (enzastaurin) can induce apoptosis of DLBCL and MCL cells
281 285
, and are 
therefore proposed to have possible use in the treatment of these diseases.  
To further show that PKC is not involved in BCR-induced IKK activation we used the Btk 
inhibitor LFM-A13. Btk controls activation of PLC2, which generates the DAG and Ca2+ 
release (because of IP3) necessary for PKC activation. We clearly show that the induction 
of IKK phosphorylation by BCR crosslinking is resistant to this compound in CLL cells. 
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However, LFM-A13 does inhibit BCR-induced IKK phosphorylation in A20 cells, which 
have been used to characterise classical BCR signalling pathways
300-302
. These data suggest 
that Btk does not play a role in BCR-induced NFB activation in CLL cells.  
I next examined expression levels of the CBM complex components downstream of PKCβ. 
This complex consists of three components (CARMA-1, Bcl-10, and MALT-1) known to 
transmit signals from PKCβ to IKK during BCR engagement133-134. Our data indicate that 
CLL cells express Bcl-10 at an eighth of the level it is expressed in normal B cells. This 
could account for the inability of BCR to transfer signals from PKCβ to the IKK complex 
because efficient signalling by the CBM complex requires all the three components of this 
complex
288-290
.  Moreover, a lack of Bcl-10 expression may also explain why BCR-induced 
JNK activation is defective in the vast majority of CLL cases
150
. Antigen receptor-induced 
JNK phosphorylation is impaired in T cells and primary splenic B cells from Bcl-10-deficient 
mice, suggesting a role for this adaptor protein in JNK activation
318
.  
Ligation of CD40 on CLL cells changes gene expression
22 23
. We examined the possibility 
that CD40 ligation induces Bcl-10 expression, and did this by co-culturing CLL cells on a 
fibroblast cell line where CD40 ligand is expressed. This experiment showed significant 
induction of Bcl-10 expression in CLL cells that were cultured under these conditions. 
However, despite increased levels of Bcl-10 in the CD40-stimulated CLL cells, activation of 
IKK was considerably lower than in CLL cells cultured on control fibroblasts and which had 
Bcl-10 expression levels similar to those of freshly-thawed cells.  
It is reported that T cells and primary splenic B cells do not require Bcl-10 or CARMA-1 for 
antigen receptor-induced IKK phosphorylation. However, in Bcl-10 and CARMA-1 deficient 
cells active IKK is unable to phosphorylate its substrate IκBα and thereby activate NFκB 294. 
This may be because Bcl-10- and CARMA-1 are required for ubiquitination of NEMO 
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(IKK) and formation of a signalosome allowing efficient NFB signalling to occur. We 
tested whether NFB became activated in BCR-stimulated CLL cells by measuring nuclear 
extracts from these cells for the presence of this transcription factor. Consistent with the 
observations of others
158
, our analysis of freshly-thawed CLL cells showed the presence of 
high levels of NFB in nuclear extracts. When we applied BCR stimulation, this did not lead 
to any change in the levels nuclear NFB. Therefore, we incubated the CLL cells in vitro for 
24 hours, and this resulted in a reduction of the basal level of active NFB. BCR crosslinking 
of these cultured CLL cells induced a clear increase in nuclear NFκB, and analysis of Bcl-10 
expression in these cultured cells showed that it was not significantly different from that in 
freshly thawed cells. These results indicate that the NFB signalling pathway is intact in 
BCR-stimulated CLL cells despite the low level of Bcl-10 expression. Thus, PKCβ and the 
CBM complex are bypassed in the mechanism of BCR-induced NFB pathway activation in 
CLL cells.  
I then examined the role of TAK1 in BCR-induced NFκB pathway in CLL using the TAK1 
inhibitor (9-Epimer-11, 12-dihydro-(5Z)-7-Oxozeaenol (antibiotic L-783277)). Our data 
show that the presence of this compound inhibits BCR-induced phosphorylation of IKK in 
CLL cells. This finding suggests that TAK1 modulates BCR-induced NFB pathway 
activation in CLL cells despite low expression of Bcl-10 and overexpression of PKCII. We 
established that IKK is constitutively ubiquitinated in CLL cells, and is therefore potentially 
able to attract TAB proteins and TAK1. Constitutive ubiquitination of IKKγ in CLL cells 
could possibly be due to downregulation of the deubiquitinase cylindromatosis (CYLD) as is 
described for these cells
319. IKKγ is a known target of CYLD which acts to downregulate 
NFκB signalling320-323. How TAK1 is induced by BCR stimulation in CLL cells is unclear. It 
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still requires activation of tyrosine kinases, and we explore this possibility by examining a 
potential role of c-Abl.   
c-Abl is highly expressed in CLL cells compared to normal B cells, and plays a role in the 
pathophysiology of CLL cells by protecting them from spontaneous apoptosis through a 
mechanism that involves activation of the NFκB pathway200. This mechanism may involve c-
Abl, PKD and PKCδ as has been described in other cell types in order to protect them against 
oxidative stress-induced cell death
309-311
. How this applies to BCR signalling is suggested by 
studies showing that c-Abl plays a role in this process through an ability to phosphorylate 
CD19
206
, and that PKD and PKC are activated in response to BCR engagement324-325. 
Therefore, c-Abl was a good candidate for further investigation of the mechanism of BCR-
induced IKK activation in CLL cells. 
Our data show that pre-treatment of CLL cells with 20µM imatinib, a known inhibitor of c-
Abl, inhibited BCR-induced phosphorylation of IKK by 50%. This indicated that this kinase 
could be playing a role in BCR-induced IKK activation in CLL cells. However, it was not 
possible to achieve full inhibition of IKK activation, even when imatinib was used at higher 
concentrations. We screened 14 CLL cases for BCR-induced phosphorylation of IKK and for 
the effect of imatinib on this phosphorylation. Our results showed that BCR stimulation 
induced variable increases in the level of IKK phosphorylation in stimulated cells. Pre-
treatment of these cells with 20µM imatinib resulted in a variable inhibition of BCR 
induction of IKK phosphorylation. A comparison of c-Abl expression with intensity of IKK 
phosphorylation showed no relationship, and there was no relationship between c-Abl 
expression and effect of imatinib on BCR-induced IKK phosphorylation. Other work has 
shown that the level of c-Abl expression relates to the ability of imatinib to induce 
apoptosis
200 326
. Ostensibly, this induction of apoptosis occurs through the inhibition of NFκB 
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pathway activation leading to IL6 release and regulation of Mcl1 expression through 
STAT3
200 207
. The experiments we present in this thesis sugest that although c-Abl does 
regulate the NFκB pathway in CLL cells, it does so independently of BCR engagement. What 
could be happening is that imatinib is affecting another kinase involved in mediating BCR 
signalling. This may be Lck because imatinib is known to inhibit this SFK at the 
concentrations we used in this study. Thus, the next chapter outlines our investigation into the 
role of Lck in mediating BCR signalling in CLL cells. 
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Chapter 4: The role of Lck in BCR signalling in CLL cells 
4.1. Introduction 
In the previous chapter we showed that imatinib, a c-Abl inhibitor, reduces BCR induced 
phosphorylation of IKK by approximately 50%, with some cases responding better than 
others. Importantly, our data show that the levels of c-Abl do not relate to the intensity of 
BCR signalling, nor to the ability of imatinib to inhibit these signals in CLL cells. This 
suggests that the effect of imatinib on BCR signalling in CLL could be caused by its non-
specific inhibition of other kinases in these cells.  
In addition to c-Abl, imatinib can inhibit other tyrosine kinases including c-Kit, platelet 
derived growth factor receptor (PDGF-R), and, in particular, Lck 
327
. Reactivity of imatinib 
with c-Kit and PDGF-R is not important for CLL pathophysiology because these two 
receptor tyrosine kinases are not expressed by CLL cells
328
. On the other hand, Lck has been 
shown to be expressed in CLL cells where its function is unknown
191 329
.  
That imatinib may affect Lck function in CLL cells is supported by studies showing that this 
SFK is a key target during antigen-receptor stimulation of T-cells
330
, and by studies showing 
that it may play a role in BCR signalling in B1 cells. One study has shown that Lck 
expression is responsible for peritoneal B1 cell hyporesponsiveness to BCR stimulation
192
, 
while another study has suggested that Lck augments BCR signals in these cells
331
. However, 
a third study has indicated that Lck does not play any role in BCR signalling in B1 cells
194
. 
Given this controversy, it was nevertheless plausible to investigate Lck function within the 
context of BCR signalling in CLL cells because of the role this SFK plays in initiating 
antigen receptor signalling in T cells
188 332
, and because it is possible for Lck to phosphorylate 
the ITAM within CD79a and potentially initiate the BCR signalling cascade
333
. 
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4.2. Results 
4.2.1. Inhibition of Lck by imatinib 
To test whether Lck is a target for imatinib in CLL cells, we induced Lck activation by 
treating the cells with the protein phosphotyrosine phosphatase inhibitor monoperoxo 
(picolinato) oxovanadate (V) mpV(pic)
334
. We then immunoprecipitated Lck from CLL 
whole cell lysates and probed for active kinase in Western blots of precipitated proteins using 
an anti-phospho- Y
416
-Src antibody (anti-pY
416
-Src). This antibody crossreacts with Lck 
when it is phosphorylated on Y
394
, and therefore can be used to detect active Lck. Figure 4.1 
shows that only low levels of active Lck could be detected in resting CLL cells. This figure 
also shows that stimulation of CLL cells with mpV(pic) increased the level of Lck activation, 
and that the presence of 20M imatinib partially inhibited this induction of Lck activity. This 
result indicates the possibility that the effects of imatinib on BCR signalling in CLL cells 
could be mediated by this SFK. 
2961
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WB: Lck (WCL)
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Figure 4.1: Effect of imatinib and Lck-i on Lck activity in CLL cells. CLL cells were pre-
treated with 1μM Lck-i or 20μM imatinib for 2h at 37ºC. To stimulate Lck activity the cells 
were then incubated with 100μM mpV(pic) for 30min. The cell lysates were 
immunoprecipitated with anti-Lck antibody and then probed with anti-pY
416
-Src antibody on 
Western blots to assess Lck activity.  
MW 
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4.2.2. Lck inhibitor concentration-response 
To test for a potential role of Lck in BCR-induced signalling we used the Lck specific 
inhibitor 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2-d]pyrimidin-7-yl-cyclopentane (Lck-
i)
335-337
. We first established a concentration-response curve to show how the presence of 
Lck-i affected BCR-induced IKK phosphorylation. Figure 4.2 shows that BCR-stimulated 
IKK activation is maximally inhibited using a concentration of 1M Lck-i. That Lck-i affects 
Lck activation is shown in Figure 4.1, mpV(pic)-induced activation of Lck in CLL cells is 
completely inhibited by the presence of 1M of this compound. Thus, the effects of imatinib 
on BCR-induced signalling could be mediated by Lck. 
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Figure 4.2: Effect of different concentrations of Lck-i on BCR-induced IKK 
phosphorylation in CLL cells. CLL cells were incubated with the indicated concentration of 
Lck-i for 2h at 37ºC prior to BCR crosslinking with 20µg/ml F(ab')2 goat anti-human IgM for 
15 min. Whole CLL cell lysates were probed by Western blot for the presence of pIKK. This 
experiment is representative of n=3 separate experiments using different CLL cases.
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4.2.3. BCR-induced activation of ERK, Akt, and IKK is inhibited in CLL 
cells treated with Lck-i 
In T cells Lck mediates activation of the MEK/ERK
338
 and PI3K/Akt
339
 pathways during 
engagement of the antigen receptor. To answer the question of whether Lck played a similar 
role in CLL cells, we tested the effect of Lck-i on CLL cell response to BCR crosslinking. 
Figure 4.3 shows that pre-treatment of CLL cells with 1μM Lck-i significantly reduces BCR-
induced phosphorylation of ERK (p=0.001), Akt (p=0.001) and IKK (p=0.039), suggesting a 
role for this SFK in regulating all three of these signalling pathways. 
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Figure 4.3. Inhibition of Lck blocks BCR-induced phosphorylation of ERK, Akt and 
IKK in cells. CLL cells were incubated for 2h with 1μM Lck-i. The CLL cells were then 
stimulated through the BCR by incubating the cells for 15min with 20μg/ml F(ab')2 goat anti-
human IgM. Whole CLL cell lysates were analysed for the indicated proteins by Western 
blotting.  A. Analysis of BCR-induced ERK phosphorylation. In the right hand panel n=10 
different cases of CLL were analysed. B. Analysis of Akt phosphorylation. In the right hand 
panel cells from n=8 cases of CLL were used. C. Analysis of IKK phosphorylation. In the 
right hand panel n=11 cases of CLL were used. Tests for statistical significance were 
performed using a student’s t-test for paired data. 
MW 
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 4.2.4. Effect of Lck-i on SFKs activity in CLL cells 
CLL cells are reported to express a variety of SFKs including Lyn, Fyn, Fgr, Hck, Blk, c-Src, 
c-Abl and Lck
174 191 340-342
. We confirmed expression of these SFKs in CLL cells (Figure 4.4). 
We found that proteins such as Lyn, Blk, Fgr and c-Src were expressed at more or less 
constant levels when we compared CLL cells from different patients. Similar to previously 
reported observations
196
, we found that Lck expression in CLL cells varied between patients. 
Examination of Fyn and Hck showed that these SFKs were also variably expressed in CLL 
cells from different patients, but this variability had no correlation with variation in Lck 
expression.  
Blk
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Lck
Fgr
Src
β-Actin
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Lyn
 
Figure 4.4. SFKs expression in CLL cells. Western blot analysis of whole CLL cell lysates 
for the indicated SFKs. β-actin was used as a loading control. 
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 c-Abl has been reported to be expressed in CLL
200
 and to play a role in BCR signalling
206
. In 
order to examine the specificity of Lck-I we first tested its effect on c-Abl. To do this we 
measured the phosphorylation of CrkL because this protein is a known substrate of c-Abl
343
, 
and because we know c-Abl to be constitutively active in CLL cells
200 207
. Figure 4.5 shows 
that incubation of CLL cells with 1M Lck-i leads to a slight reduction in the level of CrkL 
phosphorylation. In contrast, incubation of CLL cells with 20M imatinib profoundly 
reduced phospho-CrkL levels, indicating that c-Abl activity was inhibited. This indicates that 
Lck-i does not affect c-Abl-mediated signalling in CLL cells. 
2968
pCrkL
2711
CrkL
Imatinib
Lcki +
+
+
+
IP:p Y416-Src
WB: Fyn
WCL:Fyn
2872
IP:p Y416-Src
WB: Lyn
WCL:Lyn
2968
pCrkL
2711
CrkL
Imatinib
Lcki +
+
+
+
p
C
rk
L/
C
rk
L
A
rb
it
ra
ry
 u
ni
ts
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
0.2
UT Lck i Imatinib
n=6
2745
IP: Fgr (10μl)
WB:PY 4G10
WCL: Fgr
C D
E
n=6
 
Figure 4.5. Comparison of Lck-i and imatinib effect on c-Abl activity in CLL cells. CLL 
cells were treated with either 1μM Lck-i, or with 20μM imatinib for 2h. Whole cell lysates 
were analysed by Western blotting using anti-pY
207
- CrkL. The right-hand panel shows a 
graphical representation of n=6 experiments using different cases of CLL. Tests for statistical 
significance were performed using a student’s t-test for paired data.  
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Within the existing paradigm of BCR signalling, Lyn has been postulated to initiate proximal 
BCR signalling events by catalysing the phosphorylation of the ITAMs within CD79a and 
b
344
. Thus, the effect of Lck-i could be due to inhibition of this SFK during BCR stimulation, 
a notion that may be particularly important because Lyn is reported to be overexpressed and 
constitutively active in CLL
345
.  
To examine this possibility we immunoprecipitated active Lyn from CLL cell lysates using 
the anti-pY
416
-Src antibody. This antibody also cross reacts with pY
397
 of active Lyn
346
, and 
recognises the active state of many SFKs, including Lyn and Lck. When we examined the 
effect of Lck-i on active Lyn we found that the presence of this inhibitor had no effect on our 
ability to immunoprecipitate Lyn from CLL cell lysates using the anti-pY
416
-Src antibody. In 
contrast, the presence of 150nM of the pan-SFK inhibitor dasatinib, resulted in a marked 
reduction in our ability to immunoprecipitate active Lyn from lysates of CLL cells (Figure 
4.6 A).When we used BCR crosslinking to stimulate CLL cells, there was only a slight 
increase in the levels of Lyn that could be immunoprecipitated with anti-pY
416
-Src antibody 
(Figure 4.6 C). However, similar to what we observed in unstimulated cells, only treatment 
with dasatinib lowered the levels of active Lyn in BCR-stimulated CLL cells and treatment 
with Lck-i had no observable effect. These results show that Lck-i does not affect Lyn 
activity when used at a concentration of 1M. 
I next investigated whether higher concentrations of Lck-i affected Lyn activity. Figure 4.6 B 
shows that Lyn activity was partially affected by incubating CLL cells with 5M Lck-i, and 
completely inhibited with 10M Lck-i. Thus, the presence of Lck-i can affect Lyn activity in 
CLL cells, however, the concentration needed is in excess of the 1M required to inhibit 
downstream signals from the BCR.  
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I next tested the effect of 1μM Lck-i on Fyn, Fgr and c-Src activity in CLL cells. These tests 
showed that this compound had no effect on these SFKs when used at 1μM (Figure 4.6 D, E, 
F, G). As a control we included dasatinib in our experiments and showed, as expected, that 
the presence of 150nM dasatinib inhibited the activity of Fgr. Taken together, these data 
show that Lck-i is highly specific for Lck at the concentration used. Therefore, our 
experiments showing that the presence of Lck-i inhibits BCR-induced ERK, IKK and Akt 
phosphorylation strongly suggests that Lck is an important mediator of BCR signalling in 
CLL cells. 
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Figure 4.6. Specificity of Lck-i. (A) Effect of Lck-i on Lyn activity in CLL cells. CLL cells 
were incubated for 2h in the presence of 1μM Lck-i or 150nM dasatinib prior to harvest and 
lysis. CLL cell lysates were treated with anti-pY
416
-Src antibody and immunoprecipitated 
Lyn was identified by Western blot analysis (top panel). Whole cell lysates were analysed to 
ensure that equal levels of Lyn were present prior to immunoprecipitation (middle panel). 
The same whole cell lysates were analysed for the presence of active SFKs using the anti-
pY
416
-Src antibody (lower panel). (B) Effect of increasing concentrations of Lck-i on active 
Lyn and SFKs in CLL cells. Top panel shows Lyn immunoprecipitated with anti-pY
416
-Src 
antibody, middle panels shows anti-pY
416
-Src antibody reactivity with whole CLL cell lysates 
and the lower panel shows the presence of Lyn in whole CLL cell lysates. This experiment 
represents n=3 using different CLL cases.(C) Effect of Lck-i and dasatinib on Lyn activity in 
BCR-stimulated CLL cells. CLL cells were treated with Lck-i and dasatinib as in part A. 
BCR stimulation was achieved by incubating the cells with 20μg/ml F(ab')2 goat anti-human 
IgM for 15 min.(D) Effect of Lck-i on Fyn activity in CLL cells. CLL cell lysates were 
immunoprecipitated with anti-pY
416
-Src antibody and immunoprecipitated Fyn was identified 
by Western blot analysis (top panel). Whole cell lysates were analysed to ensure that equal 
levels of Fyn were present prior to immunoprecipitation (second panel). (E) Effect of Lck-i 
on Fgr activity. CLL cells were incubated for 2h in the presence of 1μM Lck-i or 150nM 
dasatinib prior to treatment with 100μM mpV(pic) for 30min to stimulate Fgr activity. CLL 
cell lysates were immunoprecipitated with anti-Fgr antibody and phospho-Fgr was identified 
using the anti-phosphotyrosine antibody 4G10 (upper panel). Whole cell lysates were 
analysed to ensure that equal levels of Fgr were present prior to immunoprecipitation (lower 
panel). (F) Effect of Lck-i on c-Src. HCL cells were incubated for 2h in the presence of 1μM 
Lck-i or 150nM dasatinib then cell lysates were probed with anti-pY
416
Src (upper panel), 
with Src (second panel), with Lyn (third panel) or with Lck (bottom panel) . (G) Effect of 
increasing concentration of Lck-i on SFKs activity in CLL: CLL cells were incubated for 2h 
in the presence of increasing concentration of Lck-i (as indicated) then cell lysates were 
probed with anti-pY
416
Src (upper panel), with Src (second panel). Abbreviations: LC = lysate 
control, Abc = Ab control, BCR-XL/XL = BCR stimulation. UT = untreated cells. 
HCL=hairy cell leukaemia. MW= molecular weight ladder 
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4.2.5. siRNA-mediated reduction of Lck expression in CLL cells inhibits 
BCR-induced IKK, ERK and Akt activation 
To confirm the specificity of Lck-i and show that Lck is an important mediator of BCR 
signalling in CLL cells, we next used specific siRNAs to reduce the expression of this SFK. 
Figure 4.7 A shows that the level of Lck expression in CLL cells was reduced to 
approximately 60% (p=0.039, n=3) of endogenous levels following treatment with specific 
siRNA. This reduction in Lck expression resulted in inhibition of BCR-induced IKK and 
ERK phosphorylation by approximately 58.52±8.03% (p=0.029, n=3) and 31.78±6.56% 
(p=0.042, n=3), respectively, of the levels induced in control siRNA-transfected cells 
(Figures 4. 7B, C). We also observed a 14.85±3.87% decrease in BCR-induced Akt 
phosphorylation, which, although small, was nevertheless significant (p=0.026, n=4) (Figure 
4.7 D). To ensure that the reduction in BCR-induced IKK and ERK phosphorylation was not 
due to off-target effects of the siRNA (from Dharmacon) we repeated these experiments with 
siRNA from Invitrogen and obtained similar results (Figure 4.7E). These data, taken together 
with our studies using Lck-i strongly suggest that Lck plays an important role in mediating 
BCR-induced distal signalling events in CLL cells. 
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Figure 4.7. siRNA knockdown of Lck expression inhibits BCR-mediated signalling in 
CLL cells. Lck expression in CLL cells was reduced by treating cells with specific siRNA 
according to the method described in chapter 2. Whole cell lysates were then analysed by 
Western blot analysis for the indicated antibodies. (A) (upper panel) Western blot analysis of 
whole cell lysates for Lck expression. (lower panel) Graphical representation of n=3 
experiments showing that Lck was reproducibly reduced by 42.81±5.08% in Lck-siRNA 
treated cells compared to non-specific siRNA treated control cells. (B) Analysis of BCR-
induced ERK phosphorylation in CLL cells. BCR induction of ERK phosphorylation was 
reduced by 31.78±6.56% (n=3) in in Lck-siRNA treated cells. (C) Analysis of BCR-induced 
IKK phosphorylation in CLL cells. BCR induction of IKK phosphorylation was reduced by 
58.52±8.03% (n=3) in Lck-siRNA treated cells. (D) Analysis of BCR-induced Akt 
phosphorylation in CLL cells. BCR induction of Akt phosphorylation was reduced by 
14.85±3.87% (n=4) in Lck-siRNA treated cells. For all parts of this figure UT indicates mock 
transfected CLL cells, C indicates non-specific siRNA treated CLL cells and Lck indicates 
Lck-siRNA treated CLL cells. X-L indicates CLL cells that have been treated with 20μg/ml 
F(ab')2 goat anti-human IgM for 15 mins in order to stimulate BCR signalling. (E) Lck 
expression in CLL cells was reduced with siRNA. However, in this case the species of 
siRNA was different to that presented in A, B, C, D. The effect of the siRNA-induced 
reduction on BCR signalling was measured by Western blot analysis of CLL cell lysates 
using the indicated antibodies. Tests for statistical significance were performed using a 
student’s t-test for paired data. 
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4.2.6. Lck expression levels in CLL cells govern BCR signal strength 
It is known that the level of Lck expression varies in CLL cells from different patients
191 196 
347
. However, the functional significance of this expression has not been fully determined.  In 
the light of our siRNA experiments showing that a reduction in Lck expression reduces BCR-
induced activation of IKK, Akt and ERK, it seemed reasonable to hypothesize that the 
endogenous level of Lck expression would dictate a similar outcome. To investigate this 
possibility we compared BCR-induced phosphorylation/activation of IKK, ERK and Akt in 
CLL cells containing high and low levels of Lck. 
Figure 4.4 confirms earlier observations of variability in expression of Lck in CLL cells from 
different patients. We then examined the effects of BCR crosslinking on CLL cells 
expressing very low or very high levels of Lck. We found that the induction of ERK, Akt and 
IKK phosphorylation was significantly stronger in CLL cells having high levels of Lck 
compared with those having low levels of Lck (Figures 4.8). Moreover, the pro-survival 
effects of BCR crosslinking also appeared to be stronger in Lck-high expressing CLL cells 
than in those expressing lower levels of this SFK (Figure 4.8C). Importantly, the level of 
ZAP70 expression was more or less equivalent in the 4 cases we tested, indicating that the 
expression of this protein was not a factor in BCR responsiveness. Taken together, these data 
agree with the experiments using siRNA to knockdown Lck expression, and show a linkage 
between signal strength and Lck expression in CLL cells responding to BCR crosslinking. 
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Figure 4.8. Comparison of BCR signalling in CLL cells expressing different levels of 
Lck. A. Comparison of CLL cell response to BCR crosslinking in cases expressing low and 
high Lck. CLL cell lysates were analysed for induction of IKK,  ERK, and Akt activation 
following BCR crosslinking by Western blot using pT
202
/pY
204
-ERK, pS
473
-Akt and pIKKα/β 
(ser180/181) antibodies. This blot is representative of at least n=4 experiments using CLL 
cells from different patients. B. Graphical representation of A, comparing the fold induction 
of pIKK, pERK and pAkt by BCR crosslinking between CLL cells with low and high 
expression levels of Lck. Statistical significance was assessed using a Mann-Whitney U-test. 
C. Comparison of BCR-induced CLL cell survival in cases expressing high and low levels of 
Lck. Cells were incubated for 1h following addition of 20μg/ml F(ab')2 goat anti-human IgM, 
and viable cell count was determined by FACS analysis of DIOC6bright/PIdim cells as 
described in materials and methods. In this experiment 2 CLL cases expressing high levels of 
Lck (left hand panels) and 2 cases expressing low Lck (right hand panels) are illustrated. Cell 
viability was measured in 3 separate experiments using each case to give the mean±SD. D. 
Lck and ZAP70 expression in CLL cells used in C. 
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4.2.7. Lck mediates proximal BCR signalling events in CLL cells 
I next examined signalling that was proximal to IKK, Akt and ERK activation in BCR-
stimulated CLL cells. One of the most proximal signalling events in B cells following 
engagement of the BCR is tyrosine phosphorylation of the ITAM domain within CD79a
115
. 
We therefore investigated the role of Lck in this event in BCR-stimulated CLL cells. Figure 
4.9A shows that resting CLL cells have low, but detectable levels of tyrosine phosphorylated 
CD79a. BCR crosslinking of CLL cells increased the level of pY-CD79a approximately 2-
fold, and prior treatment of CLL cells with 1μM Lck-i blocked this BCR-induced increase. 
Because our previous experiments showed that Lck-i did not affect either constitutive (Figure 
4.6 A and B) or BCR-induced (Figure 4.6 C) activation of Lyn, these data suggest a role for 
Lck in initiating proximal BCR signalling events in CLL cells. 
To confirm the role of Lck in BCR-induced CD79a phosphorylation we used siRNA to 
reduce the expression of this SFK. Thus, reduction of Lck expression in CLL cells resulted in 
a significantly decreased induction of CD79a phosphorylation (Figure 4.9B). This confirms 
the above data using Lck-i, and demonstrates that Lck is able to phosphorylate CD79a 
following BCR engagement on CLL cells. 
However, Lck is not solely responsible for CD79 phosphorylation in CLL cells. This is 
because BCR-induced CD79a phosphorylation was reduced to below base line levels in CLL 
cells that were pre-treated with 150nM dasatinib (Figure 4.9A). This indicates a role for an 
additional SFK, possibly Lyn. 
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Figure 4.9. BCR crosslinking on CLL cells induces Lck activation and phosphorylation 
of CD79a. A. CLL cells were treated with Lck-i (1μM) or dasatinib (150 nM) for 2h prior to 
BCR crosslinking (20μg/ml F(ab')2 goat anti-human IgM for 15 mins). Whole CLL cell 
lysates probed by Western blot analysis for pCD79a, CD79a and Lck. The right hand panel 
shows a graphical representation of n=6 experiments using different cases of CLL. B. Lck 
expression in CLL cells was reduced by treating cells with specific siRNA according to the 
method described in chapter 2. Whole CLL cell lysates were then analysed by Western blot 
analysis for the indicated antibodies. The right hand panel shows a graphical representation of 
n=3 experiments using different cases of CLL. Statistical analysis for parts A and B was 
performed using a student’s t-test for paired data. 
MW 
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4.2.8. Lck mediates phosphorylation of Syk but not ZAP70 in BCR-
stimulated CLL cells 
 In T cells the main target of active Lck following ligation of the T cell antigen receptor is 
Y
319
 in ZAP70
348
. CLL cells from a subset of patients also express ZAP70, and a high level 
of expression of this tyrosine kinase has been reported to be associated with enhanced BCR 
signalling
111
 and poor disease prognosis
349
. In order to examine whether ZAP70 in CLL cells 
is a target for Lck we used an anti-pY
319
-ZAP70 antibody. However, this antibody is known 
to crossreact with an analogous site (pY
352
) in Syk, so it was important to distinguish between 
ZAP70 and Syk phosphorylation as the target of Lck in CLL cells. We first 
immunoprecipitated these proteins from resting and BCR-stimulated CLL cells and then 
probed them for reactivity with the anti-pY
319
-ZAP70 antibody in Western blots. We found 
that anti-pY
319
-ZAP70 was only reactive with Syk immunoprecipitated from BCR-stimulated 
CLL cells and not with immunoprecipitated ZAP70 (Figure 4.10). Treatment of CLL cells 
with Lck-i, or reduction of Lck expression with siRNA, reduced BCR-induced 
phosphorylation of Syk (Figure 4.10). Taken together, these results demonstrate that Lck 
preferentially mediates the phosphorylation/activation of Syk in CLL cells responding to 
BCR crosslinking. 
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Figure 4.10: Lck mediates Syk but not ZAP70 phosphorylation in BCR-stimulated CLL 
cells. CLL cells were treated with 1M Lcki for 2h and then stimulated by BCR crosslinking 
(20μg/ml F(ab')2 goat anti-human IgM for 15 mins). CLL cell lysates were then 
immunoprecipitated with A. anti-Syk or B. with anti-ZAP70 antibodies. The 
immunoprecipitates were then analysed by Western blot for the presence of pY
352
-Syk/pY
319
-
ZAP70 using an antibody that is crossreactive to both epitopes (anti-pY
319
-ZAP70 antibody). 
This experiment is representative of n=3 using cells from different donors. C. siRNA-
knockdown of Lck expression inhibits BCR-induced Syk phosphorylation. CLL cells were 
treated with Lck-specific (Lck) and non-specific (C) siRNA, or were mock-transfected (UT). 
CLL cells were then stimulated by BCR crosslinking (BCR-XL). Induction of pY
352
-Syk in 
CLL cell lysates was then assessed by Western blot analysis using the anti-pY
352
-Syk/pY
319
-
ZAP70 antibody. The right-hand panels show graphical representation of induced 
phosphorylation of immunoprecipitated Syk, ZAP70. The graph illustrates mean±SD of n=3 
experiments using cells from different donors 
 
101 
 
4.3. Discussion 
Lyn has always been thought to be responsible for mediating proximal and distal signalling 
events following BCR ligation in CLL cells
212
. However, in this chapter we present data that 
strongly implicate a role for Lck in this process. We showed that active Lck mediated 
proximal BCR signalling by phosphorylating ITAMs within CD79a, as well as downstream 
BCR signalling events involving phosphorylation of Syk leading to activation of NFκB, 
MAPK/ERK and PI3K/Akt signalling pathways, and eventually enhanced CLL cell survival. 
In the previous chapter our data implicated a role for c-Abl in BCR-induced NFκB activation 
since inhibition of this kinase using imatinib resulted in a partial reduction of BCR-induced 
phosphorylation of IKK. The response to imatinib varied among the CLL cases, as did the 
intensity of BCR signalling. However, c-Abl levels did not seem to correlate with the 
intensity of BCR signals nor to the ability of imatinib to inhibit these signals. This suggested 
that the effect of imatinib could be due to a non-specific inhibition of other kinases that play a 
role in BCR signalling to the NFκB pathway. The work described in this chapter centres on a 
possible role for Lck because of the known ability of imatinib to inhibit this SFK
327
. Thus, 
our data show that imatinib can partially inhibit mpV(pic)-induced activity of Lck in CLL 
cells, and is consistent with a study performed in T cells that showed Lck is a target of 
imatinib during stimulation of the TCR
330
.  
Previous to this thesis, Lck was reported to be expressed in CLL cells
191 329
. However, the 
functional significance of this expression was still unclear. The data from this Chapter show 
that Lck is an important mediator of BCR signalling in CLL cells, and is demonstrated using 
two approaches; a specific Lck inhibitor Lck-i, and siRNA to reduce Lck expression. 
To address the role of Lck in BCR signalling in CLL cells we first used Lck-i. Our data show 
that Lck-i inhibits mpV(pic)-induced activation of Lck in CLL cells when used at 1µM. 
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Experiments examining concentration-response with this compound showed that the maximal 
inhibition BCR-induced phosphorylation of IKK was reached using 1µM of Lck-i. This 
concentration was also effective at reducing BCR-induced activation of the MAPK/ERK and 
PI3K/Akt signalling pathways. The ability of Lck-i to inhibit BCR-induced signalling was 
not due to off-target inhibition of other SFKs because incubation of CLL cells with this 
compound did not affect other SFKs that are known to be expressed in CLL such as c-Abl, 
Src, Fgr, Fyn and, in particular, Lyn which is known to be constitutively active in CLL 
cells
174
. This confirms the specificity of Lck-i that has been reported in other studies
335-337
, 
and further suggests that the effect of Lck-i on BCR signalling is only due to its inhibitory 
effect on Lck. 
The second approach we used to demonstrate the role of Lck in mediating BCR signalling in 
CLL cells involved using siRNA to reduce Lck expression in these cells. We found that 
siRNA treatment of CLL cells resulted in partial reduction in Lck expression, and that this 
had the effect of reducing BCR-induced activation of IKK (60% inhibition), ERK (30% 
inhibition) and Akt (15% inhibition). Previous work from our Department and in other 
studies has shown that B cells from different CLL patients express variable levels of Lck
191 
196 347
, our experiments showed that this variation correlates with BCR signalling intensity. 
Thus, our data showed that levels of induced pIKK, pERK and pAkt are higher in BCR-
stimulated CLL cells expressing high levels of Lck than in BCR-stimulated CLL cells 
expressing low levels of Lck. Taken together with the experiments using siRNA to reduce 
Lck expression, these observations suggest a direct relationship between the level of Lck 
expression and the intensity of the BCR signalling response in CLL cells. Moreover, these 
data provide compelling evidence to support a role for Lck in BCR signalling in CLL cells.  
A role for Lck in antigen receptor signalling in normal B cells is controversial. One study has 
suggested that Lck can promote BCR signalling in B1a cells 
331
, whereas a second has 
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suggested an inhibitory role of this SFK
192
 and a third has reported that Lck does not play any 
role in BCR signalling in B1 cells
194
. Our data support a role for Lck in the promotion of 
BCR signalling, and is the first study to demonstrate this in CLL cells. Previous reports have 
suggested that Lck expression may be functionally coupled with CD5
191
 and that it protects 
CLL cells against glucocorticoids
195
. One report suggested that Lck has no direct 
cytoprotective role in CLL cells by showing that its knock down does not induce apoptosis
196
. 
However this does not contradict our findings on the role of Lck because this study was done 
in unstimulated CLL cells, it is within the context of BCR signalling that Lck has a role in 
CLL pathophysiology. 
The current model of BCR-induced CD79 phosphorylation in CLL cells suggests that 
following BCR ligation Lyn enters lipid rafts where it phosphorylates CD79
96
. Our results 
contrast this model and show that the presence of Lck-i reduces induction of CD79 
phosphorylation by BCR crosslinking on CLL cells without affecting the activity of Lyn. 
This finding is complimented by experiments using siRNA to knockdown Lck expression. 
These experiments show that such knockdown inhibits BCR-induced CD79 phosphorylation, 
and strongly suggest that Lck mediates this proximal signalling event in CLL cells. However, 
our experiments do not rule out a role for Lyn in CD79 phosphorylation. Use of the pan-SFK 
inhibitor dasatinib shows that the presence of this compound in CLL cell cultures reduces 
CD79 phosphorylation to below the baseline levels we observed in resting CLL cells. Thus, 
whereas Lck may be responsible for the induction of CD79 phosphorylation following BCR 
crosslinking, Lyn, or another SFK, may be responsible for basal phosphorylation of this 
protein. Such SFK-mediated basal phosphorylation of CD79 may be pathophysiologically 
important in CLL because pan-SFK inhibitors are cytotoxic to the malignant cells of this 
disease
174
. Constitutively active Lyn may also generate signals which downregulate BCR 
signalling. Lyn is able to phosphorylate ITIMs in proteins such as CD5
219
, and thereby attract 
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phosphatases such as SHP1, SHIP1 and PTPN22 to the cell membrane where they 
downregulate Lyn-mediated positive signalling events
219 224 350-351
. Moreover, 
monophosphorylation of the ITAM within CD79a, possibly mediated by Lyn, has recently 
been proposed to play a role in the maintenance of B cell anergy through activation of an 
inhibitory signalling circuit consisting of SHIP-1 and Dok-1
352
. The net effect is a balance 
between positive and negative signalling. The results presented in this chapter suggest that 
Lck acts to tip this balance in favour of positive signals when CLL cells are stimulated 
through the BCR. 
Following TCR stimulation, the main target of active Lck is Y
319
 in ZAP70
348
. 
Phosphorylation of ZAP70 at this tyrosine residue acts to enhance the catalytic function of 
ZAP70, as well as play a scaffolding role within ZAP70 by providing a binding site for Lck 
and other proteins such as PI3K, Grb2 and CrkII
353-354
. The malignant cells from a subset of 
CLL patients also express ZAP70
144
 where it functions to enhance BCR signalling
147 355
. 
Thus, ZAP70 may be a target of Lck in CLL cells that express this protein. However, using a 
phospho-ZAP70 antibody (anti-pY
319
-ZAP70) that also crossreacts with phospho-Syk at an 
analogous site (pY
352
) we found that although Lck is involved in the induction of Syk 
phosphorylation following BCR crosslinking of CLL cells, ZAP70 remains 
unphosphorylated. This result agrees with a published report showing that BCR crosslinking 
induces Syk but not ZAP70 phosphorylation in CLL cells
355
. That Lck is directly able to 
phosphorylate Syk on Y
352
 in BCR-stimulated CLL cells is not demonstrated by our data. 
Although there is potential for Lck to target Syk based on the high homology of amino acid 
sequences flanking Y
352
 and Y
319
 in Syk and ZAP70, other SFKs could also be involved. It 
has been suggested that Lck is able to act as a downstream amplifier of Syk in antigen 
receptor-stimulated T cells by binding pY
525/526 
residues via its SH2 domain
356-357
, and, in this 
way, holds Syk in a conformation that allows Lyn or another SFK to catalyse the 
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phosphorylation of Y
352
 
357
. Such a mechanism may occur in CLL cells because recent work 
has shown that phosphorylation of Y
525/526 
in Syk enhances downstream signalling
358
.  
Alternatively, inhibition of Lck-mediated CD79 phosphorylation in BCR-stimulated CLL 
cells may inhibit Syk activation and Y
352
 phosphorylation, thereby accounting for the 
reduction we observe. Whatever the mechanism of Lck-mediated Syk activation may be, our 
results suggest that the role of ZAP70 in enhancing BCR signalling in CLL cells is 
independent of the functional relationship it plays with Lck in T cells. This independence is 
supported by our observation that there is no correlation between Lck and ZAP70 expression 
in CLL cells
196
. 
In this chapter we show that Lck expression varies in the malignant cells from different 
patients, an observation that others have also made
191 195-196 347
. We also show that this may be 
pathophysiologically important because not only does Lck inhibition block the pro-survival 
effects of BCR crosslinking in CLL cells, but the expression levels of this SFK contribute to 
the strength of pro-survival signals generated by this stimulus. This finding implies that Lck 
expression may be prognostically important and high Lck expression may be an indicator of 
aggressive disease given the established role of BCR signalling to disease pathogenesis in 
CLL
25 359
. 
In conclusion, this chapter shows that Lck plays an important role in mediating BCR 
signalling in CLL cells. This SFK participates in proximal phosphorylation of ITAM motifs 
in CD79 and induces distal activation of Syk, ERK, NFκB and Akt signalling as well as 
increased CLL cell survival. This suggests a major role for Lck in CLL pathogenesis and 
changes the paradigm on the importance of Lyn in this process. As a therapeutic approach 
Lck inhibition may be an attractive option because of the importance of BCR signalling to the 
pathophysiology of CLL cells, and because small molecule compounds that target Lck are 
being developed to inhibit antigen receptor-mediated T cell activation as means to control 
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organ rejection as well as autoimmune diseases
360
. Since BCR-generated signals are key 
contributors to CLL cell survival and disease pathogenesis, Lck may be a good therapeutic 
target for the treatment of this disease. 
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Chapter 5: Lck expression and disease prognosis in CLL: 
examination of a potential role Lck plays in modulating BCR 
signalling in CLL cells 
5.1. Introduction 
Duration and intensity of BCR signals are controlled by negative regulators that are attracted 
to the signalling complex by proteins such as CD5, CD22 and FcγRIIB. Attraction of these 
negative regulators is mediated by Lyn which phosphorylates the immunoreceptor tyrosine-
based inhibition motifs (ITIMs) within CD5
211 219, CD22 and FcγRIIB208-209. Phosphorylated 
ITIMs in turn recruit phosphatases such as SHP1, SHIP-1 and -2 and protein tyrosine 
phosphatase non-receptor type 22 (PTPN22), all of which can downregulate BCR 
signalling
168 212
. 
In the previous chapter we showed that Lck is a key mediator of BCR signalling in CLL, and 
that the levels of this kinase determine the intensity of BCR signals. Therefore, it seems 
reasonable to hypothesize that Lck expression may be linked to disease prognosis. The aim of 
this chapter was to investigate this possibility. We found, however, that high expression 
levels of Lck in CLL cells were associated with good disease prognosis. Thus, a secondary 
aim of this chapter is to more fully investigate the role of Lck in CLL cells. Others have 
reported that Lck downregulates antigen receptor signalling in T cells and B1 cells by 
phosphorylating CD5
192 220
. Considering the fact that CLL cells express CD5
361
, CD22
245
 and 
FCγRIIB262-264, which are all potential targets of Lck, we investigated whether Lck played a 
role in the phosphorylation of these proteins in CLL cells. 
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5.2. Results 
5.2.1. High Lck levels in CLL cells are associated with good disease 
prognosis 
Previous work from both this
362
 and other Departments
191 196 347
 has shown that Lck is 
variably expressed in the malignant cells of CLL (Figure 5.1). In a cohort of CLL cases 
where Lck expression had been determined, we investigated the relationship between Lck 
expression and progression-free survival (Table 5.1). Lck expression in purified CLL cells 
was determined using a Western blot technique whereby recombinant Lck was used as a 
standard
362
. Using this technique we were able to assign high and low Lck expression based 
on the mean value of Lck expression (129pg) in the entire cohort. Thus, patients with levels 
of Lck greater than 135pg were assigned to the “High Lck” group, whereas patients with 
levels of Lck less than 125pg were assigned to the “Low Lck” group. A comparison of 
progression-free survival between these groups showed that patients with high Lck levels had 
better prognosis than those with low Lck levels (Figure 5.1).  
Measuring Lck expression in purified CLL cells using the above technique was time and 
resource consumptive. Therefore, we developed a method of determining Lck expression 
using a flow cytometric approach whereby CLL cells were identified with CD20 and CD5 
antibodies followed by intracellular staining for Lck expression. Figure 5.2A shows that this 
approach was valid for determining Lck expression in CLL cells. This approach also revealed 
that Lck was expressed at different levels within the cohort of patients analysed (Figure 
5.2B). The cohort of patient samples we used in this analysis was different to the one above, 
and only overall survival data was available. We initially divided between high and low 
expression of Lck in CLL cells using the mean/median values from our analysis. This 
analysis showed that CLL cases that highly expressed Lck tended to have better overall 
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survival than did CLL cases that expressed low levels of Lck. This result did not show 
statistical significance, however, it did suggest that comparison of extremes of the 
distribution may yield results that were more interpretable. Thus, we divided the CLL cases 
into 3 subgroups; cases expressing low levels of Lck (CLL cases with less than 20% Lck 
positive cells), intermediate levels of Lck (CLL cases with greater that 20% but less than 50% 
Lck positive cells) and high levels of Lck (CLL cases with greater than 50% Lck positive 
cells).  Figure 5.2C shows that CLL cases bearing high levels of Lck had a significantly better 
prognosis than CLL cases bearing either intermediate or low levels of Lck.  
To show that the patient samples used in cohorts 1 and 2 are representative of “normal” CLL, 
we examined the relationship between IgHV mutation and either progression-free survival 
(cohort 1, Figure 5.1F) or overall survival (cohort 2, Figure 5.2F). In each case, there was a 
trend for UM-CLL cases to have a poorer disease outcome than did M-CLL cases; in cohort 1 
the trend was not significant whereas in cohort 2 the p value was 0.016. Analysis of ZAP70 
expression in both cohorts showed that higher levels of ZAP70 were associated with UM-
CLL cells compared to M-CLL cells [Figures 5.1C (cohort 1) and 5.2E (cohort 2)]. 
Moreover, in both cohorts there was a trend for CLL cases having high expression of ZAP70 
to have poor disease outcome [Figures 5.1G (cohort 1) and 5.2G (cohort 2)] although in both 
cohorts the p value did not reach significance. These data suggest that both cohorts of patients 
are representative of CLL and display expected values for disease outcome with respect to 
known biomarkers
34 97
. Interestingly, there was no correlation between IgHV mutation and 
Lck expression [Figures 5.1D (cohort 1) and 5.2D (cohort 2)], or of ZAP70 and Lck 
expression (Figure 5.1E). A multivariate analysis would be required to demonstrate the 
independence of Lck as prognostic biomarker. A larger cohort is needed to establish 
statistical significance. Nevertheless, the data suggest that Lck expression levels may be 
prognostically independent of these other biomarkers. 
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Taken together, these data show that high Lck expression is associated with good disease 
prognosis in CLL. Considering that the previous chapter showed that Lck was involved in 
mediating BCR signalling in CLL cells, we wondered whether Lck may have a dual role 
whereby high levels of expression may set a threshold for the induction of BCR signalling. 
We therefore next examined a possible role of Lck in downregulating BCR signalling, 
particularly with respect to potential interaction with CD5, CD22 and FcγRIIB. 
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Figure 5.1: Comparison of treatment-free survival between high and low Lck expressing 
CLL cases (cohort 1). A.) Western blot analysis of Lck expression in lysates of purified 
CLL cells. 10g of protein were loaded per lane. -actin expression is used as a loading 
control. Kaplan-meier plot of treatment-free survival of high and low Lck expressing 
CLL cases within this cohort. C.) Comparison of ZAP70 expression in UM- and M-CLL 
cases within this cohort using the data in Table 1. D.) Comparison of Lck expression in UM- 
and M-CLL cases within this cohort using the data in Table 1. E.) Regression analysis using 
the data in Table 1 of ZAP70 and Lck expression in the CLL cases within this cohort. F.) 
Kaplan-meier plot of treatment-free survival of UM- and M-CLL cases within this cohort. 
G.) Kaplan-meier plot of treatment-free survival of high and low ZAP70 expressing CLL 
cases within this cohort. 
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Table 5.1: Patient attributes of cohort 1. Lck expression in each CLL case is reported in pg 
of Lck / g of total cellular protein. ZAP70 expression is expressed in arbitrary units as a 
band density ratio of ZAP70/-actin derived from Western blots of whole CLL cell lysates. 
IgHV mutation is expressed as the per cent homology with germline sequence. 
CLL case Lck ZAP70 IgHV% Treated Comments 
CLL 1754 145.2  99.65 Untreated  
CLL 1801 107.0 39.3 96.84 Treated  
CLL 1851 108.5 32.4 93.9 Treated  
CLL 1958 101.4  100 Untreated  
CLL 2006 212.8 11.3 95.58 Untreated  
CLL 2045 57.7   Untreated  
CLL 2056 167.6   Untreated  
CLL 2063 116.5 43.4 100 Treated  
CLL 2120 58.0 23.0 94.63 Untreated  
CLL 2157 110.7  88.89 Treated  
CLL 2209 235.5 14.8 98.25 Untreated  
CLL 2230 181.6 42.2 100 Untreated  
CLL 2237 170.0 10.2 91.41 Untreated  
CLL 2246 186.9  98.61 Untreated  
CLL 2255 141.8 29.1 100 Treated  
CLL 2354 185.0  95.44 Untreated  
CLL 2371 61.0 5.6 91.07 Untreated  
CLL 2399 31.5 9.8 100 Untreated  
CLL 2435 low   Treated Lck level comparable to CLL 2656 
CLL 2453 186.8 8.2 100 Untreated  
CLL 2562 123.0 29.5 100 Untreated  
CLL 2581 218.5 6.7 93.39 Untreated  
CLL 2608 138.0 9.3 91.06 Untreated  
CLL 2656 19.5 30.2 99.65 Untreated  
CLL 2679 127.4   Untreated  
CLL 2683 80.9   Treated  
CLL 2689 185.0 42.1  Treated  
CLL 2701 222.4   Untreated  
CLL 2711 42.0 4.3 87.72 Untreated  
CLL 2724 74.8  98.91 Treated  
CLL 2739 65.0   Treated  
CLL 2747 123.1 42.5 100 Untreated  
CLL 2749 211.0   No 
information 
 
CLL 2764 52.0 43.7 100 Treated  
CLL 2783 189.1 3.3 96.94 Treated  
CLL 2872 256 26.97  Untreated  
CLL 2950 198.5 4.2 94.79 Untreated  
CLL 2953 49.0 17.8 100 Untreated  
CLL 2954 75.2   Untreated  
CLL 2961 195.7   Untreated  
CLL 2999 39.5 27.9 96.36 Untreated  
CLL 3113    Untreated Rebleed of CLL 2209 
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Figure 5.2: Comparison of overall survival between high and low Lck expressing CLL 
cases (cohort 2). A.) Flow cytometry analysis of Lck expression in CLL cells. (upper panel) 
Lck expression in a CLL case that is known to have high Lck levels. (lower panel) Lck 
expression in a CLL case that is known to have low Lck levels.  Comparison of Lck 
expression in the malignant cells from the CLL cases used in this cohort.C.) Kaplan-meier 
plot of overall survival between high, intermediate and low Lck expressing CLL cases within 
this cohort. D.) Comparison of Lck expression in UM- and M-CLL cases within this cohort 
using the data in Table 2. E.) Comparison of ZAP70 expression in UM- and M-CLL cases 
within this cohort using the data in Table 2. F.) Kaplan-meier plot of overall survival of UM- 
and M-CLL cases within this cohort. G.) Kaplan-meier plot of overall survival of high and 
low ZAP70, based on the median value, expressing CLL cases within this cohort.  
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Table 5.2: Patient attributes of cohort 2. Lck expression and ZAP70 expression in each 
CLL case is reported as per cent positive cells. IgHV mutation is expressed as the per cent 
homology with germline sequence, CD38is expressed as per cent CD38 positive cells. 
Samples %Lck+ ZAP70 %IgHV CD38  samples %Lck+ ZAP70 %IgHV CD38 
#2082 0  100 76  #2451 36.79 87.51  24 
#2045 0 21.5 98.65 40  #2037 37.01  92.52 22 
#2204 1.9   14  #2412 37.93 47.07  75 
#2435 2.12 30.88 100 88  #2062 39.15  100  
#2224 3.78 16.13 94.58 low  #2209 42.91  98.25 29 
#2291 4.41 10.4 97.57 28  #2116 43.9 76.91 100  
#1975 4.8 44.29  3  #2381 44.85 82.12  0 
#2218 5.14  100 8  #2329 44.92  100 85 
#2025 6.21 99.07 91.47 12  #2163 47.05 75.82 99.31 88 
#2205 6.85  100 18  #2076 49.4 58.34 97.36 39 
#1939 7.57 60.92 100 13  #1906 49.61  92.86  
#2173 7.92 23.99 96.14 19  #2177 50.93  92.01  
#2216 8.34  85.99 3  #2237 50.93 28.26 91.41  
#2246 8.35 19.58 93.88   #2040 53.07 42.16 95.58  
#2424 8.59 6.34 100 96  #2485 53.77 19.27 91.93 3 
#2010 9.33 37.23 100 19  #1913 57.16  94.67 35 
#2444 10.13 28.98  95  #1999 57.41  94.63  
#2436 10.34 30.76 91.67 0  #2143 57.49 89.57 100 7 
#1954 10.6 13.56    #2035 58.73  95.53 6 
#2098 10.83 14.83  14  #1972 59.67 82.95 100 14 
#1964 11.08 46.98 90.78 3  #1908 61.64  97.94 19 
#2085 11.2 19.23 100 14  #1936 62.67 44.62 94.9 8 
#1963 11.85 13.55 92.93 19  #2206 64.1  99.33 47 
#1952 12.38 15.65 91.1 33  #1895 69.57  96.62 43 
#2096 12.64 35.9 93.75 0  #1983 72.3 85.1 97.54 3 
#2123 15.01 58.6    #2149 77.23 96.43  1 
#2067 15.1 68.94 100 57       
#1996 18.28 31.08 91.5 5       
#1998 18.28 38.9 89.53 28       
#2233 18.45 89.95 100 98       
#2081 19.09 29.29  3       
#1937  19.44 74.28 99.66 3       
#1965 20.45 63.26 99.66 54       
#2073 20.61 70.03 93.2 9       
#2256 22.94 84.05 100 27       
#2050 24.27 56.54  5       
#2212 25.11 86.83 100 53       
#2213 26.26   72       
#1901 26.68 46.38 95.24 1       
#2429 28.62 79.42 94.65 1       
#2506 29.87 40.91  3       
 #1932 31.09  94.02 low       
#2080 32.82  91.07 3       
#2387 35.67 35.31  35       
#2343 35.77 86.02 93.88 4       
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5.2.2. Lck inhibition does not affect BCR-induced CD5 phosphorylation 
To investigate why high Lck expression in CLL cells is correlated with good disease we 
reasoned that Lck may function to activate tyrosine phosphatases that act to downregulate 
BCR signals. One logical candidate is CD5, a surface marker of CLL cells
349
. CD5 is 
expressed on T cells and B1a cells where it is thought to modulate TCR
220
 and BCR 
activation and differentiation signals
192 214 216
. In T cells Lck has been reported to play a role 
in CD5 phosphorylation on Y
429
 and  Y
463
, sites that are functionally important because they 
act as a scaffold for phosphatases such as SHP1 and SHIP
216
.  
I first investigated the kinetics of BCR-induced CD5 phosphorylation in CLL cells in order to 
determine the time point at which maximal phosphorylation of CD5 was achieved. Thus, 
BCR crosslinking on CLL cells induced a rapid increase in tyrosine phosphorylation of CD5 
from basal levels that was apparent immediately following the addition of antibody (Figure 
5.3). We found that tyrosine phosphorylation of CD5 very quickly decreased, and resumed 
basal levels following 10 min incubation with the crosslinking antibody (Figure 5.3B).  We 
next tested whether Lck phosphorylated CD5 in BCR-stimulated CLL cells. To do this we 
first treated CLL cells with 1M Lck-i or 150nM dasatinib for 2 hours prior to BCR 
crosslinking. Figure 5.4 shows that whereas the presence of dasatinib blocked the BCR-
induced increase in CD5 tyrosine phosphorylation, the presence of Lck-i had no effect. These 
results indicate that Lck is not likely to play a role in BCR-induced CD5 phosphorylation in 
CLL cells.  
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Figure 5.3: BCR-induced CD5 phosphorylation time points. 3x10
7
 CLL cells were 
incubated for the indicated time points with 20µg/ml F(ab')2 goat anti-human IgM. CLL cell 
lysates were immunoprecipitated with anti-CD5 antibody and then probed in Western blots 
with anti-pY 4G10 antibody. To stimulate CD5 phosphorylation, CLL cells were incubated 
with 100μM mpV(pic) for 30min (positive control). 
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Figure 5.4: The role of Lck in BCR-induced CD5 phosphorylation. 3x10
7
 CLL cells were 
incubated for 2 hours with 1µM Lck-i or 150nM dasatinib prior to BCR stimulation with 
20µg/ml F(ab')2 goat anti-human IgM. CLL cell lysates were prepared immediately following 
BCR crosslinking, and then immunoprecipitated with anti-CD5 antibody. The 
immunoprecipitates where probed in Western blots with (A) anti-pY PY20 or (B) anti-pY 
4G10 antibody. To stimulate CD5 phosphorylation, CLL cells were incubated with 100μM 
mpV(pic) for 30min (positive control). 
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5.2.3. CD5 transfection does not affect BCR signalling in the MEC1 cell line 
To further investigate the role of Lck and CD5 in BCR signalling we switched our approach 
to use MEC1 cells. MEC1 is a CD5 negative CLL cell line that was derived from a patient 
undergoing prolymphocytic transformation
363
. Although these cells do not strictly mimic 
CLL cells, we found that they expressed Lck (Figure 5.5A) and decided that this may be 
useful for the analysis of BCR signalling. Analysis of pIKK, pERK, pAkt levels in MEC1 
cells showed that they are constitutively high, and that BCR crosslinking only induced a 
small increase in pIKK levels but largely did not affect either pAkt or pERK (Figure 5.5B 
and C). Importantly, Figures 5.5B and C also show that these constitutive signals appear to be 
Lck dependent because the presence of Lck-i reduced the levels of pIKK, pAkt and pERK in 
resting and BCR-stimulated cells. It is reported that CD5 functions in CLL cells to reduce 
BCR signalling
224
, therefore, the lack of CD5 expression in MEC1 cells may drive 
constitutive activation of the ERK, Akt and IKK signalling pathways. We investigated this 
further by transfecting MEC1 cells with CD5. 
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Figure 5.5: Lck expression and response to BCR crosslinking in MEC1 cells. (A) Lck 
expression in MEC1 cells: 10µg of total protein in MEC1 cell lysates was analysed for Lck 
expression by Western blotting using an anti-Lck antibody (B) and (C) BCR signalling in 
MEC1 cells: MEC1 cells were serum starved overnight and then treated with Lck-i (1μM) or 
dasatinib (150nM) for 2 hours. The BCR was stimulated by incubating the cells with 20μg/ml 
F(ab')2 goat anti-human IgM for 15 min. Then the cells were harvested and lysed. The cell 
lysates were analysed by Western blotting and probed with the indicated antibodies. 
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Transient transfection of MEC1 cells with either full-length CD5 or a mutant of CD5 where 
the cytoplasmic tail was ablated showed that expression of either of these forms of CD5 had 
no effect on constitutive activation of ERK, Akt and IKK (Figure 5.6). Taken together with 
the experiments measuring BCR-stimulated CD5 phosphorylation in CLL cells, these 
experiments would suggest that induction of CD5 phosphorylation is likely not mediated by 
Lck, and that CD5 may not be involved in regulating BCR signalling in CLL cells.  
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Figure 5.6: Effect of CD5 expression on BCR signalling in transient transfection assays 
of MEC1 cells.  2x10
6
 MEC1 cells were transfected with 2 µg of pmaxGFP® Vector (GFP 
control plasmid) (N), plasmid encoding intact CD5 protein (CD5), or with plasmid encoding 
truncated CD5 protein (CD5t). Following incubation overnight at 37C, BCR was stimulated 
by incubating the cells with 20μg/ml F(ab')2 goat anti-human IgM for 15 min. The cells were 
harvested and lysed, and the lysates were probed by Western blot with the indicated 
antibodies. 
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5.2.4. Lck inhibition does not affect phosphorylation of FcγRIIB 
Another potential target of Lck that is also expressed by CLL cells
262-264
 is FcγRIIB (also 
known as CD32). This protein contains an ITIM sequence within its cytoplasmic tail
102
, 
which, in normal B cells, can be phosphorylated by Lyn when it is engaged by the Fc portion 
of IgG
102 166-168 208 253
 . Src is also reported to phosphorylate Y
292
 within the ITIM of FcRIIB 
expressed on endothelial cells, and therefore this site may also be a candidate target for Lck 
in CLL cells
364-365
. Figure 5.7A shows that CLL-cell FcγRIIB is constitutively 
phosphorylated on Y
292
,
 
and that BCR stimulation (using anti-human IgM F(ab) 2 fragments) 
does not induce any change in this level of phosphorylation. We then compared the effects of 
Lck-i and dasatinib on the phosphorylation of FcRIIB in CLL cells. Figure 5.7B shows that 
the presence of Lck-i had no effect on FcγRIIB phosphorylation, whereas the presence of 
dasatinib completely inhibits this phosphorylation (Figure 5.7B). These results suggest that 
FcγRIIB phosphorylation in CLL cells is mediated by an SFK other than Lck.  
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Figure 5.7: FcRIIB is constitutively phosphorylated on CLL cells. (A) BCR-induced 
FcγRIIB phosphorylation time points: 1x107 CLL cells were incubated for the indicated time 
points with 20µg/ml F(ab')2 goat anti-human IgM. CLL whole cell lysates were analysed by 
Western blotting using anti-pY
292
-FcγRIIB antibody. (B)The role of Lck in BCR-stimulated 
phosphorylation of FcγRIIB: Western blot analysis of whole CLL cell lysates with anti-pY292 
FcγRIIB. 1x107 CLL cells were incubated with Lck-i (1μM) or dasatinib (150 nM) for 2 
hours, then the BCR was stimulated by adding 20μg/ml F(ab')2 goat anti-human IgM for 15 
minutes. 
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5.2.6. Lck inhibition reduces BCR-induced phosphorylation of CD22 
CD22 is a B cell-specific protein that also contains ITIM motifs, and functions to 
downregulate BCR signalling. Studies of Lyn-deficient mice have shown that tyrosine 
phosphorylation of CD22 on B cells is mainly mediated by Lyn
208 234
. Once the ITIM in 
CD22 is phosphorylated, the phosphatases SHP-1and SHIP are recruited 
235
 where they act to 
terminate BCR signalling by dephosphorylating various components of the BCR signalling 
pathways
209 233-234 366
. It is reported that CLL cells from different patients express variable 
levels of CD22
245
 and we observed a similar result in the cohort of patient samples we used 
(Table 5.3 and Figure 5.8). 
Table 5.3: CD22 expression on the CLL cells. CD22 expression in each CLL case is 
reported as mean florescence intensity measured by flow cytometer. 
case # MFI case # MFI 
3074 40.32 2806 189.66 
2683 45.35 2722 192.38 
2739 52.37 2736 255.63 
2950 59.95 2435 259.94 
2918 78.15 3095 262.42 
2948 82.24 2728 278.35 
3068 88.06 2911 284.96 
3287 90.81 2536 335.47 
2990 101.8 2961 150.1 
2861 102.73   
3113 103.2   
2932 103.62   
3286 105.89   
3184 107   
2656 115.91   
2872 130.61   
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Figure 5.8. Analysis of CD22 expression in CLL cells. A) Flow cytometry analysis of 
CD22 expression on a CLL case having high expression levels of CD22 (upper panel) and 
low expression levels of CD22 (lower panel). M1 is an arbitrary setting defining a region that 
excludes>95% of the isotype control values. B) Comparison of CD22 expression on the CLL 
cells within this cohort using the data present in Table 5.3. 
 
127 
 
 
I next examined the effect of BCR crosslinking on the induction of CD22 phosphorylation. 
We first determined the kinetics of CD22 phosphorylation in BCR-stimulated CLL cells. To 
do this we first immunoprecipitated CD22 from CLL cell lysates and probed for tyrosine 
phosphorylation in Western blots using 4G10. Figure 5.9 shows that maximal tyrosine 
phosphorylation of CD22 was reached within 15 minutes following BCR ligation. 
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Figure 5.9: BCR-induced CD22 phosphorylation in CLL cells. 1x10
7
 CLL cells were 
incubated for the indicated time points with 20µg/ml F(ab')2 goat anti-human IgM. CLL cells 
were lysed in RIPA buffer and CD22 was immunoprecipitated with anti-CD22 antibody. The 
immunoprecipitates were probed in Western blots with anti-pY4G10 antibody. 
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I next examined the role of Lck in BCR-induced phosphorylation of CD22 using Lck-i and 
dasatinib.  Figure 5.10 demonstrates that Lck inhibition leads to a reduction in BCR-induced 
phosphorylation of CD22 back to basal levels. Similarly, the presence of dasatinib also 
blocked BCR-induced CD22 phosphorylation.  
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Figure 5.10: The role of Lck in BCR-induced CD22 phosphorylation in CLL cells. 1x10
7
 
CLL cells were incubated for 2 hours with 1µM Lck-i or 150nM dasatinib prior to BCR 
stimulation with 20µg/ml F(ab')2 goat anti-human IgM for 15 min. CLL cell lysates were 
immunoprecipitated with anti-CD22 antibody and then probed in Western blots with anti-
pY4G10 antibody. To stimulate CD22 phosphorylation, CLL cells were incubated with 
100μM mpV(pic) for 30min (positive control). 
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The cytoplasmic tail of CD22 contains six tyrosine residues. Three of these tyrosine residues 
(Y
762
, Y
822
, and Y
842
) are located within ITIM sequences and are likely responsible for the 
binding of SHP-1 and SHIP
246
. On the other hand, Y
807
 is thought to be important for 
recruitment of Grb2 to CD22
231 239 367-368
, while the role(s) of Y
752
 and Y
796
 is still to be 
determined. To clarify the specific role of Lck in BCR-induced phosphorylation of CD22 we 
used a commercially available phospho-specific antibody that recognises CD22 when 
phosphorylated at Y
822
. Figure 5.11 shows that BCR ligation on CLL cells results in an 
approximate 4-fold increase in the level of pY
822
-CD22. Inhibition of tyrosine phosphatases 
using mpV(pic) also resulted in an increase in pY
822
-CD22 levels. When CLL cells were pre-
treated with Lck-i, BCR and mpV(pic) induction of CD22 phosphorylation at this site was 
blocked, and only basal levels of pY
822
-CD22 remained. The presence of dasatinib also 
blocked BCR and mpV(pic)-induced CD22 phosphorylation, but in contrast to Lck-i, the 
level of pY
822
-CD22 was reduced to below detection levels. These results suggest that CD22 
is a substrate of Lck during BCR signalling in CLL cells, and opens the possibility that 
another SFK, possibly Lyn, is responsible for basal levels of pY
822
 in CD22. 
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Figure 5.11: The role of Lck in BCR-stimulated phosphorylation of CD22 on CLL cells. 
A.) 1x10
7
 CLL cells were incubated for 2 hours with 1µM Lck-i or 150nM dasatinib prior to 
BCR stimulation with 20µg/ml F(ab')2 goat anti-human IgM for 15 min. Whole CLL cell 
lysates were probed by Western blot for pY
822
-CD22. B.) Graphical representation of n=6 
different cases of CLL of the Western blots presented in part A, and comparing only the 
effects of BCR crosslinking. Statistical analysis was performed using a student’s t-test for 
paired data. 
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5.2.7. Surface IgM is differentially glycosylated in high vs low Lck 
expressing CLL cases 
The above experiments showing that Lck can function to phosphorylate the ITIM of CD22 
imply that Lck may set a threshold of activation within CLL cells. Thus, in CLL cases with 
low Lck there may be higher baseline signals through the BCR than in cases with high Lck 
levels. In this section we explore this possibility. 
One method to measure constitutive activation of the BCR is to investigate the state of 
glycosylation of the surface Ig. Normal B cells express surface IgM that is modified by 
mature complex glycans. Under conditions of persistent antigen stimulation, surface IgM on 
normal B cells loses molecular weight due to changes in the state of glycosylation 
corresponding to the appearance of immature mannosyl residues
107
. Thus, normal B cells 
experiencing constitutive BCR signalling in vivo would bear surface Ig protein having altered 
(faster) mobility on SDS-PAGE gels. This phenomenon has recently been applied to the 
study of CLL cells, and it is reported that CLL cells have higher levels of surface IgM 
bearing immature mannosyl residues than do normal B cells
108-109
. Importantly, the 
proportion of fully and immature glycosylated surface IgM on CLL cells varies between 
patient cases, with cases having primarily immature surface IgM being associated with UM-
CLL. Thus, the malignant cells from patients with UM-CLL experience high levels of in-vivo 
BCR stimulation
107
.  
To investigate a potential role for Lck in this process, we compared surface IgM 
glycosylation on CLL cases bearing high and low levels of Lck.  SDS-PAGE examination of 
surface IgM glycosylation on normal B cells shows, as expected, a single discreet band 
(Figure 5.12). In contrast, similar examination of CLL cells displayed 2 bands; a slow 
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migrating band corresponding to that observed on normal B cells, and a faster migrating band 
indicating a change in glycosylation. A comparison of the ratio of the faster and slower 
migrating bands between CLL cases containing low and high levels of Lck showed that CLL 
cases with immaturely glycosylated surface IgM corresponded to CLL cases with low levels 
of Lck (Figure 5.12). These findings suggest that CLL cells with low levels of Lck tend to 
have higher levels of in-vivo constitutive BCR engagement than do CLL cells with high Lck 
levels.  
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Figure 5.12: Comparison of BCR glycosylation on normal B and CLL cells. CLL cells 
were surface labelled with sulfo-NHS-SS-Biotin and then lysed. Labelled proteins were 
purified using NeutrAvidin™ Agarose, and then analysed by Western blot for the presence of 
IgM (left hand panel). The right hand panel is a graphical representation of n=4 CLL cases 
with high and low Lck expression levels. Statistical analysis was performed using a Mann-
Whitney U-test.  
 
133 
 
 
The data in section 5.2.6 showed that CD22 is constitutively phosphorylated in CLL cells and 
is a target of Lck. The above data suggest that BCR is constitutively active in CLL cases with 
low levels of Lck. It therefore seemed reasonable to compare the basal levels of CD22 
phosphorylation between CLL cases with high and low Lck expression, based on a 
hypothesis that CD22 phosphorylation by Lck may downregulate BCR signalling. Figure 
5.13 shows that pre-treatment of CLL cells with Lck-i reduces the levels of CD22 tyrosine 
phosphorylation in unstimulated CLL cells. However, we found that there was no quantitative 
difference in the level of CD22 tyrosine phosphorylation between CLL cases with high Lck 
levels and cases with low levels of this kinase. 
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Figure 5.13: Comparison of CD22phosphorylation in high vs low Lck expressing CLL 
cases. A.) 1x10
7
 CLL cells were incubated for 2 hours with 1µM Lck-i. Whole CLL cell 
lysates were probed by Western blot for pY
822
-CD22. B.) Graphical representation of n=3 of 
each group different cases of CLL of the Western blots presented in part A. Statistical 
analysis was performed using a Mann-Whitney U test.  
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5.3. Discussion 
In Chapter 4 we demonstrate that Lck mediates BCR signalling in CLL cells, and that its 
level of expression governs the strength of BCR-induced phosphorylation of IKK, Akt and 
Erk. This suggests a role for Lck in disease prognosis. In this chapter we focused on the link 
between Lck expression levels and CLL disease prognosis. Analysis of treatment free 
survival shows that CLL patients with high levels of Lck have better prognosis than patients 
with low Lck levels. This association between high Lck levels and good disease prognosis 
indicates that Lck could function as a negative regulator of BCR signalling in CLL cells. In 
this chapter we investigated the ability of Lck to phosphorylate co-receptors such as CD5, 
FcγRIIB and CD22 in CLL cells because of the roles these proteins have in attenuating BCR 
signalling. 
To determine a prognostic value for Lck expression in CLL cells we used two different 
methods of determination on two different cohorts of patients. Thus, in one cohort Lck 
expression was determined by Western blot analysis of lysates from purified CLL cells, and a 
second cohort where Lck expression was determined by flow cytometry. Both approaches 
yielded similar results and showed that high Lck expression in CLL cells is associated with 
good prognosis whereas low Lck expression is associated with poor prognosis. Both cohorts 
of patients were subjected to survival analysis according to IgHV mutation and ZAP70 
expression. As expected
32 34 97 143-144
, UM-CLL cases and cases where the malignant cells 
expressed high levels of ZAP70 were associated with poor disease outcome in both cohorts. 
This deserves further comment because statistical significance was not reached for this 
analysis in the smaller cohort, and was only significant for the relationship between IgHV 
mutation and disease survival in the second, larger cohort. Nevertheless, we found that there 
was concordance between ZAP70 expression and UM-CLL status in both cohorts, with the 
strength of this concordance due to the method of ZAP70 determination. In the first cohort of 
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patients ZAP70 expression was determined by Western blot whereby ZAP70 expression is 
quantitated relative to -actin. We used flow cytometry to determine ZAP70 expression in the 
second cohort, but did not use the standard monoclonal antibody for this detection
369
. This is 
because the method of preparing CLL cells for Lck detection was not conducive for the 
standard clone (clone 2F3·2)
369
 that detects ZAP70 and required the use of a different 
antibody (Mouse Monoclonal Antibody (clone 1E7.2))
35
. The overall result using either of 
these approaches showed a trend toward poor disease outcome in high ZAP70 expressing 
cases, and would require the use of much larger cohorts of patients for full validation. That 
Lck expression did not show relationship to IgHV mutation in either cohort of patients 
suggests that Lck may be an independent prognostic indicator in CLL.  
Having established that high Lck expression corresponded to good disease prognosis, we 
hypothesized that Lck may have a dual role in regulating BCR signalling; one role as a 
positive regulator as we have demonstrated in Chapter 4, and a second where it functions to 
downregulate BCR signals. There is precedent for such a dual role; Lyn is demonstrated to 
act as a positive and negative regulator of BCR signalling
165-166
 through its ability to 
phosphorylate ITAMs and ITIMs
167-168
, and a similar role for Lck in downregulating antigen 
receptor signalling in T cells is also demonstrated where it may phosphorylate the ITIM 
within CD5
220-221
. Furthermore, although controversial, such a dual function for Lck in B1a B 
cells is also possible because of its reported role in enhancing BCR signals
331
, or in 
downregulating BCR signalling leading to hyporesponsiveness of B1 cells to antigen 
stimulation
192
.  
CD5 is a quintessential marker of CLL cells
361
, and is thought to participate in 
downregulation of BCR signalling due to an established role in antigen receptor signalling in 
T cells, and possibly also in B cells
192 220
. CD5 is a target of Lck phosphorylation in T cells, 
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and studies of CD5 knockout mice showed that CD5
-/-
 T cells display increased proliferation, 
intracellular Ca
2+
 release and tyrosine phosphorylation of PLCγ-1 and LAT all in response to 
TCR stimulation
220-221
. Therefore, it seemed logical to examine whether CD5 was a target of 
Lck in CLL cells. Our data show that BCR crosslinking on CLL cells results in an immediate 
phosphorylation of tyrosine residues within CD5 as detected by Western blot analysis of 
immunoprecipitated CD5 with anti-phosphotyrosine 4G10 and PY20 antibodies. We then 
examined whether this tyrosine phosphorylation was mediated by Lck by pre-treating the 
CLL cells with Lck-i. We found that such Lck inhibition did not affect BCR-induced 
phosphorylation of CD5, whereas the presence of the pan-SFK inhibitor dasatinib did. Thus, 
other SFKs such as Lyn may be responsible for the induction of CD5 phosphorylation in 
BCR-stimulated CLL cells. This seems to be consistent with what has been shown in CD5
+
 
B1a cells
20
. In this subset of B cells BCR ligation results in induction of apoptosis, a response 
that is CD5 dependent because BCR crosslinking in CD5 knockout mice induced 
proliferation of these B cells rather than apoptosis. This study concluded that CD5 is a 
negative regulator of BCR signalling in B1 cells
218
, and is likely dependent on Lyn because 
BCR stimulation of Lyn
-/- 
B1a cells also results in proliferation
219
. Whether CD5 operates in a 
similar manner in CLL cells is not fully understood. Studies by Perez-Chacon et al have 
shown that crosslinking CD5 can induce pro-survival signalling in CLL cells, but does so 
independently of the BCR
223 370
 . However, another study has indicated that Lyn 
constitutively phosphorylates CD5 in CLL cells to allow association of SHP-1 where it 
functions as a negative regulator of BCR signalling
224
. Our results agree with a potential role 
of Lyn in the phosphorylation of CD5, but this only takes place when BCR is crosslinked in 
CLL cells. 
To further investigate a potential role of CD5 in CLL cells, we attempted to transfect CD5 or 
a truncated version of CD5 that lacks a cytoplasmic tail into MEC1 cells. MEC1 cells are a 
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CD5
- 
cell line that was derived from a patient with CLL who underwent prolymphocytic 
transformation
363
. Analysis of this cell line showed that they express Lck and exhibit 
constitutively active BCR signals with high phosphorylation levels of IKK, Akt and Erk. 
Because of the known inhibitory function of CD5 on BCR signalling, we hypothesized that 
reintroduction of CD5 expression would raise the threshold for BCR activation due to 
recruitment of SHP-1 to the plasma membrane within this cell line and result in a dampening 
of the constitutive signals. Our results show that transient expression of CD5 in MEC1 cells 
did not affect constitutive BCR signalling to IKK, ERK and Akt. In these experiments CD5 
was expressed by approximately 80% of the cells as a surface antigen. Thus, the failure of 
CD5 to affect BCR signalling in this system is not due to failure of the cells to express this 
antigen appropriately. 
FcγRIIB (also known as CD32) is another cell surface protein that is known to be expressed 
on CLL cells at comparable or higher levels than on normal B cells
263
. This may be important 
because the cytoplasmic domain of this protein contains an ITIM sequence
102
. Following 
BCR ligation FcγRIIB is phosphorylated on tyrosine residues within the ITIM sequence, and 
this function to recruit SHIP leading eventually to attenuation of BCR signals
253
. In normal B 
cells Lyn is thought to mediate phosphorylation of tyrosine 292 located within the ITIM 
domain of FcγRIIB during BCR engagement166-168 208 364-365, but in CLL cells the mechanism 
of FcγRIIB phosphorylation has not been well studied. Our data show that FcγRIIB is 
constitutively phosphorylated on Y
292 
in CLL cells, and that BCR stimulation does not seem 
to induce any change in this state. This could be because the antibody we use to crosslink 
BCR on CLL cells is a F(ab)2 fragment which does not engage FcRII. However, the fact 
that this protein is constitutively phosphorylated implies that there is some degree of 
engagement that is independent of our perturbation. We show that this constitutive 
phosphorylation of FcRIIB is not due to Lck because the treatment of CLL cells with Lck-i 
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had no effect. However, treatment of CLL cells with dasatinib completely reduced pY
292
-
FcRIIB levels suggesting that another SFK is involved. This could be Lyn because of the 
known role of this SFK in FcγRIIB phosphorylation166-168 208, and because Lyn is 
constitutively active in CLL cells
174
.  If this is indeed the case, then Lyn in CLL cells actively 
contributes to downregulation of BCR signalling through FcRIIB in a way that is already 
proposed for Lyn-mediated phosphorylation of CD5
224
.  
In this thesis we did not examine any role for FcRIIA. This isoform of CD32 contains an 
ITAM rather than an ITIM and functions in myeloid cells to facilitate signals through this 
receptor
262-264
. CLL cells have been shown to express FcγRIIA, however, studies have shown 
that it is incapable of inducing any activation signals
264
. Our study of CD32 on CLL cells is 
restricted to FcRIIB because the antibody we use to recognise phospho-tyrosine is specific 
for the ITIM within this isoform.  
An additional protein that participates in downregulating BCR signalling is CD22
226
, which 
performs this function by recruiting SHP-1
235
 and SHIP
239
 to the ITIM sequences within its 
cytoplasmic tail when they become tyrosine phosphorylated. Experiments using Lyn 
knockout mice show that phosphorylation of CD22 is mediated by this SFK in normal B 
cells
208 233-234
. CLL cells express CD22, but the level of expression of this protein can vary on 
the malignant cells from different patients
245
. Our data confirms this observation for the 
cohort of patients we employed in this study. We further examined whether CD22 is a 
possible target of Lck in CLL cells using Lck-i. Thus, BCR stimulated CD22 phosphorylation 
is inhibited in CLL cells by the presence of this compound, suggesting a role for Lck in this 
process.  However, another SFK may be additionally involved in CD22 phosphorylation 
because its complete inhibition was only achieved using dasatinib. Taken together, these 
results suggest that Lck is responsible for inducible phosphorylation of CD22 in CLL cells, 
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while another SFK is responsible for basal levels of CD22 phosphorylation. This may be 
important because we were not able to show a difference in the level of CD22 
phosphorylation in high and low Lck expressing CLL cell clones. However, this is 
complicated by the fact that CD22 and Lck are differentially expressed between CLL cases, 
and in this thesis we were unable to address if there was a relationship between CD22 and 
Lck expression in CLL cells. Thus, CLL cases with low CD22 but high Lck may have a 
greater downregulatory effect on BCR signalling than CLL cases carrying high CD22 and 
low Lck. The experiments we performed used CLL cases with high levels of CD22 in order 
to ensure detection of phosphorylated protein in the assays we used: 1.) Immunoprecipitation 
of CD22 and detection of tyrosine phosphorylation using phospho-tyrosine specific 
antibodies, and 2.) Direct detection of pY
822
-CD22 in whole cell lysates.  Little is known 
about the role of CD22 in CLL cells, with one study reporting that CD22 is constitutively 
tyrosine phosphorylated  but it does not associate with SHP-1
224
. Our experiments showed 
that CD22 phosphorylation can be induced in CLL cells by BCR crosslinking, and suggest 
that Lck is responsible for this induction. However, further experiments will be necessary in 
order to fully understand the role of CD22 and Lck in BCR signalling in CLL cells.  
If Lck does indeed participate in downregulating BCR signalling in CLL cells, then, 
according to our hypothesis, CLL cases with low levels of Lck should have higher in vivo 
signals than CLL cases with high levels of Lck. We tested this possibility by measuring the 
glycosylation of surface IgM on CLL cells. B cells exposed to chronic BCR signals change 
the glycosylation of BCR due to recycling of the IgM to the cell membrane
212
. Thus, under 
constant BCR engagement the mature N-glycosylation of surface IgM on B cells is changed 
to expose underlying mannosyl residues with the consequence of decreased molecular 
weight. This phenomenon has recently been exploited to show that CLL cells, especially 
from UM-CLL cases, experience constitutive BCR engagement in vivo
107
. We used a similar 
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approach to compare in-vivo BCR signalling in CLL cells from cases expressing high and 
low levels of Lck. We found that CLL cells bearing low levels of Lck expressed a 
significantly higher proportion of mannosylated BCR than did CLL cells bearing high levels 
of Lck. This finding supports our hypothesis that CLL cases with low levels of Lck have 
higher levels of in vivo signalling. An explanation for why this occurs is suggested by a 
recent paper by Dühren-von Minden et al
110
. Here it was demonstrated that structural 
elements within the BCR on CLL cells is conducive to antigen-independent cell-autonomous 
signalling. If this is a crucial pathogenetic mechanism, as is suggested by the authors of this 
manuscript, then the importance of mechanisms that downregulate this antigen-independent 
cell-autonomous signalling will also be important within this pathogenetic mechanism. Thus, 
our work points to a role of Lck within this pathogenetic mechanism, however, it is clear that 
more work needs to be done in order to fully characterise this role. 
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Chapter 6: General discussion and future work 
The initial aim of this thesis was to characterise any potential role of PKCII and c-Abl in the 
pathway of BCR-mediated activation of NFB. However, in address of this aim we found 
that neither of these protein kinases was involved in this pathway. Nevertheless, our 
experiments did suggest the involvement of Lck in BCR signalling. Thus, the remaining aims 
of this thesis were to fully characterise the role of Lck in BCR-mediated signalling in CLL 
cells, and determine its pathogenic importance. 
The results of our experiments are important for understanding the pathophysiology of CLL 
cells because engagement of the BCR on these cells provides them with proliferation and 
survival signals. The importance of BCR signalling in CLL pathogenesis has been 
extensively studied. However, there has been a general assumption that Lyn is the main 
mediator of proximal BCR signals. This work is the first to demonstrate an unambiguous role 
for Lck in the generation of both proximal and distal signalling events in CLL cells 
responding to antigen receptor engagement. Thus, this project proposes the possibility of 
targeting Lck as a therapeutic approach for the treatment of CLL patients. From a clinical 
point of view targeting Lck may be advantageous because inhibition of this SFK would target 
CLL cells but not alter the function of normal peripheral B cells, which lack Lck. On the 
other hand, Lck is an important mediator of T cell receptor function
188 332
, and so caution 
must be exercised when considering Lck inhibition as a therapeutic approach because T cells 
are known to be abnormal in CLL patients
371-372
 and suppression of T cell function may 
increase susceptibility of these patients to opportunistic infection.  
The initial purpose of this project was to investigate the signalling pathway that is triggered 
by BCR engagement with its cognate antigen leading to activation of NFκB in CLL cells. 
NFκB is aberrantly activated in CLL compared to non-malignant B cells, and the level of 
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active NFκB correlates with in-vitro survival of these cells and to disease prognosis157-158. 
Although the prognostic value of active NFB is independent of IgHV mutation and ZAP70 
expression
373
, its activation by BCR may still be relevant because of recent findings 
suggesting a role of antigen-independent cell autonomous signalling by BCR in the 
pathogenesis of CLL
110
. If such autonomous BCR signalling contributes to activation of the 
NFB pathway in CLL cells, then the results of our experiments indicate that a paradigm 
pathway whereby the CARMA-1/MALT-1/Bcl-10  (CBM) complex transfers BCR signals 
leading to stimulation of IKK via Btk-mediated activation of PLC2 and PKCβ115 is not 
operative. Thus, CLL cells express very low levels of Bcl-10 compared to normal B cells, 
supporting the notion that this pathway may be inoperative in these cells because of the 
importance of the CBM complex elements for efficient antigen receptor signalling to 
occur
288-290
 . Further evidence to suggest that the CBM pathway is inoperative comes from 
experiments where we cultured CLL cells on CD40L-expressing fibroblasts. Here we 
observed induction of Bcl-10 expression in the CD40L-stimulated CLL cells. However, 
BCR-induced IKK phosphorylation in these cells was attenuated compared to CLL cells 
cultured on control fibroblasts despite the increase in Bcl-10 levels. Finally, we show using 
the inhibitor LFM-A13 that Btk plays a role in BCR-induced IKK activation in A20 cells (a B 
cell line) but not in CLL cells. Taken together, our data provide evidence to suggest an 
alternative mechanism of BCR-induced IKK activation whereby PKCβ and the CBM 
complex are bypassed. 
How this alternative mechanism of BCR-induced NFB pathway activation is mediated will 
involve active Lck and induction of tyrosine phosphorylation. This is because we found that 
BCR-induced IKK activation was particularly sensitive to Lck inhibition either by siRNA 
knockdown of Lck, or using the Lck inhibitor. How Lck activates NFB pathway signalling 
in CLL cells responding to antigen receptor engagement is a topic of future investigation. 
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The work presented in this thesis points to a central role of Lck in mediating BCR signalling 
in CLL cells. We show that Lck in BCR-stimulated CLL cells catalyses the proximal 
phosphorylation of CD79a as well as the induction of distal signalling events involving 
phosphorylation of Syk, activation of ERK, NFκB and PI3K/Akt and enhanced cell survival. 
This finding may be relevant for understanding the mechanisms of how new agents entering 
clinical trials may mediate their effects. One of these agents, Ibrutinib (PCI-32765), has 
generated promising results and is described to be an irreversible inhibitor of Btk
374-375
. In 
cell-free analysis of kinase activity Ibrutinib inhibits Btk activity with an IC50 of 0.5nM, Lck 
with an IC50 of 33.2nM and Lyn with an IC50 of 200nM
375
. This consideration may be 
important because Ibrutinib is reported to inhibit BCR-induced cell survival and activation of 
ERK and Akt at concentrations greater than 1M83 374 , BCR-induced pathways we show in 
this thesis to be mediated by Lck in CLL cells. Although Lck may be upstream of Btk in the 
pathway initiated by BCR crosslinking on CLL cells, a direct role of Btk in activation of the 
PI3K/Akt pathway in B cells has not been demonstrated. Rather, in B cells it is demonstrated 
that Btk acts downstream of PI3K activation owing to the need of this tyrosine kinase to 
associate with exposed PIP3 moieties at the cell membrane for activation and subsequent 
phosphorylation of its major substrate in B cells, PLC2 which also needs to be at the plasma 
membrane to gain access to its substrate PIP2 
376
. Another factor that may be important is 
PKCII which is demonstrated to phosphorylate Btk on serine 180 and downregulate its 
activity by dissociating it from the plasma membrane
279
. Work from this Department has 
shown that CLL cells overexpress PKCII, and that, at least in some cases of CLL, this PKC 
isoform works to suppress BCR-induced intracellular Ca
2+
 release in CLL cells via this 
mechanism
197 377
.Thus, while it is clear that Ibrutinib acts to inhibit Btk in “normal” B cells 
and that this is important to the way this compound works to suppress B cell-mediated 
autoimmune disease
375
, the way it works to bring about its cytotoxic effects in CLL may be 
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different and involve inhibition of Lck owing to the high levels of this compound that are 
needed to inhibit BCR-induced signalling events in these cells. Future work is needed to 
more clearly define the mechanism of how Ibrutinib is working in CLL cells. 
The work of this thesis also revealed a potential value of Lck expression for disease 
prognosis in CLL. Considering our demonstration of a role for Lck as a mediator of BCR 
signalling in CLL, particularly the relationship between Lck and BCR signalling strength, it 
is therefore surprising that high expression of this SFK in CLL cells is linked to good disease 
prognosis. Exactly why this is the case will require further experimentation, but we propose 
that this observation may be linked to a potential threshold-setting function of Lck. Within 
this model in vivo BCR signalling would be much more prominent in CLL cells having low 
levels of Lck expression than in CLL cells with high levels of Lck expression. We found that 
this is indeed the case when we measured the proportion of BCR that has undergone re-
expression to the plasma membrane of CLL cells, which is measured by the appearance of 
mannosylated BCR and is a function of BCR engagement
107 212
. Thus, in CLL cases with low 
levels of Lck expression there is a higher proportion of mannosylated BCR than in CLL cases 
with high levels of Lck expression. How Lck sets the threshold of activation may be due to an 
ability to target ITIM motifs and/or recruit tyrosine phosphatases to the BCR signalling 
complex. Such a role for Lck has been previously reported in T cells and B1 cells where the 
target is CD5
192 220
. However, our data indicate that this is not the case in CLL cells. 
Alternatively, our investigations identify CD22 and show that BCR crosslinking induces 
significant phosphorylation within the ITIM motif of this protein that is mediated by Lck. In 
this regard CD22 could potentially act to downregulate BCR signalling in CLL cells by 
recruiting SHP1 and SHIP
235 239
, but this interpretation is complicated by differential 
expression of Lck and CD22. We were unable to show any relationship between basal levels 
of CD22 phosphorylation and Lck expression in CLL cells. Further work addressing the exact 
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role of Lck may need to identify the binding partners of this SFK in order to understand its 
full function. 
Figure 6.1 summarises a proposed mechanism through which Lck may be regulating BCR 
signalling in CLL cells.  
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Figure 6.1: Proposed role of Lck in BCR signalling in CLL cells. 
 
In conclusion, this work aimed to explore some unanswered questions about BCR signalling 
in CLL cells, and provides insight into the role(s) of different SFKs in this process. We show 
that specific inhibition of Lck blocks BCR signalling in CLL cells leaving open the question 
of a role for Lyn. An exact role for Lyn is difficult to assess owing to the stability of this 
protein in CLL cells. Thus, whether Lck acts directly to phosphorylate CD79 and initiate 
downstream signals in CLL cells, or if it “guides” Lyn in this function needs to be 
determined. This thesis provides the groundwork to justify research in this area.  
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Appendix 
 Clinical details of CLL cases studied. 
Case # WBC CD38 Binet Rai IgHV% Class 
1754 182.4 1.2 B II 93.55 M 
1801 128    96.84 M 
1851 116 4 A III 93.9 G 
1901 72.7 1 A 0 95.3 M 
1932 24.9 low A 0 94.02 M 
1937 18 3 A 0 99.66 M 
1939 624 13 C IV 100 M 
1952 13.9 33 A 0 91.1 G 
1954 32  A 0   
1958 215 2 A 0 95.53 M 
1963 17.2 19 A 0 93 M 
1964 39.5 3 A 0 91 M 
1965 16.7 54 A 0 99.66 M 
1975 21 3     
1996 15.6 5 A 0 91.5 M 
1998 108.9 28 A I 90 M 
2006 22.5 3 A 0 93.6 M 
2010 191.3 16   100 M 
2025 23.7 12 A 0 91.5 M 
2045 23.3 40 A 0 98.65 M 
2050 12.9 5     
2056  25   99.65 M 
2063 427 98 B II 100 M 
2067 138 57   100 M 
2073 10.2 9 A I 93.2 M 
2080 119.1 3 A 0 91.1 M 
2081 13.6 3 A 0   
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2082 6.7 76   100 M 
2085 17.5 14 A 0 100 M 
2096 60 0 A 0 93.75 M 
2098 28.5 14 A 0   
2120 155    94.63 G 
2123 8.2      
2157 66.4 low   88.89 M 
2173 72.6 19 A 0 96.14 M 
2204 27.8 14 A 0   
2205 147 18 A I 100 M 
2209 105 29   98.3 M 
2212 64.7 53   100 M 
2213 24.9 72 B I   
2216 31.8 3   85.99 M 
2218 58.7 8 B I 100 M 
2224 37.3 8   94.58 M 
2230 127.9    100 M 
2233 15.6 98   100 M 
2237 210  B I 91.41 M 
2238 90.1 6 A 0 94.79 M 
2246 54    93.88 M 
2255 187 18 B I 100 M 
2256 51.1 27 B I 100 M 
2291 154 28 B II 97.57 A 
2343 86 4 B II 93.88 G 
2354 165    95.44 M 
2371 158 3 C III 91.07 M 
2387 31.1 35 C III   
2389 115    98.25 M 
2399 240 97   100 A 
2424 162.3 96 C III 100 M 
2429 13.6 1 A 0 94.65 M 
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2435 370 88   100 M 
2436 20 0 A 0  M 
2444 20.9 95 A 0   
2453 387.5      
2457 283 3 C IV 97.54 M 
2506 17.3 3 A I   
2536 242.3 96 C III  M 
2562 124.7 40 A 0 100 M 
2581 175.9 6    M 
2595 23.8    97.52 M 
2608 110.7 15 A 0 91.06 G 
2656 142.1    99.65 M 
2679 123.8    93.88 G 
2683 381.9    100 M 
2689 71.5 1 C IV   
2701 174 29   98.25 M 
2709 23.1 94   100 M 
2711 242.3    87.72 G 
2722 16.9 2   100 M 
2724 86.8 14 B  98.91 M 
2728 163 18   100 M 
2736 40.4 7   100 M 
2739 412    100 M 
2745     99.66 M 
2747 147.4 60 A  100 M 
2751 802.5    100 M 
2764 184    100 M 
2783 196.4 5   96.94 M 
2806 16.2 2     
2810 44.6 1 C III 98.28 M 
2861 43.5    100 M 
2872 76.6 1 C II 98.28 M 
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2877 160.8    91.5 M 
2905 59.6 98   100 M 
2911 223.2 60   100 M 
2918 178.7    99.66 M 
2932 175.7  B II   
2948 114.2 3   100 M 
2950 150.4  C IV 94.79 M 
2953 126.5 98 C  100 M 
2954 49.3 0     
2956 266.3 low A  99.66 M 
2961 126.5  B    
2968 87.4  C  96.53 G 
2990 80.3 1   99.73 M 
2999 118.5 7   96.36 M 
3023 67.9    100 M 
3047 141.4 4   99.32 M 
3068 32.3 29 B  100 M 
3074 459.7 Low A  99.66 M 
3095 44.2 0 A  99.65 M 
3105 66 25   99.65 M 
3113 172.4 29 B  98.25 M 
3247       
3283  38     
3184 155.7 0   100 M 
WBC: White blood cell count (x10
9
/L) 
CD38: % CD38 positive cells 
Binet: Binet clinical staging 
Rai: Rai clinical staging 
IgHV: IgHV gene % homology with germline sequence 
Class: Class of immunoglobulin 
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Buffers 
TBS-T 
Tris (pH 7.4) 10mM 
Sodium chloride 150mM 
Tween-20 0.1% 
 
Resolving gel buffer (4x) 
Tris (pH 8.8) 1.5M 
SDS 0.4%(w/v) 
Bought from National diagnostics, Hessle Hull, England 
 
Resolving gel 
Acrylamide Varied (usually 10%) 
4x Running gel buffer 25% 
TEMED 0.01% 
Ammonium persulphate 0.04%(w/v) 
Made up to 100% with ddH2O 
 
Stacking gel buffer 
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Tris (pH 6.8) 0.5M 
SDS 0.4%(w/v) 
Bought from National diagnostics, Hessle Hull, England 
 
Stacking gel 
Acrylamide 5% 
Stacking gel buffer 25% 
TEMED 0.1% 
Ammonium persulphate 0.08%(w/v) 
Made up to 100% with ddH2O. 
 
Transfer buffer (10X) 
Tris (pH 6.8) 0.25M 
Glycine 1.92M 
Bought from National diagnostics, Hessle Hull, England 
 
SDS-PAGE running buffer 
Tris  25mM 
Glycine  192mM 
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SDS  0.1%(w/v) 
 
Western blot stripping buffer 
SDS  2%(w/v) 
Tris (pH6.8)  62.5mM 
β-mercaptoethanol  100mM  
 
Laemelli buffer (2x) 
Tris (pH6.8)  125mM 
Glycerol  20% 
SDS  4%(w/v) 
β –mercaptoethanol                            10% 
Bromophenol blue                0.006%(w/v)             
 
Clear lysis buffer  
SDS  1%(w/v) 
Glycerol  10% 
Tris (pH6.8)  50mM 
EDTA  5mM 
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Phosphate Buffered Saline (PBS) 
NaCl   150mM 
KCl   3mM  
Na2HPO4   4.3mM 
KH2PO4  1.5mM 
 
Purification buffer 
PBS 
BSA 0.1%(w/v) 
EDTA 2mM 
Degassed overnight prior to use.  
 
Radioimmunoprecipitation (RIPA) buffer (Triton X-100): 
Glycerol   10% 
Triton X-100   1% 
Sodium deoxycholate  1%(w/v) 
SDS  0.1%(w/v) 
Tris (pH7.6))  50mM 
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EDTA  2mM 
EGTA  2mM 
Sodium pyrophosphate  25mM 
Glycerol phosphate disodium  50mM 
Na Cl   150mM 
Na F  50mM 
Made up to 100% with ddH2O 
N-ethylmaleimide (NEM): Stock 1M dissolved in Ethanol, was added to RIPA buffer 
(10mM) to preserve IKKγ ubiquitination. 
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